BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051912 A2

(51) International Patent Classification[7]: C07K 14/18

(21) International Application Number: PCT/EP02/14480

(22) International Filing Date:
18 December 2002 (18.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/020,510 18 December 2001 (18.12.2001) US
60/418,358 16 October 2002 (16.10.2002) US

(71) Applicant *(for all designated States except US)*: **INNOGENETICS N.V.** [BE/BE]; Technologiepark 6, B-9052 Ghent (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MAERTENS, Geert** [BE/BE]; Zilversparrenstraat 64, B-8310 Brugge (BE). **DEPLA, Erik** [BE/BE]; Burgstraat 58, B-9070 Destelbergen (BE). **BOSMAN, Fons** [BE/BE]; Hulst 165, B-1745 Opwijk (BE).

(74) Common Representative: **INNOGENETICS N.V.**; Intellectual Property Department, Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/051912 A2

(54) Title: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

(57) Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

Field of the invention

The present invention relates to the general fields of recombinant protein expression, purification of recombinant proteins, synthetic peptides, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosis/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosis/monitoring of natural disease.

More particularly, the present invention relates to purification methods for hepatitis C virus envelope proteins, the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the methods described in the present invention, the use of single or specific oligomeric E1 and/or E2 and/or E1/E2 envelope proteins in assays for monitoring disease, and/or diagnosis of disease, and/or treatment of disease. The invention also relates to epitopes of the E1 and/or E2 envelope proteins and monoclonal antibodies thereto, as well their use in diagnosis, prophylaxis or treatment.

Background of the invention

The E2 protein purified from cell lysates according to the methods described in the present invention reacts with approximately 95% of patient sera. This reactivity is similar to the reactivity obtained with E2 secreted from CHO cells (Spaete et al., 1992). However, the intracellularly expressed form of E2 may more closely resemble the native viral envelope protein because it contains high mannose carbohydrate motifs, whereas the E2 protein secreted from CHO cells is further modified with galactose and sialic acid sugar moieties. When the aminoterminal half of E2 is expressed in the baculovirus system, only about 13 to 21% of sera from several patient groups can be detected (Inoue et al., 1992). After expression of E2 from E. coli, the reactivity of HCV sera was even lower and ranged from 14 (Yokosuka et al., 1992) to 17% (Mita et al., 1992). About 75% of HCV sera (and 95% of chronic patients) are anti-E1 positive using the purified, vaccinia-expressed recombinant E1 protein of the present invention, in sharp contrast with the results of Kohara et al. (1992) and Hsu et al. (1993). Kohara et al. used a vaccinia-virus expressed E1 protein and detected anti-E1 antibodies in 7 to 23% of patients, while Hsu et al. only detected 14/50 (28%) sera using baculovirus-expressed E1.

These results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the envelope proteins with human patient sera. This can be obtained using the proper expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

Clinical importance of necro-inflammation and fibrosis in HCV infection.

The natural history of liver disease after HCV infection does vary significantly from patient to patient. About 20% of the acutely infected persons are able to resolve infection spontaneously, while 80% of infected persons progresses to a chronic infection. Chronic infection results in an ongoing inflammation and/or necrosis (=necro-inflammation) in the liver which can be diagnosed by histological analysis of a liver biopsy or which can be diagnosed using a surrogate marker such as the presence of the liver enzyme ALT in serum. This chronic infection increases the risk for development of fibrosis which can lead to development of cirrhosis and ultimately liver carcinoma. Many data suggest that the ongoing necro-inflammation drives progression to fibrosis and cirrhosis. It is estimated that up to 20% of HCV chronic carriers may develop cirrhosis over a time period of about 20 years and that of those with cirrhosis between 1 to 4%/year is at risk to develop liver carcinoma. (Lauer and Walker 2001, Shiffman 1999). Both cirrhosis and liver carcinoma are end-stage liver diseases for which the treatment options are limited to liver transplantation. Consequently, the most important aim of therapy for HCV is to reduce the risk of development of end-stage liver disease by reducing liver necro-inflammation and/or reducing fibrosis progression.

For the documentation and/or diagnosis of liver damage several scoring systems have been

developed for histological interpretation of a liver biopsy. These scoring systems may combine inflammation, necrosis and fibrosis in a single score such as the Histology Activity Index (HAI). Other scoring systems have separated the scores for necro-inflammation (=grading) from the one for fibrosis/cirrhosis (=staging). These systems include the system proposed by Ishak or the Metavir scoring system. A review of these scoring systems was published by Lefkowitch in 1997.

It has been shown in several studies that treatment with interferon, and more recently treatment with interferon combined with ribavirin and most recently treatment with pegylated interferon with or without ribavirin does change the natural history of HCV and halts further progression of liver fibrosis especially in those patients with a sustained viral response (Schvarcz et al. 1999, Shiffman 1999, Reichard et al. 1999, Poynard et al. 2002). The reduction of the risk for hepatocarcinogenesis in persons with sustained virological and even with sustained biochemical response has also been documented (Takimoto et al. 2002).

For persons without sustained virological response to interferon based therapy a maintenance interferon therapy may be helpful to prevent histological progression, but this only in a subset of patients (Alric et al. 2001).

Thus, many patients who do not respond to interferon based therapies or who are excluded from these therapies for several reasons (this may mount up to 70% of patients referred to clinic, Falck-Ytter et al. 2002), remain without a therapeutic option today to reduce liver necro-inflammation and/or reduce the progression of fibrosis in order to avoid end-stage liver disease.

Aims of the invention

It is an aim of the present invention to provide a new purification method for recombinantly expressed E1 and/or E2 and/or E1/E2 proteins such that said recombinant proteins are directly usable for diagnostic and vaccine purposes as single or specific oligomeric recombinant proteins free from contaminants instead of aggregates.

It is another aim of the present invention to provide compositions comprising purified (single or specific oligomeric) recombinant E1 and/or E2 and/or E1/E2 glycoproteins comprising conformational epitopes from the E1 and/or E2 domains of HCV.

It is yet another aim of the present invention to provide novel recombinant vector constructs for recombinantly expressing E1 and/or E2 and/or E1/E2 proteins, as well as host cells transformed with said vector constructs.

It is also an aim of the present invention to provide a method for producing and purifying recombinant HCV E1 and/or E2 and/or E1/E2 proteins.

It is also an aim of the present invention to provide diagnostic and immunogenic uses of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention, as well as to provide kits for diagnostic use, vaccines or therapeutics comprising any of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention.

It is further an aim of the present invention to provide for a new use of E1, E2, and/or E1/E2 proteins, or suitable parts thereof, for monitoring/prognosing the response to treatment of patients (e.g. with interferon) suffering from HCV infection.

It is also an aim of the present invention to provide for the use of the recombinant E1, E2, and/or E1/E2 proteins of the present invention in HCV screening and confirmatory antibody tests.

It is also an aim of the present invention to provide E1 and/or E2 peptides which can be used for diagnosis of HCV infection and for raising antibodies. Such peptides may also be used to isolate human monoclonal antibodies.

It is also an aim of the present invention to provide monoclonal antibodies, more particularly human monoclonal antibodies or mouse monoclonal antibodies which are humanized, which react specifically with E1 and/or E2 epitopes, either comprised in peptides or conformational epitopes comprised in recombinant proteins.

It is also an aim of the present invention to provide possible uses of anti-E1 or anti-E2 monoclonal antibodies for HCV antigen detection or for therapy of chronic HCV infection.

It is also an aim of the present invention to provide kits for monitoring/prognosing the response to treatment (e.g. with interferon) of patients suffering from HCV infection or monitoring/prognosing the outcome of the disease.

All the aims of the present invention are considered to have been met by the embodiments as set out below.

Definitions

The following definitions serve to illustrate the different terms and expressions used in the present invention.

The term 'hepatitis C virus single envelope protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the E1 or the E2 region. These single

envelope proteins in the broad sense of the word may be both monomeric or homo-oligomeric forms of recombinantly expressed envelope proteins. Typically, the sequences defining the epitope correspond to the amino acid sequence of either the E1 or the E2 region of HCV (either identically or via substitution of analogues of the native amino acid residue that do not destroy the epitope). In general, the epitope-defining sequence will be 3 or more amino acids in length, more typically, 5 or more amino acids in length, more typically 8 or more amino acids in length, and even more typically 10 or more amino acids in length. With respect to conformational epitopes, the length of the epitope-defining sequence can be subject to wide variations, since it is believed that these epitopes are formed by the three-dimensional shape of the antigen (e.g. folding). Thus, the amino acids defining the epitope can be relatively few in number, but widely dispersed along the length of the molecule being brought into the correct epitope conformation via folding. The portions of the antigen between the residues defining the epitope may not be critical to the conformational structure of the epitope. For example, deletion or substitution of these intervening sequences may not affect the conformational epitope provided sequences critical to epitope conformation are maintained (e.g. cysteines involved in disulfide bonding, glycosylation sites, etc.). A conformational epitope may also be formed by 2 or more essential regions of subunits of a homooligomer or heterooligomer.

The HCV antigens of the present invention comprise conformational epitopes from the E1 and/or E2 (envelope) domains of HCV. The E1 domain, which is believed to correspond to the viral envelope protein, is currently estimated to span amino acids 192-383 of the HCV polyprotein (Hijikata et al., 1991). Upon expression in a mammalian system (glycosylated), it is believed to have an approximate molecular weight of 35 kDa as determined via SDS-PAGE. The E2 protein, previously called NS1, is believed to span amino acids 384-809 or 384-746 (Grakoui et al., 1993) of the HCV polyprotein and to also be an envelope protein. Upon expression in a vaccinia system (glycosylated), it is believed to have an apparent gel molecular weight of about 72 kDa. It is understood that these protein endpoints are approximations (e.g. the carboxy terminal end of E2 could lie somewhere in the 730-820 amino acid region, e.g. ending at amino acid 730, 735, 740, 742, 744, 745, preferably 746, 747, 748, 750, 760, 770, 780, 790, 800, 809, 810, 820). The E2 protein may also be expressed together with the E1, P7 (aa 747-809), NS2 (aa 810-1026), NS4A (aa 1658-1711) or NS4B (aa 1712-1972). Expression together with these other HCV proteins may be important for obtaining the correct protein folding.

It is also understood that the isolates used in the examples section of the present invention were not intended to limit the scope of the invention and that any HCV isolate from type 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or any other new genotype of HCV is a suitable source of E1 and/or E2 sequence for the practice of the present invention.

The E1 and E2 antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments which are not missing sequence essential to the formation or retention of an epitope). Furthermore, the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of the conformational epitope of interest. The presence or absence of a conformational epitope can be readily determined though screening the antigen of interest with an antibody (polyclonal serum or monoclonal to the conformational epitope) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). In such screening using polyclonal antibodies, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest.

The HCV antigens of the present invention can be made by any recombinant method that provides the epitope of intrest. For example, recombinant intracellular expression in mammalian or insect cells is a preferred method to provide glycosylated E1 and/or E2 antigens in 'native' conformation as is the case for the natural HCV antigens. Yeast cells and mutant yeast strains (e.g. mnn 9 mutant (Kniskern et al., 1994) or glycosylation mutants derived by means of vanadate resistence selection (Ballou et al., 1991)) may be ideally suited for production of secreted high-mannose-type sugars; whereas proteins secreted from mammalian cells may contain modifications including galactose or sialic acids which may be undesirable for certain diagnostic or vaccine applications. However, it may also be possible and sufficient for certain applications, as it is known for proteins, to express the antigen in other recombinant hosts (such as *E. coli*) and renature the protein after recovery.

The term 'fusion polypeptide' intends a polypeptide in which the HCV antigen(s) are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by intervening amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV.

The term 'solid phase' intends a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent

means such as hydrophobic adsorption.

The term 'biological sample' intends a fluid or tissue of a mammalian individual (e.g. an anthropoid, a human) that commonly contains antibodies produced by the individual, more particularly antibodies against HCV. The fluid or tissue may also contain HCV antigen. Such components are known in the art and include, without limitation, blood, plasma, serum, urine, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells and myelomas. Body components include biological liquids. The term 'biological liquid' refers to a fluid obtained from an organism. Some biological fluids are used as a source of other products, such as clotting factors (e.g. Factor VIII;C), serum albumin, growth hormone and the like. In such cases, it is important that the source of biological fluid be free of contamination by virus such as HCV.

The term 'immunologically reactive' means that the antigen in question will react specifically with anti-HCV antibodies present in a body component from an HCV infected individual.

The term 'immune complex' intends the combination formed when an antibody binds to an epitope on an antigen.

'E1' as used herein refers to a protein or polypeptide expressed within the first 400 amino acids of an HCV polyprotein, sometimes referred to as the E, ENV or S protein. In its natural form it is a 35 kDa glycoprotein which is found in strong association with membranes. In most natural HCV strains, the E1 protein is encoded in the viral polyprotein following the C (core) protein. The E1 protein extends from approximately amino acid (aa) 192 to about aa 383 of the full-length polyprotein.

The term 'E1' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E1, and includes E1 proteins of genotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any other newly identified HCV type or subtype.

'E2' as used herein refers to a protein or polypeptide expressed within the first 900 amino acids of an HCV polyprotein, sometimes referred to as the NS1 protein. In its natural form it is a 72 kDa glycoprotein that is found in strong association with membranes. In most natural HCV strains, the E2 protein is encoded in the viral polyprotein following the E1 protein. The E2 protein extends from approximately amino acid position 384 to amino acid position 746, another form of E2 extends to amino acid position 809. The term 'E2' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E2. For example, insertions of multiple codons between codon 383 and 384, as

well as deletions of amino acids 384-387 have been reported by Kato et al. (1992).

'E1/E2' as used herein refers to an oligomeric form of envelope proteins containing at least one E1 component and at least one E2 component.

The term 'specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to all possible oligomeric forms of recombinantly expressed E1 and/or E2 envelope proteins which are not aggregates. E1 and/or E2 specific oligomeric envelope proteins are also referred to as homo-oligomeric E1 or E2 envelope proteins (see below).

The term 'single or specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to single monomeric E1 or E2 proteins (single in the strict sense of the word) as well as specific oligomeric E1 and/or E2 and/or E1/E2 recombinantly expressed proteins. These single or specific oligomeric envelope proteins according to the present invention can be further defined by the following formula $(E1)_x(E2)_y$ wherein x can be a number between 0 and 100, and y can be a number between o and 100, provided that x and y are not both 0. With x=1 and y=0 said envelope proteins include monomeric E1.

The term 'homo-oligomer' as used herein refers to a complex of E1 and/or E2 containing more than one E1 or E2 monomer, e.g. E1/E1 dimers, E1/E1/E1 trimers or E1/E1/E1/E1 tetramers and E2/E2 dimers, E2/E2/E2 trimers or E2/E2/E2/E2 tetramers, E1 pentamers and hexamers, E2 pentamers and hexamers or any higher-order homo-oligomers of E1 or E2 are all 'homo-oligomers' within the scope of this definition. The oligomers may contain one, two, or several different monomers of E1 or E2 obtained from different types or subtypes of hepatitis C virus including for example those described in an international application published under WO 94/25601 and European application No. 94870166.9 both by the present applicants. Such mixed oligomers are still homo-oligomers within the scope of this invention, and may allow more universal diagnosis, prophylaxis or treatment of HCV.

The term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition. The desired protein preferably comprises at least 40%, more preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, and most preferably at least about 95% of the total protein component. The composition may contain other compounds such as carbohydrates, salts, lipids, solvents, and the like, withouth affecting the determination of the percentage purity as used herein. An 'isolated' HCV protein intends an HCV protein composition that is at least 35% pure.

The term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins, vector-derived proteins or other HCV viral components. Usually these proteins are purified to homogeneity (at least 80% pure, preferably, 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods like SDS-PAGE and silver staining.

The term 'recombinantly expressed' used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below.

The term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within *Saccharomyces, Schizosaccharomyces*, *Kluyveromyces*, *Pichia* (e.g. *Pichia pastoris*), *Hansenula* (e.g. *Hansenula polymorpha*), *Yarowia, Schwaniomyces, Schizosaccharomyces*, *Zygosaccharomyces* and the like. *Saccharomyces cerevisiae*, *S. carlsbergensis* and *K. lactis* are the most commonly used yeast hosts, and are convenient fungal hosts.

The term 'prokaryotes' refers to hosts such as *E. coli*, *Lactobacillus*, *Lactococcus*, *Salmonella*, *Streptococcus*, *Bacillus subtilis* or *Streptomyces*. Also these hosts are contemplated within the present invention.

The term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like. Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. *Spodoptera frugiperda*). The host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like. Alternatively the host cells may also be transgenic animals.

The term 'polypeptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations

and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term 'recombinant polynucleotide or nucleic acid' intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation : (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

The term 'recombinant host cells', 'host cells', 'cells', 'cell lines', 'cell cultures', and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

The term 'replicon' is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

The term 'vector' is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame.

The term 'control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers. The term 'control sequences' is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.

The term 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.

The expression 'operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence 'operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

An 'open reading frame'. (ORF) is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons; this region may represent a portion of a coding sequence or a total coding sequence.

A 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include but is not limited to mRNA, DNA (including cDNA), and recombinant polynucleotide sequences.

As used herein, 'epitope' or 'antigenic determinant' means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 4 amino acids, and more usually, consists of at least 5 or 6 amino acids, sometimes the epitope consists of about 7 to 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amino acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof. Such equivalents also include strain, subtype (=genotype), or type(group)-specific variants, e.g. of the currently known sequences or strains belonging to genotypes 1a, 1b, 1c, 1d, 1e, 1f, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 5a, 5b, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 9a, 9b, 10a, or any other newly defined HCV (sub)type. It is to be understood that the amino acids constituting the epitope need not be part of a linear sequence, but may be interspersed by any number of amino acids, thus forming a conformational epitope.

The term 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. A 'vaccine' is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. A vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine.

The term 'therapeutic' refers to a composition capable of treating HCV infection.

The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary according to the application. For vaccine applications or for the generation of polyclonal antiserum / antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. It is also believed that effective amounts will be found within a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation. Preferred ranges of E1 and/or E2 and/or E1/E2 single or specific oligomeric envelope proteins for prophylaxis of HCV disease are 0.01 to 100 μg/dose, preferably 0.1 to 50 μg/dose. Several doses may be needed per individual in order to achieve a sufficient immune response and subsequent protection against HCV disease.

Detailed description of the invention

More particularly, the present invention contemplates a method for isolating or purifying recombinant HCV single or specific oligomeric envelope protein selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disculphide bond cleaving agent.

The essence of these 'single or specific oligomeric' envelope proteins of the invention is that they are free from contaminating proteins and that they are not disulphide bond linked with contaminants.

The proteins according to the present invention are recombinantly expressed in lower or higher eukaryotic cells or in prokaryotes. The recombinant proteins of the present invention are preferably glycosylated and may contain high-mannose-type, hybrid, or complex glycosylations. Preferentially said proteins are expressed from mammalian cell lines as discussed in detail in the Examples section, or in yeast such as in mutant yeast strains also as detailed in the Examples section.

The proteins according to the present invention may be secreted or expressed within components of the cell, such as the ER or the Golgi Apparatus. Preferably, however, the proteins of the present invention bear high-mannose-type glycosylations and are retained in

the ER or Golgi Apparatus of mammalian cells or are retained in or secreted from yeast cells, preferably secreted from yeast mutant strains such as the mnn9 mutant (Kniskern et al., 1994), or from mutants that have been selected by means of vanadate resistence (Ballou et al., 1991).

Upon expression of HCV envelope proteins, the present inventors could show that some of the free thiol groups of cysteines not involved in intra- or inter-molecular disulphide bridges, react with cysteines of host or expression-system-derived (e.g. vaccinia) proteins or of other HCV envelope proteins (single or oligomeric), and form aspecific intermolecular bridges. This results in the formation of 'aggregates' of HCV envelope proteins together with contaminating proteins. It was also shown in WO 92/08734 that 'aggregates' were obtained after purification, but it was not described which protein interactions were involved. In patent application WO 92/08734, recombinant E1/E2 protein expressed with the vaccinia virus system were partially purified as aggregates and only found to be 70% pure, rendering the purified aggregates not useful for diagnostic, prophylactic or therapeutic purposes.

Therefore, a major aim of the present invention resides in the separation of single or specific-oligomeric HCV envelope proteins from contaminating proteins, and to use the purified proteins (> 95% pure) for diagnostic, prophylactic and therapeutic purposes. To those purposes, the present inventors have been able to provide evidence that aggregated protein complexes ('aggregates') are formed on the basis of disulphide bridges and non-covalent protein-protein interactions. The present invention thus provides a means for selectively cleaving the disulphide bonds under specific conditions and for separating the cleaved proteins from contaminating proteins which greatly interfere with diagnostic, prophylactic and therapeutic applications. The free thiol groups may be blocked (reversibly or irreversibly) in order to prevent the reformation of disulphide bridges, or may be left to oxidize and oligomerize with other envelope proteins (see definition homo-oligomer). It is to be understood that such protein oligomers are essentially different from the 'aggregates' described in WO 92/08734 and WO 94/01778, since the level of contaminating proteins is undetectable.

Said disuphide bond cleavage may also be achieved by:

(1) performic acid oxidation by means of cysteic acid in which case the cysteine residues are modified into cysteic acid (Moore et al., 1963).

(2) Sulfitolysis (R-S-S-R $\rightarrow$ 2 R-SO^{-}_{3}) for example by means of sulphite (SO^{2-}_{3}) together with a proper oxidant such as Cu^{2+} in which case the cysteine is modified into S-sulpho-cysteine

(Bailey and Cole, 1959).

(3) Reduction by means of mercaptans, such as dithiotreitol (DDT), ß-mercapto-ethanol, cysteine, glutathione Red, ε-mercapto-ethylamine, or thioglycollic acid, of which DTT and ß-mercapto-ethanol are commonly used (Cleland, 1964), is the preferred method of this invention because the method can be performed in a water environment and because the cysteine remains unmodified.

(4) Reduction by means of a phosphine (e.g. Bu_3P) (Ruegg and Rudinger, 1977).

All these compounds are thus to be regarded as agents or means for cleaving disulphide bonds according to the present invention.

Said disulphide bond cleavage (or reducing) step of the present invention is preferably a partial disulphide bond cleavage (reducing) step (carried out under partial cleavage or reducing conditions).

A preferred disulphide bond cleavage or reducing agent according to the present invention is dithiothreitol (DTT). Partial reduction is obtained by using a low concentration of said reducing agent, i.e. for DTT for example in the concentration range of about 0.1 to about 50 mM, preferably about 0.1 to about 20 mM, preferably about 0.5 to about 10 mM, preferably more than 1 mM, more than 2 mM or more than 5 mM, more preferably about 1.5 mM, about 2.0 mM, about 2.5 mM, about 5 mM or about 7.5 mM.

Said disulphide bond cleavage step may also be carried out in the presence of a suitable detergent (as an example of a means for cleaving disulphide bonds or in combination with a cleaving agent) able to dissociate the expressed proteins, such as DecylPEG, EMPIGEN-BB, NP-40, sodium cholate, Triton X-100.

Said reduction or cleavage step (preferably a partial reduction or cleavage step) is carried out preferably in in the presence of (with) a detergent. A preferred detergent according to the present invention is Empigen-BB. The amount of detergent used is preferably in the range of 1 to 10 %, preferably more than 3%, more preferably about 3.5% of a detergent such as Empigen-BB.

A particularly preferred method for obtaining disulphide bond cleavage employs a combination of a classical disulphide bond cleavage agent as detailed above and a detergent (also as detailed above). As contemplated in the Examples section, the particular combination of a low concentration of DTT (1.5 to 7.5 mM) and about 3.5 % of Empigen-BB is proven to be a particularly preferred combination of reducing agent and detergent for the purification of recombinantly expressed E1 and E2 proteins. Upon gelfiltration chromatography, said partial

reduction is shown to result in the production of possibly dimeric E1 protein and separation of this E1 protein from contaminating proteins that cause false reactivity upon use in immunoassays.

It is, however, to be understood that also any other combination of any reducing agent known in the art with any detergent or other means known in the art to make the cysteines better accessible is also within the scope of the present invention, insofar as said combination reaches the same goal of disulphide bridge cleavage as the preferred combination examplified in the present invention.

Apart from reducing the disulphide bonds, a disulphide bond cleaving means according to the present invention may also include any disulphide bridge exchanging agents (competitive agent being either organic or proteinaeous, see for instance Creighton, 1988) known in the art which allows the following type of reaction to occur:

$$R1\ S - S\ R2 + R3\ SH \rightarrow R1\ S - S\ R3 + R2\ SH$$

* R1, R2: compounds of protein aggregates
* R3 SH: competitive agent (organic, proteinaeous)

The term 'disulphide bridge exchanging agent' is to be interpretated as including disulphide bond reforming as well as disulphide bond blocking agents.

The present invention also relates to methods for purifying or isolating HCV single or specific oligomeric envelelope proteins as set out above further including the use of any SH group blocking or binding reagent known in the art such as chosen from the following list:

- Glutathion
- 5,5'-dithiobis-(2-nitrobenzoic acid) or bis-(3-carboxy-4-nitrophenyl)-disulphide (DTNB or Ellman's reagent) (Elmann, 1959)
- N-ethylmaleimide (NEM; Benesch et al., 1956)
- N-(4-dimethylamino-3,5-dinitrophenyl) maleimide or Tuppy's maleimide which provides a color to the protein
- P-chloromercuribenzoate (Grassetti et al., 1969)
- 4-vinylpyridine (Friedman and Krull, 1969) can be liberated after reaction by acid hydrolysis
- acrylonitrile, can be liberated after reaction by acid hydrolysis (Weil and Seibles, 1961)
- NEM-biotin (e.g. obtained from Sigma B1267)
- 2,2'-dithiopyridine (Grassetti and Murray, 1967)

- 4,4'-dithiopyridine (Grassetti and Murray, 1967)
- 6,6'-dithiodinicontinic acid (DTDNA; Brown and Cunnigham, 1970)
- 2,2'-dithiobis-(5'-nitropyridine) (DTNP; US patent 3597160) or other dithiobis (heterocyclic derivative) compounds (Grassetti and Murray, 1969)

A survey of the publications cited shows that often different reagents for sulphydryl groups will react with varying numbers of thiol groups of the same protein or enzyme molecule. One may conclude that this variation in reactivity of the thiol groups is due to the steric environment of these groups, such as the shape of the molecule and the surrounding groups of atoms and their charges, as well as to the size, shape and charge of the reagent molecule or ion. Frequently the presence of adequate concentrations of denaturants such as sodium dodecylsulfate, urea or guanidine hydrochoride will cause sufficient unfolding of the protein molecule to permit equal access to all of the reagents for thiol groups. By varying the concentration of denaturant, the degree of unfolding can be controlled and in this way thiol groups with different degrees of reactivity may be revealed. Although up to date most of the work reported has been done with p-chloromercuribenzoate, N-ethylmaleimide and DTNB, it is likely that the other more recently developed reagents may prove equally useful. Because of their varying structures, it seems likely, in fact, that they may respond differently to changes in the steric environment of the thiol groups.

Alternatively, conditions such as low pH (preferably lower than pH 6) for preventing free SH groups from oxidizing and thus preventing the formation of large intermolecular aggregates upon recombinant expression and purification of E1 and E2 (envelope) proteins are also within the scope of the present invention.

A preferred SH group blocking reagent according to the present invention is N-ethylmaleimide (NEM). Said SH group blocking reagent may be administrated during lysis of the recombinant host cells and after the above-mentioned partial reduction process or after any other process for cleaving disulphide bridges. Said SH group blocking reagent may also be modified with any group capable of providing a detectable label and/or any group aiding in the immobilization of said recombinant protein to a solid substrate, e.g. biotinylated NEM.

Methods for cleaving cysteine bridges and blocking free cysteines have also been described in Darbre (1987), Means and Feeney (1971), and by Wong (1993).

A method to purify single or specific oligomeric recombinant E1 and/or E2 and/or E1/E2 proteins according to the present invention as defined above is further characterized as comprising the following steps:

- lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BB,
- recovering said HCV envelope protein by affinity purification for instance by means lectin-chromatography, such as lentil-lectin chromatography, or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, followed by,
- reduction or cleavage of disulphide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM, and,
- recovering the reduced HCV E1 and/or E2 and/or E1/E2 envelope proteins for instance by gelfiltration (size exclusion chromatography or molecular sieving) and possibly also by an additional Ni^{2+}-IMAC chromatography and desalting step.

It is to be understood that the above-mentioned recovery steps may also be carried out using any other suitable technique known by the person skilled in the art.

Preferred lectin-chromatography systems include *Galanthus nivalis* agglutinin (GNA) - chromatography, or *Lens culinaris* agglutinin (LCA) (lentil) lectin chromatography as illustrated in the Examples section. Other useful lectins include those recognizing high-mannose type sugars, such as *Narcissus pseudonarcissus* agglutinin (NPA), *Pisum sativum* agglutinin (PSA), or *Allium ursinum* agglutinin (AUA).

Preferably said method is usable to purify single or specific oligomeric HCV envelope protein produced intracellularly as detailed above.

For secreted E1 or E2 or E1/E2 oligomers, lectins binding complex sugars such as *Ricinus communis* agglutinin I (RCA I), are preferred lectins.

The present invention more particularly contemplates essentially purified recombinant HCV single or specific oligomeric envelope proteins, selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized as being isolated or purified by a method as defined above.

The present invention more particularly relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant mammalian cells such as vaccinia.

The present invention also relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant yeast cells.

The present invention equally relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant bacterial (prokaryotic) cells.

The present invention also contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single or specific oligomeric E1 and/or E2 and/or E1/E2 of the invention.

Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E1 of the invention.

Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E2 of the invention.

The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector sequence may be attached to a signal sequence. Said signal sequence may be that from a non-HCV source, e.g. the IgG or tissue plasminogen activator (tpa) leader sequence for expression in mammalian cells, or the α-mating factor sequence for expression into yeast cells, but particularly preferred constructs according to the present invention contain signal sequences appearing in the HCV genome before the respective start points of the E1 and E2 proteins. The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector may also include deletions e.g. of the hydrophobic domain(s) as illustrated in the examples section, or of the E2 hypervariable region I.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 1 and 192 and ending in the region between positions 250 and 400 of the HCV polyprotein, more preferably ending in the region between positions 250 and 341, even more preferably ending in the region between positions 290 and 341 for expression of the HCV single E1 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA seqment encoding part of the HCV polyprotein starting in the region between positions 117 and 192, and ending at any position in the region between positions 263 and 326, for expression of HCV single E1 protein. Also within the scope of the present invention are forms that have the first

hydrophobic domain deleted (positions 264 to 293 plus or minus 8 amino acids), or forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 290 and 406 and ending in the region between positions 600 and 820 of the HCV polyprotein, more preferably starting in the region between positions 322 and 406, even more preferably starting in the region between positions 347 and 406, even still more preferably starting in the region between positions 364 and 406 for expression of the HCV single E2 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA seqment encoding the polyprotein starting in the region between positions 290 and 406, and ending at any position of positions 623, 650, 661, 673, 710, 715, 720, 746 or 809, for expression of HCV single E2 protein. Also within the scope of the present invention are forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

A variety of vectors may be used to obtain recombinant expression of HCV single or specific oligomeric envelope proteins of the present invention. Lower eukaryotes such as yeasts and glycosylation mutant strains are typically transformed with plasmids, or are transformed with a recombinant virus. The vectors may replicate within the host independently, or may integrate into the host cell genome.

Higher eukaryotes may be transformed with vectors, or may be infected with a recombinant virus, for example a recombinant vaccinia virus. Techniques and vectors for the insertion of foreign DNA into vaccinia virus are well known in the art, and utilize, for example homologous recombination. A wide variety of viral promoter sequences, possibly terminator sequences and poly(A)-addition sequences, possibly enhancer sequences and possibly amplification sequences, all required for the mammalian expression, are available in the art. Vaccinia is particularly preferred since vaccinia halts the expression of host cell proteins. Vaccinia is also very much preferred since it allows the expression of E1 and E2 proteins of HCV in cells or individuals which are immunized with the live recombinant vaccinia virus. For vaccination of humans the avipox and Ankara Modified Virus (AMV) are particularly useful vectors.

Also known are insect expression transfer vectors derived from baculovirus

Autographa californica nuclear polyhedrosis virus (AcNPV), which is a helper-independent viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive the expression of heterologous genes. Different vectors as well as methods for the introduction of heterologous DNA into the desired site of baculovirus are available to the man skilled in the art for baculovirus expression. Also different signals for posttranslational modification recognized by insect cells are known in the art.

Also included within the scope of the present invention is a method for producing purified recombinant single or specific oligomeric HCV E1 or E2 or E1/E2 proteins, wherein the cysteine residues involved in aggregates formation are replaced at the level of the nucleic acid sequence by other residues such that aggregate formation is prevented. The recombinant proteins expressed by recombinant vectors caarying such a mutated E1 and/or E2 protein encoding nucleic acid are also within the scope of the present invention.

The present invention also relates to recombinant E1 and/or E2 and/or E1/E2 proteins characterized in that at least one of their glycosylation sites has been removed and are consequently termed glycosylation mutants. As explained in the Examples section, different glycosylation mutants may be desired to diagnose (screening, confirmation, prognosis, etc.) and prevent HCV disease according to the patient in question. An E2 protein glycosylation mutant lacking the GLY4 has for instance been found to improve the reactivity of certain sera in diagnosis. These glycosylation mutants are preferably purified according to the method disclosed in the present invention. Also contemplated within the present invention are recombinant vectors carrying the nucleic acid insert encoding such a E1 and/or E2 and/or E1/E2 glycosylation mutant as well as host cells tranformed with such a recombinant vector.

The present invention also relates to recombinant vectors including a polynucleotide which also forms part of the present invention. The present invention relates more particularly to the recombinant nucleic acids as represented in SEQ ID NO 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

The present invention also contemplates host cells transformed with a recombinant vector as defined above, wherein said vector comprises a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as defined above in addition to a regulatory sequence operably linked to said HCV E1 and/or E2 and/or E1/E2 sequence and capable of regulating the expression of said HCV E1 and/or E2 and/or E1/E2 protein.

Eukaryotic hosts include lower and higher eukaryotic hosts as described in the definitions section. Lower eukaryotic hosts include yeast cells well known in the art. Higher eukaryotic hosts mainly include mammalian cell lines known in the art and include many immortalized cell lines available from the ATCC, inluding HeLa cells, Chinese hamster ovary (CHO) cells, Baby hamster kidney (BHK) cells, PK15, RK13 and a number of other cell lines.

The present invention relates particularly to a recombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell as defined above containing a recombinany vector as defined above. These recombinant proteins are particularly purified according to the method of the present invention.

A preferred method for isolating or purifying HCV envelope proteins as defined above is further characterized as comprising at least the following steps:

- growing a host cell as defined above transformed with a recombinant vector according to the present invention or with a known recombinant vector expressing E1 and/or E2 and/or E1/E2 HCV envelope proteins in a suitable culture medium,
- causing expression of said vector sequence as defined above under suitable conditions, and,
- lysing said transformed host cells, preferably in the presence of a SH group blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BB,
- recovering said HCV envelope protein by affinity purification such as by means of lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin or GNA, followed by,
- incubation of the eluate of the previous step with a disulphide bond cleavage means, such as DTT, preferably followed by incubation with an SH group blocking agent, such as NEM or Biotin-NEM, and,
- isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins such as by means of gelfiltration and possibly also by a subsequent Ni^{2+}-IMAC chromatography followed by a desalting step.

As a result of the above-mentioned proces, E1 and/or E2 and/or E1/E2 proteins may be produced in a form which elute differently from the large aggregates containing vector-derived components and/or cell components in the void volume of the gelfiltration column or

the IMAC column as illustrated in the Examples section. The disulphide bridge cleavage step advantageously also eliminates the false reactivity due to the presence of host and/or expression-system-derived proteins. The presence of NEM and a suitable detergent during lysis of the cells may already partly or even completely prevent the aggregation between the HCV envelope proteins and contaminants.

Ni^{2+}-IMAC chromatography followed by a desalting step is preferably used for contructs bearing a $(His)_6$ as described by Janknecht et al., 1991, and Hochuli et al., 1988.

The present invention also relates to a method for producing monoclonal antibodies in small animals such as mice or rats, as well as a method for screening and isolating human B-cells that recognize anti-HCV antibodies, using the HCV single or specific oligomeric envelope proteins of the present invention.

The present invention further relates to a composition comprising at least one of the following E1 peptides as listed in Table 3 and described elsewhere herein:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

The present invention also relates to a composition comprising at least one of the following E2 peptides as listed in Table 3:

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 416 of the E2 region (epitope A, recognized by monoclonal antibody 2F10H10, see Figure 19),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 566 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C; recognized by monoclonal antibody 16A6E7, see Figure 19).

The present invention also relates to a composition comprising at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1 and 8G10D1H9,

epitope G recognized by monoclonal antibody 9G3E6,

epitope H (or C) recognized by monoclonal antibody 10D3C4 and 4H6B2, or,

epitope I recognized by monoclonal antibody 17F2C2.

The present invention also relates to an E1 or E2 specific antibody raised upon immunization with a peptide or protein composition, with said antibody being specifically reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

The present invention also relates to an E1 or E2 specific antibody screened from a variable chain library in plasmids or phages or from a population of human B-cells by means of a process known in the art, with said antibody being reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

The E1 or E2 specific monoclonal antibodies of the invention can be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly from a mouse or rat, immunized against the HCV polypeptides or peptides according to the invention, as defined above on the one hand, and of cells of a myeloma cell line on the other hand, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing the polypeptides which has been initially used for the immunization of the animals.

The antibodies involved in the invention can be labelled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

The monoclonal antibodies according to this preferred embodiment of the invention may be humanized versions of mouse monoclonal antibodies made by means of recombinant

DNA technology, departing from parts of mouse and/or human genomic DNA sequences coding for H and L chains from cDNA or genomic clones coding for H and L chains.

Alternatively the monoclonal antibodies according to this preferred embodiment of the invention may be human monoclonal antibodies. These antibodies according to the present embodiment of the invention can also be derived from human peripheral blood lymphocytes of patients infected with HCV, or vaccinated against HCV. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice (for recent review, see Duchosal et al., 1992).

The invention also relates to the use of the proteins or peptides of the invention, for the selection of recombinant antibodies by the process of repertoire cloning (Persson et al., 1991).

Antibodies directed to peptides or single or specific oligomeric envelope proteins derived from a certain genotype may be used as a medicament, more particularly for incorporation into an immunoassay for the detection of HCV genotypes (for detecting the presence of HCV E1 or E2 antigen), for prognosing/monitoring of HCV disease, or as therapeutic agents.

Alternatively, the present invention also relates to the use of any of the above-specified E1 or E2 specific monoclonal antibodies for the preparation of an immunoassay kit for detecting the presence of E1 or E2 antigen in a biological sample, for the preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

The present invention also relates to the a method for *in vitro* diagnosis or detection of HCV antigen present in a biological sample, comprising at least the following steps :

(i) contacting said biological sample with any of the E1 and/or E2 specific monoclonal antibodies as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,

(ii) removing unbound components,

(iii) incubating the immune complexes formed with heterologous antibodies, which specifically bind to the antibodies present in the sample to be analyzed, with said heterologous antibodies having conjugated to a detectable label under appropriate conditions,

(iv) detecting the presence of said immune complexes visually or mechanically

(e.g. by means of densitometry, fluorimetry, colorimetry).

The present invention also relates to a kit for in vitro diagnosis of HCV antigen present in a biological sample, comprising:

- at least one monoclonal antibody as defined above, with said antibody being preferentially immobilized on a solid substrate,
- a buffer or components necessary for producing the buffer enabling binding reaction between these antibodies and the HCV antigens present in the biological sample,
- a means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also including an automated scanning and interpretation device for inferring the HCV antigens present in the sample from the observed binding pattern.

The present invention also relates to a composition comprising E1 and/or E2 and/or E1/E2 recombinant HCV proteins purified according to the method of the present invention or a composition comprising at least one peptides as specified above for use as a medicament.

The present invention more particularly relates to a composition comprising at least one of the above-specified envelope peptides or a recombinant envelope protein composition as defined above, for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administering a sufficient amount of the composition possibly accompanied by pharmaceutically acceptable adjuvant(s), to produce an immune response.

More particularly, the present invention relates to the use of any of the compositions as described here above for the preparation of a vaccine as described above.

Also, the present invention relates to a vaccine composition for immunizing a mammal, preferably humans, against HCV, comprising HCV single or specific oligomeric proteins or peptides derived from the E1 and/or the E2 region as described above.

Immunogenic compositions can be prepared according to methods known in the art. The present compositions comprise an immunogenic amount of a recombinant E1 and/or E2 and/or E1/E2 single or specific oligomeric proteins as defined above or E1 or E2 peptides as defined above, usually combined with a pharmaceutically acceptable carrier, preferably further comprising an adjuvant.

The single or specific oligomeric envelope proteins of the present invention, either E1

and/or E2 and/or E1/E2, are expected to provide a particularly useful vaccine antigen, since the formation of antibodies to either E1 or E2 may be more desirable than to the other envelope protein, and since the E2 protein is cross-reactive between HCV types and the E1 protein is type-specific. Cocktails including type 1 E2 protein and E1 proteins derived from several genotypes may be particularly advantageous. Cocktails containing a molar excess of E1 versus E2 or E2 versus E1 may also be particularly useful. Immunogenic compositions may be administered to animals to induce production of antibodies, either to provide a source of antibodies or to induce protective immunity in the animal.

Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers; and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to : aluminim hydroxide (alum), N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP) as found in U.S. Patent No. 4,606,918, N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE) and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Any of the 3 components MPL, TDM or CWS may also be used alone or combined 2 by 2. Additionally, adjuvants such as Stimulon (Cambridge Bioscience, Worcester, MA) or SAF-1 (Syntex) may be used. Further, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA) may be used for non-human applications and research purposes.

The immunogenic compositions typically will contain pharmaceutically acceptable vehicles, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, preservatives, and the like, may be included in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect. The E1 and E2 proteins may also be

incorporated into Immune Stimulating Complexes together with saponins, for example Quil A (ISCOMS).

Immunogenic compositions used as vaccines comprise a 'sufficient amount' or 'an immunologically effective amount' of the envelope proteins of the present invention, as well as any other of the above mentioned components, as needed. 'Immunologically effective amount', means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment, as defined above. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, the strain of infecting HCV, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vary from 0.01 to 1000 μg/dose, more particularly from 0.1 to 100 μg/dose.

The single or specific oligomeric envelope proteins may also serve as vaccine carriers to present homologous (e.g. T cell epitopes or B cell epitopes from the core, NS2, NS3, NS4 or NS5 regions) or heterologous (non-HCV) haptens, in the same manner as Hepatitis B surface antigen (see European Patent Application 174,444). In this use, envelope proteins provide an immunogenic carrier capable of stimulating an immune response to haptens or antigens conjugated to the aggregate. The antigen may be conjugated either by conventional chemical methods, or may be cloned into the gene encoding E1 and/or E2 at a location corresponding to a hydrophilic region of the protein. Such hydrophylic regions include the V1 region (encompassing amino acid positions 191 to 202), the V2 region (encompassing amino acid positions 213 to 223), the V3 region (encompassing amino acid positions 230 to 242), the V4 region (encompassing amino acid positions 230 to 242), the V5 region (encompassing amino acid positions 294 to 303) and the V6 region (encompassing amino acid positions 329 to 336). Another useful location for insertion of haptens is the hydrophobic region (encompassing approximately amino acid positions 264 to 293). It is shown in the present invention that this region can be deleted without affecting the reactivity of the deleted E1 protein with antisera. Therefore, haptens may be inserted at the site of the deletion.

The immunogenic compositions are conventionally administered parenterally,

typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

The present invention also relates to a composition comprising peptides or polypeptides as described above, for *in vitro* detection of HCV antibodies present in a biological sample.

The present invention also relates to the use of a composition as described above for the preparation of an immunoassay kit for detecting HCV antibodies present in a biological sample.

The present invention also relates to a method for *in vitro* diagnosis of HCV antibodies present in a biological sample, comprising at least the following steps :

(i) contacting said biological sample with a composition comprising any of the envelope peptide or proteins as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex, wherein said peptide or protein can be a biotinylated peptide or protein which is covalently bound to a solid substrate by means of streptavidin or avidin complexes,

(ii) removing unbound components,

(iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies having conjugated to a detectable label under appropriate conditions,

(iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry).

Alternatively, the present invention also relates to competition immunoassay formats in which recombinantly produced purified single or specific oligomeric protein E1 and/or E2 and/or E1/E2 proteins as disclosed above are used in combination with E1 and/or E2 peptides in order to compete for HCV antibodies present in a biological sample.

The present invention also relates to a kit for determining the presence of HCV antibodies, in a biological sample, comprising :

- at least one peptide or protein composition as defined above, possibly in combination with other polypeptides or peptides from HCV or other types of HCV, with said peptides or proteins being preferentially immobilized on a

solid substrate, more preferably on different microwells of the same ELISA plate, and even more preferentially on one and the same membrane strip,

- a buffer or components necessary for producing the buffer enabling binding reaction between these polypeptides or peptides and the antibodies against HCV present in the biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also including an automated scanning and interpretation device for inferring the HCV genotypes present in the sample from the observed binding pattern.

The immunoassay methods according to the present invention utilize single or specific oligomeric antigens from the E1 and/or E2 domains that maintain linear (in case of peptides) and conformational epitopes (single or specific oligomeric proteins) recognized by antibodies in the sera from individuals infected with HCV. It is within the scope of the invention to use for instance single or specific oligomeric antigens, dimeric antigens, as well as combinations of single or specific oligomeric antigens. The HCV E1 and E2 antigens of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies. Of course, a format that denatures the HCV conformational epitope should be avoided or adapted. A common feature of all of these assays is that the antigen is contacted with the body component suspected of containing HCV antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strenght using an excess of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen.

Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

The immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type. In a heterogeneous format, the

polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride (known as Immunolon™), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech Immunolon™ 1 or Immunlon™ 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used in the heterogeneous format. The solid support containing the antigenic polypeptides is typically washed after separating it from the test sample, and prior to detection of bound antibodies. Both standard and competitive formats are know in the art.

In a homogeneous format, the test sample is incubated with the combination of antigens in solution. For example, it may be under conditions that will precipitate any antigen-antibody complexes which are formed. Both standard and competitive formats for these assays are known in the art.

In a standard format, the amount of HCV antibodies in the antibody-antigen complexes is directly monitored. This may be accomplished by determining whether labeled anti-xenogeneic (e.g. anti-human) antibodies which recognize an epitope on anti-HCV antibodies will bind due to complex formation. In a competitive format, the amount of HCV antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled antibody (or other competing ligand) in the complex.

Complexes formed comprising anti-HCV antibody (or in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabeled HCV antibodies in the complex may be detected using a conjugate of anti-xenogeneic Ig complexed with a label (e.g. an enzyme label).

In an immunoprecipitation or agglutination assay format the reaction between the HCV antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-HCV antibody is present in the test specimen, no visible precipitate is formed.

There currently exist three specific types of particle agglutination (PA) assays. These assays are used for the detection of antibodies to various antigens when coated to a support. One type of this assay is the hemagglutination assay using red blood cells (RBCs) that are sensitized by passively adsorbing antigen (or antibody) to the RBC. The addition of specific

antigen antibodies present in the body component, if any, causes the RBCs coated with the purified antigen to agglutinate.

To eliminate potential non-specific reactions in the hemagglutination assay, two artificial carriers may be used instead of RBC in the PA. The most common of these are latex particles. However, gelatin particles may also be used. The assays utilizing either of these carriers are based on passive agglutination of the particles coated with purified antigens.

The HCV single or specifife oligomeric E1 and/or E2 and/or E1/E2 antigens of the present invention comprised of conformational epitopes will typically be packaged in the form of a kit for use in these immunoassays. The kit will normally contain in separate containers the native HCV antigen, control antibody formulations (positive and/or negative), labeled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly. The native HCV antigen may be already bound to a solid matrix or separate with reagents for binding it to the matrix. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.

Immunoassays that utilize the native HCV antigen are useful in screening blood for the preparation of a supply from which potentially infective HCV is lacking. The method for the preparation of the blood supply comprises the following steps. Reacting a body component, preferably blood or a blood component, from the individual donating blood with HCV E1 and/or E2 proteins of the present invention to allow an immunological reaction between HCV antibodies, if any, and the HCV antigen. Detecting whether anti-HCV antibody - HCV antigen complexes are formed as a result of the reacting. Blood contributed to the blood supply is from donors that do not exhibit antibodies to the native HCV antigens, E1 or E2.

In cases of a positive reactivity to the HCV antigen, it is preferable to repeat the immunoassay to lessen the possibility of false positives. For example, in the large scale screening of blood for the production of blood products (e.g. blood transfusion, plasma, Factor VIII, immunoglobulin, etc.) 'screening' tests are typically formatted to increase sensitivity (to insure no contaminated blood passes) at the expense of specificity; i.e. the false-positive rate is increased. Thus, it is typical to only defer for further testing those donors who are 'repeatedly reactive'; i.e. positive in two or more runs of the immunoassay on the donated sample. However, for confirmation of HCV-positivity, the 'confirmation' tests are typically formatted to increase specificity (to insure that no false-positive samples are

confirmed) at the expense of sensitivity. Therefore the purification method described in the present invention for E1 and E2 will be very advantageous for including single or specific oligomeric envelope proteins into HCV diagnostic assays.

The solid phase selected can include polymeric or glass beads, nitrocellulose, microparticles, microwells of a reaction tray, test tubes and magnetic beads. The signal generating compound can include an enzyme, a luminescent compound, a chromogen, a radioactive element and a chemiluminescent compound. Examples of enzymes include alkaline phosphatase, horseradish peroxidase and beta-galactosidase. Examples of enhancer compounds include biotin, anti-biotin and avidin. Examples of enhancer compounds binding members include biotin, anti-biotin and avidin. In order to block the effects of rheumatoid factor-like substances, the test sample is subjected to conditions sufficient to block the effect of rheumatoid factor-like substances. These conditions comprise contacting the test sample with a quantity of anti-human IgG to form a mixture, and incubating the mixture for a time and under conditions sufficient to form a reaction mixture product substantially free of rheumatoid factor-like substance.

The present invention further contemplates the use of E1 proteins, or parts thereof, more particularly HCV single or specific oligomeric E1 proteins as defined above, for *in vitro* monitoring HCV disease or prognosing the response to treatment (for instance with Interferon) of patients suffering from HCV infection comprising:

- incubating a biological sample from a patient with hepatitis C infection with an E1 protein or a suitable part thereof under conditions allowing the formation of an immunological complex,
- removing unbound components,
- calculating the anti-E1 titers present in said sample (for example at the start of and/or during the course of (interferon) therapy),
- monitoring the natural course of HCV disease, or prognosing the response to treatment of said patient on the basis of the amount anti-E1 titers found in said sample at the start of treatment and/or during the course of treatment.

Patients who show a decrease of 2, 3, 4, 5, 7, 10, 15, or preferably more than 20 times of the initial anti-E1 titers could be concluded to be long-term, sustained responders to HCV therapy, more particularly to interferon therapy. It is illustrated in the Examples section, that an anti-E1 assay may be very useful for prognosing long-term response to IFN treatment, or to treatment of Hepatitis C virus disease in general.

More particularly the following E1 peptides as listed in Table 3 were found to be useful for *in vitro* monitoring HCV disease or prognosing the response to interferon treatment of patients suffering from HCV infection:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region.

It is to be understood that smaller fragments of the above-mentioned peptides also fall within the scope of the present invention. Said smaller fragments can be easily prepared by chemical synthesis and can be tested for their ability to be used in an assay as detailed above and in the Examples section.

The present invention also relates to a kit for monitoring HCV disease or prognosing the response to treatment (for instance to interferon) of patients suffering from HCV infection comprising:

- at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide as defined above,
- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

It is to be understood that also E2 protein and peptides according to the present invention can be used to a certain degree to monitor/prognose HCV treatment as indicated

above for the E1 proteins or peptides because also the anti-E2 levels decrease in comparison to antibodies to the other HCV antigens. It is to be understood, however, that it might be possible to determine certain epitopes in the E2 region which would also be suited for use in an test for monitoring/prognosing HCV disease.

The present invention also relates to a serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, comprising at least the following steps :

(i) contacting the biological sample to be analyzed for the presence of HCV antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions or at least one of the E1 or E2 peptide compositions as defined above, preferantially in an immobilized form under appropriate conditions which allow the formation of an immune complex,

(ii) removing unbound components,

(iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions,

(iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

It is to be understood that the compositions of proteins or peptides used in this method are recombinantly expressed type-specific envelope proteins or type-specific peptides.

The present invention further relates to a kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV comprising:

- at least one E1 and/or E2 and/or E1/E2 protein or E1 or E2 peptide, as defined above,
- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding

reaction,

- possibly also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

The present invention also relates to the use of a peptide or protein composition as defined above, for immobilization on a solid substrate and incorporation into a reversed phase hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method as defined above. Combination with other type-specific antigens from other HCV polyprotein regions also lies within the scope of the present invention.

The present invention provides a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from E1 and/or E2 and/or E1/E2 proteins which have been produced by a recombinant process comprising contacting said proteins with a disulphide bond cleavage or reducing agent. The contacting of the method of the invention may be carried out under partial cleavage or reducing conditions. Preferably, the disulphide bond cleavage agent is dithiothreitol (DTT), preferably in a concentration range of 0.1 to 50 mM, preferably 0.1 to 20 mM, more preferably 0.5 to 10 mM. Alternatively, the disulphide bond cleavage agent may be a detergent, such as Empigen-BB (which is a mixture containing N-Docecyl-N,N-dimethylglycine as a major component), preferably at a concentration of 1 to 10%, more preferably at a concentration of 3.5%. Mixtures of detergents, disulphide bond cleavage agents and/or reducing agents may also be used. In one embodiment, disulphide bond reformation is prevented with an SH group blocking agent, such as N-ethylmaleimide (NEM) or a derivative thereof. In a preferred embodiment, the disulphide bond reformation is blocked by use of low pH conditions.

The present invention further provides a method as described herein, further involving the following steps: lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, optionally in the presence of an SH blocking agent such as N-ethylmaleimide (NEM); recovering said HCV envelope proteins by affinity purification such as by means of lectin-chromatography, such as lentil-lectin chromatography, or by means of immunoaffinity using anti-E1 and/or anti-E2 specific monoclonal antibodies; reducing or cleaving of the disulfide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH blocking agent, such as NEM or Biotin-NEM; and, recovering the reduced E1 and/or E2 and/or E1/E2 envelope proteins by gelfiltration

and optionally additionally by a subsequent Ni^{2+}-IMAC chromatography and desalting step.

The present invention provides a composition containing substantially isolated and/or purified, and/or isolated and/or purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from E1 and/or E2 and/or E1/E2, which have preferably been isolated from the methods described herein. In a preferred embodiment, the recombinant HCV envelope proteins of the invention have been expressed in recombinant mammalian cells, such as vaccinia, recombinant yeast cells.

The present invention provides a recombinant vector containing a vector sequence, a prokaryotic, eukaryotic or viral promoter sequence and a nucleotide sequence allowing the expression of a single or specific oligomeric E1 and/or E2 and/or E1/E2 protein, in operable combination. In one embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein starting in the region between amino acid positions 1 and 192 and ending in the region between amino acid positions 250 and 400, more particularly ending in the region between positions 250 and 341, even more preferably ending in the region between position 290 and 341. In another embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein starting in the region between amino acid positions 117 and 192 and ending in the region between amino acid positions 263 and 400, more particularly ending in the region between positions 250 and 326. In yet another embodiment, the nucleotide sequence of the vector encodes a single HCV E1 protein bearing a deletion of the first hydrophobic domain between positions 264 to 293, plus or minus 8 amino acids. In a further embodiment, the nucleotide sequence of the vector encodes a single HCV E2 protein starting in the region between amino acid positions 290 and 406 and ending in the region between amino acid positions 600 and 820, more particularly starting in the region between positions 322 and 406, even more preferably starting in the region between position 347 and 406 and most preferably starting in the region between positions 364 and 406; and preferably ending at any of amino acid positions 623, 650, 661, 673, 710, 715, 720, 746 or 809. The vector of the present invention, in one embodiment, contains a 5'-terminal ATG codon and a 3'-terminal stop codon operably linked to the nucleotide sequence. The vector further contains, in one embodiment, a nucleotide sequence further containing at a factor Xa cleavage site and/or 3 to 10, preferably 6, histidine codons added 3'-terminally to the coding region. The vector of the present invention optionally contains a nucleotide sequence wherein at least one of

the glycosylation sites present in the E1 or E2 proteins has been removed at the nucleic acid level.

The present invention provides a nucleic acid containing any one of SEQ ID N0s: 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof. The vector of the invention may preferably contain a nucleotide sequence containing a nucleic acid containing any one of SEQ ID N0s: 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

The composition of the present invention further contains recombinant HCV envelope proteins which have been expressed or are the expression product of a vector described herein.

The present invention provides a host cell transformed with at least one recombinant vector as described herein, wherein the vector contains a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as described herein in addition to a regulatory sequence operable in the host cell and capable of regulating expression of the HCV E1 and/or E2 and/or E1/E2 protein. Moreover, the present invention provides a ecombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell of the invention.

The present invention further provides a method as described herein and containing the following steps: growing a host cell as described herein which has been transformed with a recombinant vector as described herein in a suitable culture medium; causing expression of the vector nucleotide sequence of the vector, as described herein under suitable conditions; lysing the transformed host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM); recovering the HCV envelope protein by affinity purification by means of for instance lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin, followed by, incubation of the eluate of the previous step with a disulphide bond cleavage agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM; and, isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins by means of gelfiltration and possibly also by means of an additional Ni^{2+}-IMAC chromatography and desalting step.

The present invention provides a composition containing at least one of the following E1 and/or E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1

V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region.

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 416 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 566 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C).

The present invention provides a composition containing at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1, and 8G10D1H9,

epitope G recognized by monoclonal antibody 9G3E6,

epitope H (or C) recognized by monoclonal antibodies 10D3C4 and 4H6B2,

epitope I recognized by monoclonal antibody 17F2C2.

The present invention provides an E1 and/or E2 specific monoclonal antibody raised upon immunization with a composition as described herein. The antibodies of the present invention may be used, for example, as a medicament, for incorporation into an immunoassay kit for detecting the presence of HCV E1 or E2 antigen, for prognosis/monitoring of disease or for HCV therapy. The present invention provides for the use of an E1 and/or E2 specific monoclonal antibody as described herein for the preparation of an immunoassay kit for detecting HCV E1 or E2 antigens, for the preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

The present invention provides a method for in vitro diagnosis of HCV antigen present in a biological sample, containing at least the following steps:

(i) contacting said biological sample with an E1 and/or E2 specific monoclonal antibody as described herein, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,

(ii) removing unbound components,

(iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions,

(iv) detecting the presence of the immune complexes visually or mechanically.

The present invention provides a kit for determining the presence of HCV antigens present in a biological sample, which includes at least the following: at least one E1 and/or E2 specific monoclonal antibody as described herein, preferably in an immobilized form on a solid substrate, a buffer or components necessary for producing the buffer enabling binding reaction between these antibdodies and the HCV antigens present in a biological sample, and optionally a means for detecting the immune complexes formed in the preceding binding reaction.

The composition of the present invention may be provided in the form of a medicament.

The present invention provides a composition, as described herein for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administrating an effective amount of said composition being optionally accompanied by pharmaceutically acceptable adjuvants, to produce an immune response.

The present invention provides a method of using the composition, as described

herein, for the preparation of a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administrating an effective amount of said composition, optionally accompanied by pharmaceutically acceptable adjuvants, to produce an immune response.

The present invention provides a vaccine composition for immunzing a mammal, preferably humans, against HCV, which contains an effective amount of a composition containing an E1 and/or E2 containing composition as described herein, optionally also accompanied by pharmaceutically acceptable adjuvants.

The composition of the present invention may be provided in a form for *in vitro* detection of HCV antibodies present in a biological sample. The present invention also provides a method of preparing an immunoassay kit for detecting HCV antibodies present in a biological sample and a method of detecting HCV antibodies present in a biological sample using the kit of the invention to diagnose HCV antibodies present in a biological sample. Such a method of the present invention includes at least the following steps:

(i) contacting said biological sample with a composition as described herein, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex with HCV antibodies present in the biological sample,

(ii) removing unbound components,

(iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions,

(iv) detecting the presence of the immune complexes visually or mechanically.

The present invention provides a kit for determining the presence of HCV antibodies present in a biological sample, containing: at least one peptide or protein composition as described herein, preferably in an immobilized form on a solid substrate; a buffer or components necessary for producing the buffer enabling binding reaction between these proteins or peptides and the antibodies against HCV present in the biological sample; and, optionally, a means for detecting the immune complexes formed in the preceding binding reaction.

The present invention provides a method of *in vitro* monitoring HCV disease or diagnosing the response of a patient suffering from HCV infection to treatment, preferably with interferon, the method including: incubating a biological sample from the patient with HCV infection with an E1 protein or a suitable part thereof under conditions allowing the

formation of an immunological complex; removing unbound components; calculating the anti-E1 titers present in the sample at the start of and during the course of treatment; monitoring the natural course of HCV disease, or diagnosing the response to treatment of the patient on the basis of the amount anti-E1 titers found in the sample at the start of treatment and/or during the course of treatment.

The present invention provides a kit for monitoring HCV disease or prognosing the response to treatment, particularly with interferon, of patients suffering from HCV infection, wherein the kit contains: at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide as described herein; a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample; and optionally, means for detetecting the immune complexes formed in the preceding binding reaction, optionally, also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

The present invention provides a serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, including at least the following steps: (i) contacting the biological sample to be analyzed for the presence of HCV antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions as described herein or at least one of the E1 or E2 peptide compositions described herein, preferentially in an immobilized form under appropriate conditions which allow the formation of an immune complex; (ii) removing unbound components; (iii) incubating the immune complexes formed with heterologous antibodies, with the heterologous antibodies being conjugated to a detectable label under appropriate conditions; and optionally, (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

The present invention provides a kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV containing: at least one E1 and/or E2 and/or E1/E2 protein as described herein or an E1 or E2 peptide as described herein; a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or

peptides and the anti-E1 antibodies present in a biological sample; optionally, means for detecting the immune complexes formed in the preceding binding reaction, optionally, also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

The present invention provides a peptide or protein composition as described herein, for immobilization on a solid substrate and incorporation into a reversed phase hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method as described herein.

The present invention provides a therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, containing or comprising a therapeutically effective amount of: a composition containing at least one purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and E2 proteins, an E1/E2 protein complex formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a pharmaceutically acceptable adjuvant. Another therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, of the invention may be comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

The HCV envelope proteins of the vaccine, or more particularly the HCV vaccine, of the present invention are optionally produced by recombinant mammalian cells, by recombinant yeast cells, or by or via a recombinant virus. The invention provides a therapeutic vaccine composition, such as a therapeutic HCV vaccine composition, containing or comprising a therapeutically effective amount of a composition comprising at least one of the following E1 and E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope

B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 418 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 586 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C),

IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),

IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),

IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),

IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),

IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),

IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),

IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),

IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),

IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and

IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);
and wherein said peptides may be of recombinant or synthetic origin, and optionally combined with a pharmaceutically acceptable adjuvant.

Any of the above mentioned therapeutic vaccine compositions may also be considered or regarded as therapeutic HCV vaccine compositions, or as therapeutic compositions or therapeutic HCV compositions, or as compositions or HCV compositions.

The present invention provides a method of treating a mammal, such as a human, infected with HCV comprising administering an effective amount of a composition as described herein, such as the above described vaccines or therapeutic compositions, and optionally, a pharmaceutically acceptable adjuvant. In one embodiment, the composition of the invention is administered in combination with or at a time in conjunction with antiviral therapy, either soon prior to or subsequent to or with administration of the composition of the invention. It will be clear that any of the compositions of the invention, e.g. a therapeutic HCV vaccine composition, can be used for treating a mammal chronically infected with HCV (a "chronic HCV-infected mammal").

The present invention provides a composition, such as a therapeutic HCV composition or a HCV composition, containing or comprising at least one purified recombinant HCV recombinant envelope proteins selected from the group consisting of an E1 protein and an E2 protein, and optionally an adjuvant. In a preferred embodiment, the composition contains at least one of the following E1 and E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 418 of the E2

region (epitope A),
Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),
Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),
Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),
Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),
Env 17B or E2-17B (SEQ ID NO:83) spanning positions 547 to 586 of the E2 region (epitope D),
Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C),
IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),
IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),
IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),
IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),
IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),
IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),
IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),
IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),
IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and
IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122),
and wherein said peptides may be of recombinant or synthetic origin, and optionally combined with a pharmaceutically acceptable adjuvant.

Another composition, such as a therapeutic HCV composition or HCV composition, of the invention may be comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof,

derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

The present invention provides a therapeutic composition or therapeutic vaccine composition or composition for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production. The present invention provides a therapeutic HCV composition or therapeutic HCV vaccine composition or HCV composition for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production.

The therapeutic composition according to the present invention, such as a therapeutic HCV vaccine composition or therapeutic HCV composition, may also be therapeutically effective in a HCV carrier infected with a HCV genotype different from the HCV genotype or HCV genotypes from which said E1, E2, or E1/E2 protein complexes are derived.

The recombinant HCV envelope proteins may be produced by recombinant mammalian cells, recombinant HCV envelope proteins are produced by recombinant yeast cells, or recombinant HCV envelope proteins are produced by or via a recombinant virus. The present invention provides a method of treating a mammal, such as a human, infected with HCV including administering an effective amount of a composition described herein, such as a therapeutic HCV vaccine composition, and, optionally, a pharmaceutically acceptable adjuvant. It will be clear that any of the compositions of the invention, such as a therapeutic HCV vaccine composition, can be used for treating a chronic HCV-infected mammal. The present invention provides a therapeutic composition for inducing HCV-specific antibodies, for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production, said composition containing a therapeutic effective amount of a composition containing at least one purified recombinant HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein and an E2 protein; and optionally a pharmaceutically acceptable adjuvant.

In particular, any of the compositions according to this invention (including the vaccine compositions and therapeutic compositions) may comprise recombinant HCV envelope proteins wherein the cysteines of said recombinant HCV envelope proteins are blocked, or may comprise E1 and/or E2 peptides wherein the cysteines of said E1 or E2 peptides are blocked.

In another embodiment of the invention, the compositions (including the vaccine

compositions and therapeutic compositions) according to the invention may comprise recombinant HCV envelope proteins which are added to said compositions as viral-like particles (VLPs).

In a further embodiment, a composition of the invention such as a therapeutic HCV vaccine composition may comprise as recombinant HCV E1 envelope protein an E1s protein. More particularly, said E1s protein is defined by SEQ ID NO:123.

Another aspect of the invention relates to an immunogenic composition, in particular a HCV immunogenic composition, comprising a recombinant virus allowing expression of at least one HCV recombinant envelope protein chosen from an E1 protein and/or an E2 protein, and parts of said E1 and E2 proteins; and, optionally, a pharmaceutically acceptable adjuvant.

In yet a further aspect, the invention is envisaging a vaccine composition such as a HCV vaccine composition comprising a recombinant virus allowing expression of at least one HCV recombinant envelope protein chosen from an E1 protein and/or an E2 protein, and parts of said E1 and E2 proteins; and, optionally, a pharmaceutically acceptable adjuvant.

In one embodiment, the above recombinant virus compositions may be effective against a HCV genotype or subtype different from the HCV genotype or subytpe from which said E1 protein and/or E2 protein, or said parts thereof, are derived.

In another embodiment, the above recombinant virus compositions may be used for inducing HCV-specific antibodies or for stimulating T-cell activity or for stimulating cytokine secretion or cytokine production.

In another embodiment to the recombinant virus compositions, said recombinant virus is a vaccinia virus, a recombinant avipox virus or a recombinant Ankara Modified Virus.

Another aspect of the invention relates to a method of treating a mammal infected with HCV comprising administering an effective amount of a recombinant vaccine composition as described above.

The mammal in any of the above aspects of the invention may in particular be a human.

One further aspect of the present invention relates to a method to reduce liver disease in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

In another aspect, a method to reduce liver fibrosis progression in a chronic HCV-

infected mammal or human comprising administering a therapeutic vaccine to said mammal or human is covered.

A further aspect relates to a method to reduce liver fibrosis in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

A further aspect relates to a method to reduce liver steatosis in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Yet another aspect of the invention embodies a method to reduce liver disease by at least 2 points according to the overall Ishak score or Ishak activity score in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Another further aspect relates to a method to reduce liver disease or liver fibrosis by at least 1 point according to the Ishak fibrosis score in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

A further aspect of the invention provides a method to reduce serum ALT levels in a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Yet another aspect of the invention relates to a method to reduce anti-E1 and/or anti-E2 immunoreactivity in the liver of a chronic HCV-infected mammal or human comprising administering a therapeutic vaccine to said mammal or human.

Furthermore included in the invention is a method for treating a chronic HCV-infected mammal or human wherein said method is comprising administration of multiple doses of any of the compositions of the invention, such as a therapeutic HCV vaccine composition, to said mammal or human and wherein said multiple doses are administrated to said mammal or human separated by a specified time interval. Thus, said plurality of administrations of a composition of the invention to treat a chronic HCV-infected carrier may be separated, e.g., by a time-interval of 4 weeks or less. Thus, said time intervals could be 1 or 1.5 or 2 or 2.5 or 3 or 3.5 or 4 weeks, or could be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 days. In particular, said method of treating a chronic HCV-infected mammal or human comprises a plurality of administrations of a composition of the invention, such as a therapeutic HCV vaccine composition, to said mammal or human wherein said administrations are separated by a

time interval of 3 weeks. In a further embodiment, said plurality of administrations consists of a first series of at least 5 administrations followed by an administration-free period of at least 12 weeks followed by a second series of at least 3 administrations. In particular, a series of administrations may comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more administrations. The administration-free period may be at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more weeks.

It will furthermore be clear that any of the compositions of the invention, such as a therapeutic HCV vaccine composition, can be used for obtaining any of the effects aimed at in the various methods as described above. Said therapeutic vaccine as applied in the methods described above may be any composition of the current invention, such as a therapeutic HCV vaccine composition.

The use of the HCV E1/E2 proteins or parts thereof or E1/E2 peptides as outlined throughout the above description for the manufacture of a composition, HCV composition, vaccine, HCV vaccine, therapeutic vaccine or therapeutic HCV vaccine for use in any of the methods outlined above or used for obtaining any of the effects aimed at in the various methods outlined above is also envisaged by the current invention.

In any of these methods said therapeutic vaccine comprises at least one HCV antigen and, optionally, a pharmaceutically acceptable adjuvant such as alum. In one embodiment thereto said HCV antigen is an E1 or E2 antigen, or an immunogenic part of an E1 or E2 antigen. When referring to the HCV antigen as being an E1s antigen, the E1s antigen may be defined by SEQ ID NO:123.

With the term "liver disease" is meant in this context any abnormal liver condition caused by infection with the hepatitis C virus including inflammation, fibrosis, cirrhosis, necrosis, necro-inflammation and hepatocellular carcinoma.

With "steatosis" is meant a histological feature of lipid accumulation in the hepatocytes that is indicative of liver involvement in a wide variety of systemic disorders, toxic or drug-induced liver injury, as well as of various specific liver diseases, including hepatitis C infection, Wilson's disease, and galactosemia.

With "reducing liver disease" is meant any stabilization or reduction of the liver disease status. Liver disease can be determined, e.g., by the Knodell scoring system or the Knodell scoring system adapted by Ishak. A reduction of this score by two points is accepted as therapeutically beneficial effect in several studies (see, e.g., studies published after 1996 as indicated in Table 2 of Shiffman 1999).

With "reducing liver fibrosis progression" is meant any slowing down, halting or reverting of the normally expected progression of liver fibrosis. Liver fibrosis progression can be determined, e.g., by the Metavir scoring system. Normal expected progression of liver fibrosis according to this system was published to be an increase of the Metavir score of an untreated chronic HCV patient of approximately 0.133 per year (Poynard et al. 1997). Fibrosis is considered to include any form of fibrosis, e.g. as scored by the Metavir or Ishak system, including perisinusoidal fibrosis.

With the term "HCV antigen" is meant any HCV protein or fragment thereof comprising at least one T cell epitope or B cell epitope.

A further aspect of the current invention provides a method to predict changes in liver disease in a chronic HCV-infected mammal or human, said method comprising:

(i) determining the level of serum anti-E1 antibody level prior to therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;

(ii) determining the level of serum anti-E1 antibody level after therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;

(iii) inferring the difference in level of serum anti-E1 antibody level determined in (i) and (ii) and, therefrom, predicting the change in liver disease.

It will be clear to the skilled artisan that a significantly high and positive difference in level of serum anti-E1 antibody, calculated as the value measured in (ii) minus the value measured in (i), would tip the balance in favor of a positive prediction, i.e., a prediction that the degree of liver disease will decrease. It will also be clear that a sustained significantly high and positive difference would add to the positive character of the prediction of decreased liver disease. When said difference is, however, not significantly high, is zero, is negative, or is significantly high and positive at one point in time but is not sustained, this would then tip the balance in favor of a negative prediction, i.e., a prediction that the degree of liver disease will remain unchanged or will increase. A sustained high level of serum anti-E1 antibody could be reached trough additional immunizations either by administering a new series of immunizations after an administration free period or by repeating immunizations with a larger time interval, e.g. 6 weeks, after an initial priming series consisting of administrations with a short time interval, e.g. 3 weeks.

Figure and Table legends

Figure 1 : Restriction map of plasmid pgpt ATA 18

Figure 2 : Restriction map of plasmid pgs ATA 18

Figure 3 : Restriction map of plasmid pMS 66

Figure 4 : Restriction map of plasmid pv HCV-11A

Figure 5 : Anti-E1 levels in non-responders to IFN treatment

Figure 6 : Anti-E1 levels in responders to IFN treatment

Figure 7 : Anti-E1 levels in patients with complete response to IFN treatment

Figure 8 : Anti-E1 levels in incomplete responders to IFN treatment

Figure 9 : Anti-E2 levels in non-responders to IFN treatment

Figure 10 : Anti-E2 levels in responders to IFN treatment

Figure 11 : Anti-E2 levels in incomplete responders to IFN treatment

Figure 12 : Anti-E2 levels in complete responders to IFN treatment

Figure 13 : Human anti-E1 reactivity competed with peptides

Figure 14 : Competition of reactivity of anti-E1 monoclonal antibodies with peptides

Figure 15 : Anti-E1 (epitope 1) levels in non-responders to IFN treatment

Figure 16 : Anti-E1 (epitope 1) levels in responders to IFN treatment

Figure 17 : Anti-E1 (epitope 2) levels in non-responders to IFN treatment

Figure 18 : Anti-E1 (epitope 2) levels in responders to IFN treatment

Figure 19 : Competition of reactivity of anti-E2 monoclonal antibodies with peptides

Figure 20: Human anti-E2 reactivity competed with peptides

Figure 21: Nucleic acid sequences of the present invention. The nucleic acid sequences encoding an E1 or E2 protein according to the present invention may be translated (SEQ ID NO 3 to 13, 21-31, 35 and 41-49 are translated in a reading frame starting from residue number 1, SEQ ID NO 37-39 are translated in a reading frame starting from residue number 2), into the amino acid sequences of the respective E1 or E2 proteins as shown in the sequence listing.

Figure 22: ELISA results obtained from lentil lectin chromatography eluate fractions of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a).

Figure 23: Elution profiles obtained from the lentil lectin chromatography of the 4

different E1 constructs on the basis of the values as shown in Figure 22.

Figure 24: ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a).

Figure 25: Profiles obtained from purifications of E1 proteins of type 1b (1), type 3a (2), and type 5a (3) (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in example 5.2 - 5.3) and a standard (4). The peaks indicated with '1', '2', and '3', represent pure E1 protein peaks (see Figure 24, E1 reactivity mainly in fractions 26 to 30).

Figure 26: Silver staining of an SDS-PAGE as described in example 4 of a raw lysate of E1 vvHCV40 (type 1b) (lane 1), pool 1 of the gelfiltration of vvHCV40 representing fractions 10 to 17 as shown in Figure 25 (lane 2), pool 2 of the gelfiltration of vvHCV40 representing fractions 18 to 25 as shown in Figure 25 (lane 3), and E1 pool (fractions 26 to 30) (lane 4).

Figure 27: Streptavidine-alkaline phosphatase blot of the fractions of the gelfiltration of E1 constructs 39 (type 1b) and 62 (type 3a). The proteins were labelled with NEM-biotin. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction 27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14: fraction 30 construct 62, lane 15: fraction 31 construct 62.

Figure 28: Siver staining of an SDS-PAGE gel of the gelfiltration fractions of vvHCV-39 (E1s, type 1b) and vvHCV-62 (E1s, type 3a) run under identical conditions as Figure 26. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction

27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14: fraction 30 construct 62, lane 15: fraction 31 construct 62.

Figure 29: Western Blot analysis with anti-E1 mouse monoclonal antibody 5E1A10 giving a complete overview of the purification procedure. Lane 1: crude lysate, Lane 2: flow through of lentil chromagtography, Lane 3: wash with Empigen BB after lentil chromatography, Lane 4: Eluate of lentil chromatography, Lane 5: Flow through during concentration of the lentil eluate, Lane 6: Pool of E1 after Size Exclusion Chromatography (gelfiltration).

Figure 30: OD_{280} profile (continuous line) of the lentil lectin chromatography of E2 protein from RK13 cells infected with vvHCV44. The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

Figure 31A: OD_{280} profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool is applied immediately on the gelfiltration column (non-reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

Figure 31B: OD_{280} profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool was reduced and blocked according to Example 5.3 (reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).

Figure 32: Ni^{2+}-IMAC chromatography and ELISA reactivity of the E2 protein as expressed from vvHCV44 after gelfiltration under reducing conditions as shown in Figure 31B.

Figure 33: Silver staining of an SDS-PAGE of 0.5 μg of purified E2 protein recovered by a 200 mM imidazole elution step (lane 2) and a 30mM imidazole wash (lane 1) of the Ni^{2+}-IMAC chromatography as shown in Figure 32.

Figure 34: OD profiles of a desalting step of the purified E2 protein recovered by 200 mM imidazole as shown in Figure 33, intended to remove imidazole.

Figure 35A: Antibody levels to the different HCV antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12

months after treatment determined by means of the LIAscan method. The average values are indicated by the curves with the open squares.

Figure 35B: Antibody levels to the different HCV antigens (NS4, NS5, E1 and E2) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curve with the open squares.

Figure 36: Average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups.

Figure 37: Averages E1 antibody (E1Ab) levels for non-responders (NR) and long term responders (LTR) for type 1b and type 3a.

Figure 38: Relative map positions of the anti-E2 monoclonal antibodies.

Figure 39: Partial deglycosylation of HCV E1 envelope protein. The lysate of vvHCV10A-infected RK13 cells were incubated with different concentrations of glycosidases according to the manufacturer's instructions. Right panel: Glycopeptidase F (PNGase F). Left panel: Endoglycosidase H (Endo H).

Figure 40: Partial deglycosylation of HCV E2 envelope proteins. The lysate of vvHCV64-infected (E2) and vvHCV41-infected (E2s)RK13 cells were incubated with different concentrations of Glycopeptidase F (PNGase F) according to the manufacturer's instructions.

Figure 41: In vitro mutagenesis of HCV E1 glycoproteins. Map of the mutated sequences and the creation of new restriction sites.

Figure 42A: In vitro mutagenesis of HCV E1 glycoprotein (part 1). First step of PCR amplification.

Figure 42B: In vitro mutagensis of HCV E1 glycoprotein (part 2). Overlap extension and nested PCR.

Figure 43: In vitro mutagesesis of HCV E1 glycoproteins. Map of the PCR mutated fragments (GLY-# and OVR-#) synthesized during the first step of amplification.

Figure 44A: Analysis of E1 glycoprotein mutants by Western blot expressed in HeLa (left) and RK13 (right) cells. Lane 1: wild type VV (vaccinia virus), Lane 2: original E1 protein (vvHCV-10A), Lane 3: E1 mutant Gly-1 (vvHCV-81),

Lane 4: E1 mutant Gly-2 (vvHCV-82), Lane 5: E1 mutant Gly-3 (vvHCV-83), Lane 6: E1 mutant Gly-4 (vvHCV-84), Lane 7: E1 mutant Gly-5 (vvHCV-85), Lane 8: E1 mutant Gly-6 (vvHCV-86).

Figure 44B: Analysis of E1 glycosylation mutant vaccinia viruses by PCR amplification/restriction. Lane 1: E1 (vvHCV-10A), *BspE I,* Lane 2: E1.GLY-1 (vvHCV-81), *BspE I,* Lane 4: E1 (vvHCV-10A), *Sac I,* Lane 5: E1.GLY-2 (vvHCV-82), *Sac I,* Lane 7: E1 (vvHCV-10A), *Sac I,* Lane 8: E1.GLY-3 (vvHCV-83), *Sac I,* Lane 10: E1 (vvHCV-10A), *Stu I,* Lane 11: E1.GLY-4 (vvHCV-84), *Stu I,* Lane 13: E1 (vvHCV-10A), *Sma I,* Lane 14: E1.GLY-5 (vvHCV-85), *Sma I,* Lane 16: E1 (vvHCV-10A), *Stu I,* Lane 17: E1.GLY-6 (vvHCV-86), *Stu I,* Lane 3 - 6 - 9 - 12 - 15 : Low Molecular Weight Marker, pBluescript SK+, *Msp I.*

Figure 45: SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in *S. cerevisiae.* Innoculates were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28°C, medium samples were taken. The equivalent of 200 µl of culture supernatant concentrated by speedvac was loaded on the gel. Two independent transformants were analysed.

Figure 46: SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in a glycosylation deficient *S. cerevisiae* mutant. Innoculae were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28°C, medium samples were taken. The equivalent of 350 µl of culture supernatant, concentrated by ion exchange chromatography, was loaded on the gel.

Figure 47: Profile of chimpanzees and immunization schedule.

Figure 48: Cellular response after 3 immunizations.

Figure 49: Evolution of cellular response upon repeated E1 immunizations.

Figure 50: Cellular response upon NS3 immunizations.

Figure 51: Stimulation index through week 28. The stimulation index (SI; cellular immune response) was obtained by culturing PBMC (10^5 cells), drawn from the individuals before immunization (week 0), two weeks after the third immunization (week 8), before the booster immunization (week 26) and two weeks after the booster immunization (week 28), in the presence or absence

of 3 μg of recombinant E1s or 2 μg tetanos toxoid and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. Samples of week 0 and 8 were determined in a first assay (A), while the samples of week 26 and 28 were determined in a second assay (B) in which the samples of week 0 were reanalyzed. Results are expressed as the geometric mean stimulation index of all 20 (A, experiment) or 19 (B, experiment) volunteers.

Figure 52: Cytokine production of PBMCs. PBMC (10^5 cells), drawn from the individuals before the booster immunization (week 26) and two weeks after the booster immunization (week 28), were cultured in the presence of 3 μg of recombinant E1s (E1) or 2 μg of tetanos toxoid (TT) or no antigen (Bl). Cytokines were measured in the supernatant taken after 24 hours (interleukin-5) or after 120 hours (interferon-gamma) by means of ELISA. The stimulation index is the ratio of cytokine measured in the supernatants of cells cultured with envelope antigen versus the ones cultured without antigen. Results are expressed as the geometric mean of pg cytokine/ml secreted of all 19 volunteers. Samples with a cytokine amount below detection limit were assigned the value of the detection limit. Similarly samples with extremely high concentrations of cytokine out of the linear range of the assay were assigned the value of the limit of the linear range of the assay.

Figure 53: Thymidine incorporation results. The stimulation index (cellular immune response) was obtained by culturing PBMC (3 x10^5 cells), in the presence or absence of peptides and determining the amount of tritiated thymidine incorporated in these cells during a pulse after 5-6 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with peptide versus the ones cultured without peptide. Results are expressed as individual values for vaccinated persons (top panel) or non vaccinated or controls (lower panel).

Figure 54: Three-dimensional graph showing for the individual patients (each represented by a dot) the % change in ALT-levels (absolute change from

baseline) on the X-axis, the change in serum anti-E1 antibody levels (in mU/mL) on the Y-axis, and the change in Ishak fibrosis score on the Z-axis.

Figure 55: Three-dimensional graph showing for the individual patients (each represented by a dot) the % change in ALT-levels (absolute change from baseline) on the X-axis, the change in serum anti-E1 antibody levels (in mU/mL) on the Y-axis, and the change in Metavir fibrosis score on the Z-axis.

Figure 56: For each individual patient (represented by a dot or a "★"), the Ishak fibrosis score (on the X-axis) and the ALT values (on the Y-axis) are given. In panel A (top), the baseline (pre-vaccination) situation is given whereas panel B (bottom) is illustrating the situation at the time of taking of liver biopsies. The seven patients with the highest increase in serum anti-E1 antibody level are represented by a "★".

Figure 57: The influence of the age (on the X-axis) of each individual patient (represented by a dot or a "★") on the Ishak fibrosis score (on the Y-axis) is given. In panel A (top), the baseline (pre-vaccination) situation is given whereas panel B (bottom) is illustrating the situation at the time of taking of liver biopsies. The seven patients with the highest increase in serum anti-E1 antibody level are represented by a "★".

Table 1 : Features of the respective clones and primers used for amplification for constructing the different forms of the E1 protein as despected in Example 1.

Table 2 : Summary of Anti-E1 tests

Table 3 : Synthetic peptides for competition studies

Table 4: Changes of envelope antibody levels over time.

Table 5: Difference between LTR and NR

Table 6: Competition experiments between murine E2 monoclonal antibodies

Table 7: Primers for construction of E1 glycosylation mutants

Table 8: Analysis of E1 glycosylation mutants by ELISA

Table 9: Profile of adjuvanted E1 Balb/c mice.

Table 10: Humoral responses: No. of immunizations required for different E1-antibodies levels.

Table 11: Chimpanzee antibody titers.

Table 12: Human antibody titers.

Table 13: Human antibody titers (8-28 weeks).

Table 14: Stimulation index (SI) of cultured PBMC, drawn from the individuals four weeks (W16) after the fourth immunization and two weeks (W26) after the fifth immunization in the presence or absence of 3 µg of E1s. A stimulation index of >3 is considered a positive signal.

Table 15: Ishak grading of necro-inflammatory intensities for periportal hepatitis, confluent necrosis, focal inflammation, portal inflammation and the overall total inflammation grading. Scores are indicated as the change from baseline (mean and 95 % confidence interval) and the mean baseline- to end-values.

Table 16: Overview of frequencies (given as number of patients) of changes of a given baseline Metavir score (given in top row; Baseline 0 to 4) to a given Metavir score at the end of the second course of therapeutic E1s vaccination (given in left row; EOT 0 to 4). For instance, the "5" marked with a "*" (i.e., "5*") means that 5 patients had a baseline Metavir score of 1 and a Metavir score of 0 at the end of the second course treatment (EOT = end of treatment).

Table 17: Correlation between serum anti-E1 antibody levels induced by therapeutic E1s vaccination and change in overall Ishak scores. Given are the number of patients corresponding to the possible criteria as outlined in the Table.

Example 1: Cloning and expression of the hepatitis C virus E1 protein

1. Construction of vaccinia virus recombination vectors

The pgptATA18 vaccinia recombination plasmid is a modified version of pATA18 (Stunnenberg et al, 1988) with an additional insertion containing the *E. coli* xanthine guanine phosphoribosyl transferase gene under the control of the vaccinia virus I3 intermediate promoter (Figure 1). The plasmid pgsATA18 was constructed by inserting an oligonucleotide linker with SEQ ID NO 1/94, containing stop codons in the three reading frames, into the *Pst* I and *Hin*dIII-cut pATA18 vector. This created an extra *Pac* I restriction site (Figure 2). The original *Hin*dIII site was not restored.

Oligonucleotide linker with SEQ ID NO 1/94:

```
5'      G GCATGC AAGCTT AATTAATT       3'   (SEQ ID NO:1)
3'  ACGTC CGTACG TTCGAA TTAATTAA TCGA   5'   (SEQ ID NO:94)
      PstI  SphI  HindIII  Pac I (HindIII)
```

In order to facilitate rapid and efficient purification by means of Ni^{2+} chelation of engineered histidine stretches fused to the recombinant proteins, the vaccinia recombination vector pMS66 was designed to express secreted proteins with an additional carboxy-terminal histidine tag. An oligonucleotide linker with SEQ ID NO 2/95, containing unique sites for 3 restriction enzymes generating blunt ends (*Sma* I, *Stu* I and *Pml* I/*Bbr* PI) was synthesized in such a way that the carboxy-terminal end of any cDNA could be inserted in frame with a sequence encoding the protease factor Xa cleavage site followed by a nucleotide sequence encoding 6 histidines and 2 stop codons (a new *Pac* I restriction site was also created downstream the 3'end). This oligonucleotide with SEQ ID NO 2/95 was introduced between the *Xma* I and *Pst* I sites of pgptATA18 (Figure 3).

Oligonucleotide linker with SEQ ID NO 2/95:

```
5'-CCGGG GAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCA/
   3'-C CTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGT/
    XmaI
                    /TCACTAATAGTTAATTAA CTGCA-3'  (SEQ ID
NO:2)
                    /AGTGATTATCAATTAATT G-5'      (SEQ ID
NO:95)
                                                  PstI
```

Plasmid pgptATA-18 contained within *Escherichia coli* MC1061 (lambda) has been deposited under the terms of the Budapest Treaty at BCCM/LMBP (Belgian Coordinated Collections of microorganisms/Laboratorium voor Moleculaire Biologie - Plasmidencollectie, Universiteit Gent, K.L. Ledeganckstraat 35, B-9000 Ghent, Belgium), and bears accession number LMBP4486. Said deposit was made on January 9, 2002.

Example 2. Construction of HCV recombinant plasmids

2.1. Constructs encoding different forms of the E1 protein

Polymerase Chain Reaction (PCR) products were derived from the serum samples by RNA preparation and subsequent reverse-transcription and PCR as described previously (Stuyver et al., 1993b). Table 1 shows the features of the respective clones and the primers used for amplification. The PCR fragments were cloned into the Sma I-cut pSP72 (Promega) plasmids. The following clones were selected for insertion into vaccinia reombination vectors: HCCl9A (SEQ ID NO:3), HCCl10A (SEQ ID NO:5), HCCl11A (SEQ ID NO:7), HCCl12A (SEQ ID NO:9), HCCl13A (SEQ ID NO:11), and HCCl17A (SEQ ID NO:13) as depicted in Figure 21. cDNA fragments containing the E1-coding regions were cleaved by EcoRI and HindIII restriction from the respective pSP72 plasmids and inserted into the EcoRI/HindIII-cut pgptATA-18 vaccinia recombination vector (described in example 1), downstream of the 11K vaccinia virus late promoter. The respective plasmids were designated pvHCV-9A, pvHCV-10A, pvHCV-11A, pvHCV-12A, pvHCV-13A and pvHCV-17A, of which pvHCV-11A is shown in Figure 4.

2.2. Hydrophobic region E1 deletion mutants

Clone HCCl37, containing a deletion of codons Asp264 to Val287 (nucleotides 790 to 861, region encoding hydrophobic domain I) was generated as follows: 2 PCR fragments were generated from clone HCCl10A with primer sets HCPr52 (SEQ ID NO:16)/HCPr107 (SEQ ID NO:19) and HCPr108 (SEQ ID NO:20)/HCPR54 (SEQ ID NO:18). These primers are shown in Figure 21. The two PCR fragments were purified from agarose gel after electrophoresis and 1 ng of each fragment was used together as template for PCR by means of primers HCPr52 (SEQ ID NO:16) and HCPr54 (SEQ ID NO:18). The resulting fragment was cloned into the Sma I-cut pSP72 vector and clones containing the deletion were readily identified because of the deletion of 24 codons (72 base pairs). Plasmid pSP72HCCl37

containing clone HCCl37 (SEQ ID 15) was selected. A recombinant vaccinia plasmid containing the full-length E1 cDNA lacking hydrophobic domain I was constructed by inserting the HCV sequence surrounding the deletion (fragment cleaved by Xma I and BamH I from the vector pSP72-HCCl37) into the Xma I-Bam H I sites of the vaccinia plasmid pvHCV-10A. The resulting plasmid was named pvHCV-37. After confirmatory sequencing, the amino-terminal region containing the internal deletion was isolated from this vector pvHCV-37 (cleavage by EcoR I and BstE II) and reinserted into the Eco RI and Bst EII-cut pvHCV-11A plasmid. This construct was expected to express an E1 protein with both hydrophobic domains deleted and was named pvHCV-38. The E1-coding region of clone HCCl38 is represented by SEQ ID NO:23.

As the hydrophilic region at the E1 carboxyterminus (theoretically extending to around amino acids 337-340) was not completely included in construct pvHCV-38, a larger E1 region lacking hydrophobic domain I was isolated from the pvHCV-37 plasmid by EcoR I/Bam HI cleavage and cloned into an EcoRI/BamHI-cut pgsATA-18 vector. The resulting plasmid was named pvHCV-39 and contained clone HCCl39 (SEQ ID NO:25). The same fragment was cleaved from the pvHCV-37 vector by BamH I (of which the sticky ends were filled with Klenow DNA Polymerase I (Boehringer)) and subsequently by EcoR I (5' cohesive end). This sequence was inserted into the EcoRI and Bbr PI-cut vector pMS-66. This resulted in clone HCCl40 (SEQ ID NO:27) in plasmid pvHCV-40, containing a 6 histidine tail at its carboxy-terminal end.

2.3. E1 of other genotypes

Clone HCCl62 (SEQ ID NO:29) was derived from a type 3a-infected patient with chronic hepatitis C (serum BR36, clone BR36-9-13, SEQ ID NO:19 in WO 94/25601, and see also Stuyver et al. 1993a) and HCCl63 (SEQ ID NO:31) was derived from a type 5a-infected child with post-transfusion hepatitis (serum BE95, clone PC-4-1, SEQ ID NO:45 in WO 94/25601).

2.4. E2 constructs

The HCV E2 PCR fragment 22 was obtained from serum BE11 (genotype 1b) by means of primers HCPr109 (SEQ ID NO:33) and HCPr72 (SEQ ID NO:34) using techniques of RNA preparation, reverse-transcription and PCR, as described in Stuyver et al., 1993b, and the fragment was cloned into the Sma I-cut pSP72 vector. Clone HCCl22A (SEQ ID

NO:35) was cut with NcoI/AlwNI or by BamHI/AlwNI and the sticky ends of the fragments were blunted (NcoI and BamHI sites with Klenow DNA Polymerase I (Boehringer), and AlwNI with T4 DNA polymerase (Boehringer)). The BamHI/AlwNI cDNA fragment was then inserted into the vaccinia pgsATA-18 vector that had been linearized by EcoR I and Hind III cleavage and of which the cohesive ends had been filled with Klenow DNA Polymerase (Boehringer). The resulting plasmid was named pvHCV-41 and encoded the E2 region from amino acids Met347 to Gln673, including 37 amino acids (from Met347 to Gly383) of the E1 protein that can serve as signal sequence. The same HCV cDNA was inserted into the EcoR I and Bbr PI-cut vector pMS66, that had subsequently been blunt ended with Klenow DNA Polymerase. The resulting plasmid was named pvHCV-42 and also encoded amino acids 347 to 683. The NcoI/AlwNI fragment was inserted in a similar way into the same sites of pgsATA-18 (pvHCV-43) or pMS-66 vaccinia vectors (pvHCV-44). pvHCV-43 and pvHCV-44 encoded amino acids 364 to 673 of the HCV polyprotein, of which amino acids 364 to 383 were derived from the natural carboxyterminal region of the E1 protein encoding the signal sequence for E2, and amino acids 384 to 673 of the mature E2 protein.

2.5. Generation of recombinant HCV-vaccinia viruses

Rabbit kidney RK13 cells (ATCC CCL 37), human osteosarcoma 143B thymidine kinase deficient (TK$^-$) (ATCC CRL 8303), HeLa (ATCC CCL 2), and Hep G2 (ATCC HB 8065) cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, Md, USA). The cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10 % foetal calf serum, and with Earle's salts (EMEM) for RK13 and 143 B (TK-), and with glucose (4 g/l) for Hep G2. The vaccinia virus WR strain (Western Reserve, ATTC VR119) was routinely propagated in either 143B or RK13 cells, as described previously (Panicali & Paoletti, 1982; Piccini et al., 1987; Mackett et al., 1982, 1984, and 1986). A confluent monolayer of 143B cells was infected with wild type vaccinia virus at a multiplicity of infection (m.o.i.) of 0.1 (= 0.1 plaque forming unit (PFU) per cell). Two hours later, the vaccinia recombination plasmid was transfected into the infected cells in the form of a calcium phosphate coprecipitate containing 500 ng of the plasmid DNA to allow homologous recombination (Graham & van der Eb, 1973; Mackett et al., 1985). Recombinant viruses expressing the *E.coli* xanthine-guanine phosphoribosyl transferase (gpt) protein were selected on rabbit kidney RK13 cells incubated in selection medium (EMEM

containing 25 μg/ml mycophenolic acid (MPA), 250 μg/ml xanthine, and 15 μg/ml hypoxanthine; Falkner and Moss, 1988; Janknecht et al, 1991). Single recombinant viruses were purified on fresh monolayers of RK13 cells under a 0.9% agarose overlay in selection medium. Thymidine kinase deficient (TK) recombinant viruses were selected and then plaque purified on fresh monolayers of human 143B cells (TK-) in the presence of 25 μg/ml 5-bromo-2'-deoxyuridine. Stocks of purified recombinant HCV-vaccinia viruses were prepared by infecting either human 143 B or rabbit RK13 cells at an m.o.i. of 0.05 (Mackett et al, 1988). The insertion of the HCV cDNA fragment in the recombinant vaccinia viruses was confirmed on an aliquot (50 μl) of the cell lysate after the MPA selection by means of PCR with the primers used to clone the respective HCV fragments (see Table 1). The recombinant vaccinia-HCV viruses were named according to the vaccinia recombination plasmid number, e.g. the recombinant vaccinia virus vvHCV-10A was derived from recombining the wild type WR strain with the pvHCV-10A plasmid.

Example 3: infection of cells with recombinant vaccinia viruses

A confluent monolayer of RK13 cells was infected at a m.o.i. of 3 with the recombinant HCV-vaccinia viruses as described in example 2 . For infection, the cell monolayer was washed twice with phosphate-buffered saline pH 7.4 (PBS) and the recombinant vaccinia virus stock was diluted in MEM medium. Two hundred μl of the virus solution was added per 10^6 cells such that the m.o.i. was 3, and incubated for 45 min at 24°C. The virus solution was aspirated and 2 ml of complete growth medium (see example 2) was added per 10^6 cells. The cells were incubated for 24 hr at 37°C during which expression of the HCV proteins took place.

Example 4: Analysis of recombinant proteins by means of western blotting

The infected cells were washed two times with PBS, directly lysed with lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM $MgCl_2$, 1 μg/ml aprotinin (Sigma, Bornem, Belgium)) or detached from the flasks by incubation in 50 mM Tris.HCL pH 7.5/ 10 mM EDTA/ 150 mM NaCl for 5 min, and collected by centrifugation (5 min at 1000g). The cell pellet was then resuspended in 200 μl lysis buffer (50 mM Tris.HCL pH 8.0, 2 mM EDTA, 150 mM NaCl, 5 mM $MgCl_2$ aprotinin, 1% Triton X-100) per 10^6 cells.

The cell lysates were cleared for 5 min at 14,000 rpm in an Eppendorf centrifuge to remove the insoluble debris. Proteins of 20 μl lysate were separated by means of sodium

dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then electro-transferred from the gel to a nitrocellulose sheet (Amersham) using a Hoefer HSI transfer unit cooled to 4°C for 2 hr at 100 V constant voltage, in transfer buffer (25 mM Tris.HCl pH 8.0, 192 mM glycine, 20% (v/v) methanol). Nitrocellulose filters were blocked with Blotto (5 % (w/v) fat-free instant milk powder in PBS; Johnson et al., 1981) and incubated with primary antibodies diluted in Blotto/0.1 % Tween 20. Usually, a human negative control serum or serum of a patient infected with HCV were 200 times diluted and preincubated for 1 hour at room temperature with 200 times diluted wild type vaccinia virus-infected cell lysate in order to decrease the non-specific binding. After washing with Blotto/0.1% Tween 20, the nitrocellulose filters were incubated with alkaline phosphatase substrate solution diluted in Blotto/0.1 % Tween 20. After washing with 0.1% Tween 20 in PBS, the filters were incubated with alkaline phosphatase substrate solution (100 mM Tris.HCl pH 9.5, 100 mM NaCl, 5 mM $MgCl_2$, 0,38 µg/ml nitroblue tetrazolium, 0.165 µg/ml 5-bromo-4-chloro-3-indolylphosphate). All steps, except the electrotransfer, were performed at room temperature.

Example 5: Purification of recombinant E1 or E2 protein

5.1. Lysis

Infected RK13 cells (carrying E1 or E2 constructs) were washed 2 times with phosphate-buffered saline (PBS) and detached from the culture recipients by incubation in PBS containing 10 mM EDTA. The detached cells were washed twice with PBS and 1 ml of lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM $MgCl_2$, 1 µg/ml aprotinin (Sigma, Bornem, Belgium) containing 2 mM biotinylated N-ethylmaleimide (biotin-NEM) (Sigma) was added per 10^5 cells at 4°C. This lysate was homogenized with a type B douncer and left at room temperature for 0.5 hours. Another 5 volumes of lysis buffer containing 10 mM N-ethylmaleimide (NEM, Aldrich, Bornem, Belgium) was added to the primary lysate and the mixture was left at room temperature for 15 min. Insoluble cell debris was cleared from the solution by centrifugation in a Beckman JA-14 rotor at 14,000 rpm (30100 g at r_{max}) for 1 hour at 4°C.

5.2. Lectin Chromatography

The cleared cell lysate was loaded at a rate of 1ml/min on a 0.8 by 10 cm Lentil-lectin

Sepharose 4B column (Pharmacia) that had been equilibrated with 5 column volumes of lysis buffer at a rate of 1ml/min. The lentil-lectin column was washed with 5 to 10 column volumes of buffer 1 (0.1M potassium phosphate pH 7.3, 500 mM KCl, 5% glycerol, 1 mM 6-NH_2-hexanoic acid, 1 mM $MgCl_2$, and 1% DecylPEG (KWANT, Bedum, The Netherlands). In some experiments, the column was subsequently washed with 10 column volumes of buffer 1 containing 0.5% Empigen-BB (Calbiochem, San Diego, CA, USA) instead of 1% DecylPEG. The bound material was eluted by applying elution buffer (10 mM potassium phosphate pH 7.3, 5% glycerol, 1 mM hexanoic acid, 1mM $MgCl_2$, 0.5% Empigen-BB, and 0.5 M α-methyl-mannopyranoside). The eluted material was fractionated and fractions were screened for the presence of E1 or E2 protein by means of ELISA as described in example 6. Figure 22 shows ELISA results obtained from lentil lectin eluate fractions of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a). Figure 23 shows the profiles obtained from the values shown in Figure 22. These results show that the lectin affinity column can be employed for envelope proteins of the different types of HCV.

5.3. Concentration and partial reduction

The E1- or E2-positive fractions were pooled and concentrated on a Centricon 30 kDa (Amicon) by centrifugation for 3 hours at 5,000 rpm in a Beckman JA-20 rotor at 4°C. In some experiments the E1- or E2-positive fractions were pooled and concentrated by nitrogen evaporation. An equivalent of 3.10^8 cells was concentrated to approximately 200 µl. For partial reduction, 30% Empigen-BB (Calbiochem, San Diego, CA, USA) was added to this 200 µl to a final concentration of 3.5 %, and 1M DTT in H_2O was subsequently added to a final concentration of 1.5 to 7.5 mM and incubated for 30 min at 37 °C. NEM (1M in dimethylsulphoxide) was subsequently added to a final concentration of 50 mM and left to react for another 30 min at 37°C to block the free sulphydryl groups.

5.4. Gel filtration chromatography

A Superdex-200 HR 10/20 column (Pharmacia) was equilibrated with 3 column volumes PBS/3% Empigen-BB. The reduced mixture was injected in a 500 µl sample loop of the Smart System (Pharmacia) and PBS/3% Empigen-BB buffer was added for gelfiltration. Fractions of 250 µl were collected from V_0 to V_t. The fractions were screened for the

presence of E1 or E2 protein as described in example 6.

Figure 24 shows ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a). Figure 25 shows the profiles obtained from purifications of E1 proteins of types 1b, 3a, and 5a (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in the previous examples). The peaks indicated with '1', '2', and '3', represent pure E1 protein peaks (E1 reactivity mainly in fractions 26 to 30). These peaks show very similar molecular weights of approximately 70 kDa, corresponding to dimeric E1 protein. Other peaks in the three profiles represent vaccinia virus and/or cellular proteins which could be separated from E1 only because of the reduction step as outlined in example 5.3. and because of the subsequent gelfiltration step in the presence of the proper detergent. As shown in Figure 26 pool 1 (representing fractions 10 to 17) and pool 2 (representing fractions 18 to 25) contain contaminating proteins not present in the E1 pool (fractions 26 to 30). The E1 peak fractions were ran on SDS/PAGE and blotted as described in example 4. Proteins labelled with NEM-biotin were detected by streptavidin-alkaline phosphatase as shown in Figure 27. It can be readily observed that, amongst others, the 29 kDa and 45kDa contaminating proteins present before the gelfiltration chromatography (lane 1) are only present at very low levels in the fractions 26 to 30. The band at approximately 65kDa represents the E1 dimeric form that could not be entirely disrupted into the monomeric E1 form. Similar results were obtained for the type 3a E1 protein (lanes 10 to 15), which shows a faster mobility on SDS/PAGE because of the presence of only 5 carbohydrates instead of 6. Figure 28 shows a silver stain of an SDS/PAGE gel run in identical conditions as in Figure 26. A complete overview of the purification procedure is given in Figure 29.

The presence of purified E1 protein was further confirmed by means of western blotting as described in example 4. The dimeric E1 protein appeared to be non-aggregated and free of contaminants. The subtype 1b E1 protein purified from vvHCV40-infected cells according to the above scheme was aminoterminally sequenced on an 477 Perkin-Elmer sequencer and appeared to contain a tyrosine as first residue. This confirmed that the E1 protein had been cleaved by the signal peptidase at the correct position (between A191 and Y192) from its signal sequence. This confirms the finding of Hijikata et al. (1991) that the aminoterminus of the mature E1 protein starts at amino acid position 192.

5.5. Purification of the E2 protein

The E2 protein (amino acids 384 to 673) was purified from RK13 cells infected with vvHCV44 as indicated in Examples 5.1 to 5.4. Figure 30 shows the OD_{280} profile (continuous line) of the lentil lectin chromatography. The dotted line represents the E2 reactivity as detected by ELISA (see example 6). Figure 31 shows the same profiles obtained from gelfiltration chromatography of the lentil-lectin E2 pool (see Figure 30), part of which was reduced and blocked according to the methods as set out in example 5.3., and part of which was immediately applied to the column. Both parts of the E2 pool were run on separate gelfiltration columns. It could be demonstrated that E2 forms covalently-linked aggregates with contaminating proteins if no reduction has been performed. After reduction and blocking, the majority of contaminating proteins segregated into the V_0 fraction. Other contaminating proteins copurified with the E2 protein, were not covalently linked to the E2 protein any more because these contaminants could be removed in a subsequent step. Figure 32 shows an additional Ni^{2+}-IMAC purification step carried out for the E2 protein purification. This affinity purification step employs the 6 histidine residues added to the E2 protein as expressed from vvHCV44. Contaminating proteins either run through the column or can be removed by a 30 mM imidazole wash. Figure 33 shows a silver-stained SDS/PAGE of 0.5 µg of purified E2 protein and a 30 mM imidazole wash. The pure E2 protein could be easily recovered by a 200 mM imidazole elution step. Figure 34 shows an additional desalting step intended to remove imidazole and to be able to switch to the desired buffer, e.g. PBS, carbonate buffer, saline.

Starting from about 50,000 cm^2 of RK13 cells infected with vvHCV11A (or vvHCV40) for the production of E1 or vvHCV41, vvHCV42, vvHCV43, or vvHCV44 for production of E2 protein, the procedures described in examples 5.1 to 5.5 allow the purification of approximately 1.3 mg of E1 protein and 0.6 mg of E2 protein.

It should also be remarked that secreted E2 protein (constituting approximately 30-40%, 60-70% being in the intracellular form) is characterized by aggregate formation (contrary to expectations). The same problem is thus posed to purify secreted E2. The secreted E2 can be purified as disclosed above.

Example 6: ELISA for the detection of anti-E1 or anti-E2 antibodies or for the detection of E1 or E2 proteins

Maxisorb microwell plates (Nunc, Roskilde, Denmark) were coated with 1 volume

(e.g. 50 µl or 100 µl or 200 µl) per well of a 5 µg/ml solution of Streptavidin (Boehringer Mannheim) in PBS for 16 hours at 4°C or for 1 hour at 37°C. Alternatively, the wells were coated with 1 volume of 5 µg/ml of *Galanthus nivalis* agglutinin (GNA) in 50 mM sodium carbonate buffer pH 9.6 for 16 hours at 4°C or for 1 hour at 37°C. In the case of coating with GNA, the plates were washed 2 times with 400 µl of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). Unbound coating surfaces were blocked with 1.5 to 2 volumes of blocking solution (0.1% casein and 0.1% NaN_3 in PBS) for 1 hour at 37°C or for 16 hours at 4°C. Blocking solution was aspirated. Purified E1 or E2 was diluted to 100-1000 ng/ml (concentration measured at A = 280 nm) or column fractions to be screened for E1 or E2 (see example 5), or E1 or E2 in non-purified cell lysates (example 5.1.) were diluted 20 times in blocking solution, and 1 volume of the E1 or E2 solution was added to each well and incubated for 1 hour at 37°C on the Streptavidin- or GNA-coated plates. The microwells were washed 3 times with 1 volume of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). Serum samples were diluted 20 times or monoclonal anti-E1 or anti-E2 antibodies were diluted to a concentration of 20 ng/ml in Sample Diluent of the Innotest HCV Ab III kit and 1 volume of the solution was left to react with the E1 or E2 protein for 1 hour at 37°C. The microwells were washed 5 times with 400 µl of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium). The bound antibodies were detected by incubating each well for 1 hour at 37°C with a goat anti-human or anti-mouse IgG, peroxidase-conjugated secondary antibody (DAKO, Glostrup, Denmark) diluted 1/80,000 in 1 volume of Conjugate Diluent of the Innotest HCV Ab III kit (Innogenetics, Belgium), and color development was obtained by addition of substrate of the Innotest HCV Ab III kit (Innogenetics, Belgium) diluted 100 times in 1 volume of Substrate Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium) for 30 min at 24°C after washing of the plates 3 times with 400 µl of Washing Solution of the Innotest HCV Ab III kit (Innogenetics, Belgium).

Example 7: Follow up of patient groups with different clinical profiles

7.1. Monitoring of anti-E1 and anti-E2 antibodies

The current hepatitis C virus (HCV) diagnostic assays have been developed for screening and confirmation of the presence of HCV antibodies. Such assays do not seem to provide information useful for monitoring of treatment or for prognosis of the outcome of

disease. However, as is the case for hepatitis B, detection and quantification of anti-envelope antibodies may prove more useful in a clinical setting. To investigate the possibility of the use of anti-E1 antibody titer and anti-E2 antibody titer as prognostic markers for outcome of hepatitis C disease, a series of IFN-α treated patients with long-term sustained response (defined as patients with normal transaminase levels and negative HCV-RNA test (PCR in the 5' non-coding region) in the blood for a period of at least 1 year after treatment) was compared with patients showing no response or showing biochemical response with relapse at the end of treatment.

A group of 8 IFN-α treated patients with long-term sustained response (LTR, follow up 1 to 3.5 years, 3 type 3a and 5 type 1b) was compared with 9 patients showing non-complete responses to treatment (NR, follow up 1 to 4 years, 6 type 1b and 3 type 3a). Type 1b (vvHCV-39, see example 2.5.) and 3a E1 (vvHCV-62, see example 2.5.) proteins were expressed by the vaccinia virus system (see examples 3 and 4) and purified to homogeneity (example 5). The samples derived from patients infected with a type 1b hepatitis C virus were tested for reactivity with purified type 1b E1 protein, while samples of a type 3a infection were tested for reactivity of anti-type 3a E1 antibodies in an ELISA as desribed in example 6. The genotypes of hepatitis C viruses infecting the different patients were determined by means of the Inno-LiPA genotyping assay (Innogenetics, Belgium). Figure 5 shows the anti-E1 signal-to-noise ratios of these patients followed during the course of interferon treatment and during the follow-up period after treatment. LTR cases consistently showed rapidly declining anti-E1 levels (with complete negativation in 3 cases), while anti-E1 levels of NR cases remained approximately constant. Some of the obtained anti-E1 data are shown in Table 2 as average S/N ratios ± SD (mean anti-E1 titer). The anti-E1 titer could be deduced from the signal to noise ratio as show in Figures 5, 6, 7, and 8.

Already at the end of treatment, marked differences could be observed between the 2 groups. Anti-E1 antibody titers had decreased 6.9 times in LTR but only 1.5 times in NR. At the end of follow up, the anti-E1 titers had declined by a factor of 22.5 in the patients with sustained response and even slightly increased in NR. Therefore, based on these data, decrease of anti-E1 antibody levels during monitoring of IFN-α therapy correlates with long-term, sustained response to treatment. The anti-E1 assay may be very useful for prognosis of long-term response to IFN treatment, or to treatment of the hepatitis C disease in general.

This finding was not expected. On the contrary, the inventors had expected the anti-E1 antibody levels to increase during the course of IFN treatment in patients with long term

response. As is the case for hepatitis B, the virus is cleared as a consequence of the seroconversion for anti-HBsAg antibodies. Also in many other virus infections, the virus is eliminated when anti-envelope antibodies are raised. However, in the experiments of the present invention, anti-E1 antibodies clearly decreased in patients with a long-term response to treatment, while the antibody-level remained approximately at the same level in non-responding patients. Although the outcome of these experiments was not expected, this non-obvious finding may be very important and useful for clinical diagnosis of HCV infections. As shown in Figures 9, 10, 11, and 12, anti-E2 levels behaved very differently in the same patients studied and no obvious decline in titers was observed as for anti-E1 antibodies. Figure 35 gives a complete overview of the pilot study.

As can be deduced from Table 2, the anti-E1 titers were on average at least 2 times higher at the start of treatment in long term responders compared with incomplete responders to treatment. Therefore, measuring the titer of anti-E1 antibodies at the start of treatment, or monitoring the patient during the course of infection and measuring the anti-E1 titer, may become a useful marker for clinical diagnosis of hepatitis C. Furthermore, the use of more defined regions of the E1 or E2 proteins may become desirable, as shown in example 7.3.

7.2. Analysis of E1 and E2 antibodies in a larger patient cohort

The pilot study lead the inventors to conclude that, in case infection was completely cleared, antibodies to the HCV envelope proteins changed more rapidly than antibodies to the more conventionally studied HCV antigens, with E1 antibodies changing most vigorously. We therefore included more type 1b and 3a-infected LTR and further supplemented the cohort with a matched series of NR, such that both groups included 14 patients each. Some partial responders (PR) and responders with relapse (RR) were also analyzed.

Figure 36 depicts average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups and Tables 4 and 5 show the statistical analyses. In this larger cohort, higher E1 antibody levels before IFN-α therapy were associated with LTR ($P < 0.03$). Since much higher E1 antibody levels were observed in type 3a-infected patients compared with type 1b-infected patients (Figure 37), the genotype was taken into account (Table 4). Within the type 1b-infected group, LTR also had higher E1 antibody levels than NR at the initiation of treatment [$P < 0.05$]; the limited number of type 3a-infected NR did not allow statistical analysis.

Of antibody levels monitored in LTR during the 1.5-year follow up period, only E1

antibodies cleared rapidly compared with levels measured at initiation of treatment [P = 0.0058, end of therapy; P = 0.0047 and P = 0.0051 at 6 and 12 months after therapy, respectively]. This clearance remained significant within type 1- or type 3-infected LTR (average P values < 0.05). These data confirmed the initial finding that E1Ab levels decrease rapidly in the early phase of resolvement. This feature seems to be independent of viral genotype. In NR, PR, or RR, no changes in any of the antibodies measured were observed throughout the follow up period. In patients who responded favourably to treatment with normalization of ALT levels and HCV-RNA negative during treatment, there was a marked difference between sustained responders (LTR) and responders with a relapse (RR). In contrast to LTR, RR did not show any decreasing E1 antibody levels, indicating the presence of occult HCV infection that could neither be demonstrated by PCR or other classical techniques for detection of HCV-RNA, nor by raised ALT levels. The minute quantities of viral RNA, still present in the RR group during treatment, seemed to be capable of anti-E1 B cell stimulation. Anti-E1 monitoring may therefore not only be able to discriminate LTR from NR, but also from RR.

7.3. Monitoring of antibodies of defined regions of the E1 protein

Although the molecular biological approach of identifying HCV antigens resulted in unprecedented breakthrough in the development of viral diagnostics, the method of immune screening of λgt11 libraries predominantly yielded linear epitopes dispersed throughout the core and non-structural regions, and analysis of the envelope regions had to await cloning and expression of the E1/E2 region in mammalian cells. This approach sharply contrasts with many other viral infections of which epitopes to the envelope regions had already been mapped long before the deciphering of the genomic structure. Such epitopes and corresponding antibodies often had neutralizing activity useful for vaccine development and/or allowed the development of diagnostic assays with clinical or prognostic significance (e.g. antibodies to hepatitis B surface antigen).

As no HCV vaccines or tests allowing clinical diagnosis and prognosis of hepatitis C disease are available today, the characterization of viral envelope regions exposed to immune surveillance may significantly contribute to new directions in HCV diagnosis and prophylaxis.

Several 20-mer peptides (Table 3) that overlapped each other by 8 amino acids, were synthesized according to a previously described method (EP-A-0 489 968) based on the HC-

J1 sequence (Okamoto et al., 1990). None of these, except peptide env35 (also referred to as E1-35), was able to detect antibodies in sera of approximately 200 HCV cases. Only 2 sera reacted slightly with the env35 peptide. However, by means of the anti-E1 ELISA as described in example 6, it was possible to discover additional epitopes as follows: The anti-E1 ELISA as described in example 6 was modified by mixing 50 μg/ml of E1 peptide with the 1/20 diluted human serum in sample diluent. Figure 13 shows the results of reactivity of human sera to the recombinant E1 (expressed from vvHCV-40) protein, in the presence of single or of a mixture of E1 peptides. While only 2% of the sera could be detected by means of E1 peptides coated on strips in a Line Immunoassay format, over half of the sera contained anti-E1 antibodies which could be competed by means of the same peptides, when tested on the recombinant E1 protein. Some of the murine monoclonal antibodies obtained from Balb/C mice after injection with purified E1 protein were subsequently competed for reactivity to E1 with the single peptides (Figure 14). Clearly, the region of env53 contained the predominant epitope, as the addition of env53 could substantially compete reactivity of several sera with E1, and antibodies to the env31 region were also detected. This finding was surprising, since the env53 and env31 peptides had not shown any reactivity when coated directly to the solid phase.

Therefore peptides were synthesized using technology described by applicant previously (in WO 93/18054). The following peptides were synthesized:

peptide env35A-biotin

NH_2-SNSSEAADMIMHTPGCV-GKbiotin (SEQ ID NO:51)

spanning amino acids 208 to 227 of the HCV polyprotein in the E1 region

peptide biotin-env53 ('epitope A')

biotin-GG-ITGHRMAWDMMMNWSPTTAL-COOH (SEQ ID NO:52)

spanning amino acids to 313 of 332 of the HCV polyprotein in the E1 region

peptide 1bE1 ('epitope B')

H_2N-YEVRNVSGIYHVTNDCSNSSIVYEAADMIMHTPGCGK -biotin (SEQ ID NO:53)

spanning amino acids 192 to 228 of the HCV polyprotein in the E1 region

and compared with the reactivities of peptides E1a-BB (biotin-GG-TPTVATRDGKLPATQLRRHIDLL, SEQ ID NO:54) and E1b-BB (biotin-GG-TPTLAARDASVPTTTIRRHVDLL, SEQ ID NO:55) which are derived from the same region of sequences of genotype 1a and 1b respectively and which have been described at the

IXth international virology meeting in Glasgow, 1993 ('epitope C'). Reactivity of a panel of HCV sera was tested on epitopes A, B and C and epitope B was also compared with env35A (of 47 HCV-positive sera, 8 were positive on epitope B and none reacted with env35A). Reactivity towards epitopes A, B, and C was tested directly to the biotinylated peptides (50 μg/ml) bound to streptavidin-coated plates as described in example 6. Clearly, epitopes A and B were most reactive while epitopes C and env35A-biotin were much less reactive. The same series of patients that had been monitored for their reactivity towards the complete E1 protein (example 7.1.) was tested for reactivity towards epitopes A, B, and C. Little reactivity was seen to epitope C, while as shown in Figures 15, 16, 17, and 18, epitopes A and B reacted with the majority of sera. However, antibodies to the most reactive epitope (epitope A) did not seem to predict remission of disease, while the anti-1bE1 antibodies (epitope B) were present almost exclusively in long term responders at the start of IFN treatment. Therefore, anti-1bE1 (epitope B) antibodies and anti-env53 (epitope A) antibodies could be shown to be useful markers for prognosis of hepatitis C disease. The env53 epitope may be advantageously used for the detection of cross-reactive antibodies (antibodies that cross-react between major genotypes) and antibodies to the env53 region may be very useful for universal E1 antigen detection in serum or liver tissue. Monoclonal antibodies that recognized the env53 region were reacted with a random epitope library. In 4 clones that reacted upon immunoscreening with the monoclonal antibody 5E1A10, the sequence -GWD- was present. Because of its analogy with the universal HCV sequence present in all HCV variants in the env53 region, the sequence AWD is thought to contain the essential sequence of the env53 cross-reactive murine epitope. The env31 clearly also contains a variable region which may contain an epitope in the amino terminal sequence -YQVRNSTGL- (SEQ ID NO:93) and may be useful for diagnosis. Env31 or E1-31 as shown in Table 3, is a part of the peptide 1bE1. Peptides E1-33 and E1-51 also reacted to some extent with the murine antibodies, and peptide E1-55 (containing the variable region 6 (V6); spanning amino acid positions 329-336) also reacted with some of the patient sera.

Anti-E2 antibodies clearly followed a different pattern than the anti-E1 antibodies, especially in patients with a long-term response to treatment. Therefore, it is clear that the decrease in anti-envelope antibodies could not be measured as efficiently with an assay employing a recombinant E1/E2 protein as with a single anti-E1 or anti-E2 protein. The anti-E2 response would clearly blur the anti-E1 response in an assay measuring both kinds of antibodies at the same time. Therefore, the ability to test anti-envelope antibodies to the

single E1 and E2 proteins, was shown to be useful.

7.4. Mapping of anti-E2 antibodies

Of the 24 anti-E2 Mabs only three could be competed for reactivity to recombinant E2 by peptides, two of which reacted with the HVRI region (peptides E2-67 and E2-69, designated as epitope A) and one which recognized an epitope competed by peptide E2-13B (epitope C). The majority of murine antibodies recognized conformational anti-E2 epitopes (Figure 19). A human response to HVRI (epitope A), and to a lesser extent HVRII (epitope B) and a third linear epitope region (competed by peptides E2-23, E2-25 or E2-27, designated epitope E) and a fourth linear epitope region (competed by peptide E2-17B, epitope D) could also frequently be observed, but the majority of sera reacted with conformational epitopes (Figure 20). These conformational epitopes could be grouped according to their relative positions as follows: the IgG antibodies in the supernatant of hybridomas 15C8C1, 12D11F1, 9G3E6, 8G10D1H9, 10D3C4, 4H6B2, 17F2C2, 5H6A7, 15B7A2 recognizing conformational epitopes were purified by means of protein A affinity chromatography and 1 mg/ml of the resulting IgG's were biotinylated in borate buffer in the presence of biotin. Biotinylated antibodies were separated from free biotin by means of gelfiltration chromatography. Pooled biotinylated antibody fractions were diluted 100 to 10,000 times. E2 protein bound to the solid phase was detected by the biotinylated IgG in the presence of 100 times the amount of non-biotinylated competing antibody and subsequently detected by alkaline phosphatase labeled streptavidin.

Percentages of competition are given in Table 6. Based on these results, 4 conformational anti-E2 epitope regions (epitopes F, G, H and I) could be delineated (Figure 38). Alternatively, these Mabs may recognize mutant linear epitopes not represented by the peptides used in this study. Mabs 4H6B2 and 10D3C4 competed reactivity of 16A6E7, but unlike 16A6E7, they did not recognize peptide E2-13B. These Mabs may recognize variants of the same linear epitope (epitope C) or recognize a conformational epitope which is sterically hindered or changes conformation after binding of 16A6E7 to the E2-13B region (epitope H).

Example 8: E1 glycosylation mutants

8.1. Introduction

The E1 protein encoded by vvHCV10A, and the E2 protein encoded by vvHCV41 to 44 expressed from mammalian cells contain 6 and 11 carbohydrate moieties, respectively. This could be shown by incubating the lysate of vvHCV10A-infected or vvHCV44-infected RK13 cells with decreasing concentrations of glycosidases (PNGase F or Endoglycosidase H, (Boehringer Mannhein Biochemica) according to the manufacturer's instructions), such that the proteins in the lysate (including E1) are partially deglycosylated (Fig. 39 and 40, respectively).

Mutants devoid of some of their glycosylation sites could allow the selection of envelope proteins with improved immunological reactivity. For HIV for example, gp120 proteins lacking certain selected sugar-addition motifs, have been found to be particularly useful for diagnostic or vaccine purpose. The addition of a new oligosaccharide side chain in the hemagglutinin protein of an escape mutant of the A/Hong Kong/3/68 (H3N2) influenza virus prevents reactivity with a neutralizing monoclonal antibody (Skehel et al, 1984). When novel glycosylation sites were introduced into the influenza hemaglutinin protein by site-specific mutagenesis, dramatic antigenic changes were observed, suggesting that the carbohydrates serve as a modulator of antigenicity (Gallagher et al., 1988). In another analysis, the 8 carbohydrate-addition motifs of the surface protein gp70 of the Friend Murine Leukemia Virus were deleted. Although seven of the mutations did not affect virus infectivity, mutation of the fourth glycosylation signal with respect to the amino terminus resulted in a non-infectious phenotype (Kayman et al., 1991). Furthermore, it is known in the art that addition of N-linked carbohydrate chains is important for stabilization of folding intermediates and thus for efficient folding, prevention of malfolding and degradation in the endoplasmic reticulum, oligomerization, biological activity, and transport of glycoproteins (see reviews by Rose et al., 1988; Doms et al., 1993; Helenius, 1994).

After alignment of the different envelope protein sequences of HCV genotypes, it may be inferred that not all 6 glycosylation sites on the HCV subtype 1b E1 protein are required for proper folding and reactivity, since some are absent in certain (sub)types. The fourth carbohydrate motif (on Asn251), present in types 1b, 6a, 7, 8, and 9, is absent in all other types known today. This sugar-addition motif may be mutated to yield a type 1b E1 protein with improved reactivity. Also the type 2b sequences show an extra glycosylation site

in the V5 region (on Asn299). The isolate S83, belonging to genotype 2c, even lacks the first carbohydrate motif in the V1 region (on Asn), while it is present on all other isolates (Stuyver et al., 1994). However, even among the completely conserved sugar-addition motifs, the presence of the carbohydrate may not be required for folding, but may have a role in evasion of immune surveillance. Therefore, identification of the carbohydrate addition motifs which are not required for proper folding (and reactivity) is not obvious, and each mutant has to be analyzed and tested for reactivity. Mutagenesis of a glycosylation motif (NXS or NXT sequences) can be achieved by either mutating the codons for N, S, or T, in such a way that these codons encode amino acids different from N in the case of N, and/or amino acids different from S or T in the case of S and in the case of T. Alternatively, the X position may be mutated into P, since it is known that NPS or NPT are not frequently modified with carbohydrates. After establishing which carbohydrate-addition motifs are required for folding and/or reactivity and which are not, combinations of such mutations may be made.

8.2. Mutagenesis of the E1 protein

All mutations were performed on the E1 sequence of clone HCCl10A (SEQ ID NO:5). The first round of PCR was performed using sense primer 'GPT' (see Table 7) targetting the GPT sequence located upstream of the vaccinia 11K late promoter, and an antisense primer (designated GLY#, with # representing the number of the glycosylation site, see Fig. 41) containing the desired base change to obtain the mutagenesis. The six GLY# primers (each specific for a given glycosylation site) were designed such that:

- Modification of the codon encoding for the N-glycosylated Asn (AAC or AAT) to a Gln codon (CAA or CAG). Glutamine was chosen because it is very similar to asparagine (both amino acids are neutral and contain non-polar residues, glutamine has a longer side chain (one more $-CH_2-$ group).
- The introduction of silent mutations in one or several of the codons downstream of the glycosylation site, in order to create a new unique or rare (e.g. a second SmaI site for E1Gly5) restriction enzyme site. Without modifying the amino acid sequence, this mutation will provide a way to distinguish the mutated sequences from the original E1 sequence (pvHCV-10A) or from each other (Figure 41) . This additional restriction site may also be useful for the construction of new hybrid (double, triple, etc.) glycosylation mutants.
- 18 nucleotides extend 5' of the first mismatched nucleotide and 12 to 16 nucleotides extend to the 3' end. Table 7 depicts the sequences of the six GLY# primers overlapping the

sequence of N-linked glycosylation sites.

For site-directed mutagenesis, the 'mispriming' or 'overlap extension' (Horton, 1993) was used. The concept is illustrated in Figures 42 and 43. First, two separate fragments were amplified from the target gene for each mutated site. The PCR product obtained from the 5' end (product GLY#) was amplified with the 5' sense GPT primer (see Table 7) and with the respective 3' antisense GLY# primers. The second fragment (product OVR#) was amplified with the 3' antisense TK_R primer and the respective 5' sense primers (OVR# primers, see Table 7, Figure 43).

The OVR# primers target part of the GLY# primer sequence. Therefore, the two groups of PCR products share an overlap region of identical sequence. When these intermediate products are mixed (GLY-1 with OVR-1, GLY-2 with OVR-2, etc.), melted at high temperature, and reannealed, the top sense strand of product GLY# can anneal to the antisense strand of product OVR# (and vice versa) in such a way that the two strands act as primers for one another (see Fig. 42.B.). Extension of the annealed overlap by Taq polymerase during two PCR cycles created the full-length mutant molecule E1Gly#, which carries the mutation destroying the glycosylation site number #. Sufficient quantities of the E1GLY# products for cloning were generated in a third PCR by means of a common set of two internal nested primers. These two new primers are respectively overlapping the 3' end of the vaccinia 11K promoter (sense GPT-2 primer) and the 5' end of the vaccinia thymidine kinase locus (antisense TK_R-2 primer, see Table 7). All PCR conditions were performed as described in Stuyver et al. (1993).

Each of these PCR products was cloned by EcoRI/BamHI cleavage into the EcoRI/BamHI-cut vaccinia vector containing the original E1 sequence (pvHCV-10A).

The selected clones were analyzed for length of insert by EcoRI/BamH I cleavage and for the presence of each new restriction site. The sequences overlapping the mutated sites were confirmed by double-stranded sequencing.

8.3. Analysis of E1 glycosylation mutants

Starting from the 6 plasmids containing the mutant E1 sequences as described in example 8.2, recombinant vaccinia viruses were generated by recombination with wt vaccinia virus as described in example 2.5. Briefly, 175 cm^2-flasks of subconfluent RK13 cells were infected with the 6 recombinant vaccinia viruses carrying the mutant E1 sequences, as well as with the vvHCV-10A (carrying the non-mutated E1 sequence) and wt

vaccinia viruses. Cells were lysed after 24 hours of infection and analyzed on western blot as described in example 4 (see Figure 44A). All mutants showed a faster mobility (corresponding to a smaller molecular weight of approximately 2 to 3 kDa) on SDS-PAGE than the original E1 protein; confirming that one carbohydrate moiety was not added. Recombinant viruses were also analyzed by PCR and restriction enzyme analysis to confirm the identity of the different mutants. Figure 44B shows that all mutants (as shown in Figure 41) contained the expected additional restriction sites. Another part of the cell lysate was used to test the reactivity of the different mutant by ELISA. The lysates were diluted 20 times and added to microwell plates coated with the lectin GNA as described in example 6. Captured (mutant) E1 glycoproteins were left to react with 20-times diluted sera of 24 HCV-infected patients as described in example 6. Signal to noise (S/N) values (OD of GLY#/OD of wt) for the six mutants and E1 are shown in Table 8. The table also shows the ratios between S/N values of GLY# and E1 proteins. It should be understood that the approach to use cell lysates of the different mutants for comparison of reactivity with patient sera may result in observations that are the consequence of different expression levels rather then reactivity levels. Such difficulties can be overcome by purification of the different mutants as described in example 5, and by testing identical quantities of all the different E1 proteins. However, the results shown in table 5 already indicate that removal of the 1st (GLY1), 3rd (GLY3), and 6th (GLY6) glycosylation motifs reduces reactivity of some sera, while removal of the 2nd and 5th site does not. Removal of GLY4 seems to improve the reactivity of certain sera. These data indicate that different patients react differently to the glycosylation mutants of the present invention. Thus, such mutant E1 proteins may be useful for the diagnosis (screening, confirmation, prognosis, etc.) and prevention of HCV disease.

Example 9: Expression of HCV E2 protein in glycosylation-deficient yeasts

The E2 sequence corresponding to clone HCCI41 was provided with the α-mating factor pre/pro signal sequence, inserted in a yeast expression vector and *S. cerevisiae* cells transformed with this construct secreted E2 protein into the growth medium. It was observed that most glycosylation sites were modified with high-mannose type glycosylations upon expression of such a construct in *S. cerevisiae* strains (Figure 45). This resulted in a too high level of heterogeneity and in shielding of reactivity, which is not desirable for either vaccine or diagnostic purposes. To overcome this problem, *S. cerevisiae* mutants with modified glycosylation pathways were generated by means of selection of vanadate-resistant clones.

Such clones were analyzed for modified glycosylation pathways by analysis of the molecular weight and heterogeneity of the glycoprotein invertase. This allowed us to identify different glycosylation deficient *S. cerevisiae* mutants. The E2 protein was subsequently expressed in some of the selected mutants and left to react with a monoclonal antibody as described in example 7, on western blot as described in example 4 (Figure 46).

Example 10. General utility

The present results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the HCV envelope proteins with human patient sera. This can be obtained using the proper HCV envelope protein expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

The purification method dislcosed in the present invention may also be used for 'viral envelope proteins' in general. Examples are those derived from Flaviviruses, the newly discovered GB-A, GB-B and GB-C Hepatitis viruses, Pestiviruses (such as Bovine viral Diarrhoea Virus (BVDV), Hog Cholera Virus (HCV), Border Disease Virus (BDV)), but also less related virusses such as Hepatitis B Virus (mainly for the purification of HBsAg).

The envelope protein purification method of the present invention may be used for intra- as well as extracellularly expressed proteins in lower or higher eukaryotic cells or in prokaryotes as set out in the detailed description section.

Example 11. Demonstration of Prophylactic and Therapeutic Utility

Liver disease in chimpanzees chronically infected with HCV can be reduced by

immunization with E1. Multiple immunizations, however, were required in order to reach a significant immune response. One of ordinary skill will appreciate that viral persistence is produced with immune modulation which is either orchestrated by the virus itself or by the host. In order to analyze if such an immune modulation does exist in HCV, the immune responses against E1 and NS3 in naive and chronically infected chimpanzees were compared. Since a lower response in the chronically infected animals was anticipated, this group of animals was selected for a more rigorous immunization schedule including the following: use of an adjuvant proven in mice to be more potent for inducing cellular responses (Table 9) compared to alum, which was the adjuvant used for naive animals; and the immunization schedule for chronically infected animals consisted of 12 immunizations compared to 6 for naive animals (Fig. 47).

Although the number of immunized animals does not allow statistical analysis, the following clear tendency can be detected in the humoral responses (Table 10): the number of immunizations for seroconversion is lower in naive animals; and the magnitude of the immune response is substantially greater in the naive animals, 2/3 infected animals do not reach the level of 10 internal units, even after 12 immunizations.

The analysis of the cellular responses, after three immunizations, reveals an even larger difference (Fig. 48a-d), including the following: E1-specific T-cell proliferation is almost absent in the chronically infected animals, while a clear stimulation can be seen in the naive setting; IL-2 measurements confirmed that the low stimulation of the T-cell compartment in chronic carriers; and, a clear Th2 (IL-4) response in naive animals is induced, as expected for an alum-adjuvant containing vaccine.

This confirms that at least E1 immunization provides a prophylactic effect in naïve animals and suggest that E2 and/or combinations of E1 and E2 proteins and/or peptides may provide useful therapeutic and/or prophylactic benefits in naive animals.

The 'impairment' to induce both cellular and humoral responses against an HCV E1 antigen can be only partially overcome by multiple immunizations, as demonstrated by the following results: an increase in antibody titer after each injection was noted but the levels as in naive animals were not reached in 2/3 animals; and the T-cell proliferative responses remain very low (Fig. 49). The ELISPOT results show, however, a minor increase in IL-2 (not shown), no change in IFN-g (not shown) and an increase in IL-4 (Fig. 49) which indicates that Th2 type responses are more readily induced. IL-4 was noted to remain at a low level compared to the level reached after three immunizations in naive animals.

A quite similar observation was made for NS3 immunizations where an even stronger adjuvant (RIBI) was used in the chronic chimpanzee. As compared with an alum formulation in naive animals the following has been noted: the induced antibody titers are comparable in both groups (not shown); and both cytokine secretion and T-cell proliferation are almost absent in the chronic animals compared to the responses in naive animals (Fig. 49a-b).

Currently there have been some indications that immune responses against HCV in chronic carriers are low or at least insufficient to allow clearance of infection. The above results support the hypothesis that the immune system of HCV chronic carriers may be impaired and that they do not respond to HCV antigens as efficiently as in a naive situation.

In a study by Wiedmann et al., (Hepatology 2000; 31: 230-234), vaccination for HBV was less effective in HCV chronic carriers, which indicates that such an immune impairment is not limited to HCV antigens. De Maria et al. (Hepatology 2000; 32: 444-445) confirmed these data and have proposed adapted vaccine dosing regimens for HCV patients. The data presented herein indicates that increasing the number of immunizations may indeed augment humoral responses but that cellular (especially Th1) responses are difficult to induce, even when powerful adjuvants are used. It may be advantageous to begin immunization at the time of antiviral therapy, when the immune system is more prone to respond.

Table 1: Recombinant vaccinia plasmids and viruses

Plasmid	HCV cDNA subIcone			Vector
Name	Name	Construction	Length (nt/aa)	used for insertion
pvHCV-13A	E1s	EcoR I - Hind III	472/157	pgptATA-18
pvHCV-12A	E1s	EcoR I - Hind III	472/158	pgptATA-18
pvHCV-9A	E1	EcoR I - Hind III	631/211	pgptATA-18
pvHCV-11A	E1s	EcoR I - Hind III	625/207	pgptATA-18
pvHCV-17A	E1s	EcoR I - Hind III	625/208	pgptATA-18
pvHCV-10A	E1	EcoR I - Hind III	783/262	pgptATA-18
pvHCV-18A	COREs	Acc I (Kl) – EcoR I (Kl)	403/130	pgptATA-18
pvHCV-34	CORE	Acc I (Kl) - Fsp I	595/197	pgptATA-18
pvHCV-33	CORE-E1	Acc I (Kl)	1150/380	pgptATA-18
pvHCV-35	CORE-E1b.his	EcoR I - BamH I (Kl)	1032/352	pMS-66
pvHCV-36	CORE-E1n.his	EcoR I - Nco I (Kl)	1106/376	pMS-66
pvHCV-37	E1Δ	Xma I - BamH I	711/239	pvHCV-10A
pvHCV-38	E1Δs	EcoR I - BstE II	553/183	pvHCV-11A
pvHCV-39	E1Δb	EcoR I - BamH I	960/313	pgsATA-18
pvHCV-40	E1Δb.his	EcoR I - BamH I (Kl)	960/323	pMS-66
pvHCV-41	E2bs	BamH I (Kl)-AlwN I (T4)	1005/331	pgsATA-18
pvHCV-42	E2bs.his	BamH I (Kl)-AlwN I (T4)	1005/341	pMS-66
pvHCV-43	E2ns	Nco I (Kl) – AlwN I (T4)	932/314	pgsATA-18
pvHCV-44	E2ns.his	Nco I (Kl) – AlwN I (T4)	932/321	pMS-66
pvHCV-62	E1s (type 3a)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-63	E1s (type 5)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-64	E2	BamH I - Hind III	1410/463	pgsATA-18
pvHCV-65	E1-E2	BamH I - Hind III	2072/691	pvHCV-10A
pvHCV-66	CORE-E1-E2	BamH I - Hind III	2427/809	pvHCV-33

nt: nucleotide; aa: amino acid; Kl: Klenow DNA Pol filling; T4: T4 DNA Pol filling
Position: amino acid position in the HCV polyprotein sequence

Table 1 - continued: Recombinant vaccinia plasmids and viruses

Plasmid Name	HCV cDNA subclone			Vector used for insertion
	Name	Construction	Length (nt/aa)	
pvHCV-81	E1*-GLY 1	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-82	E1*-GLY 2	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-83	E1*-GLY 3	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-84	E1*-GLY 4	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-85	E1*-GLY 5	EcoRI – BamH I	783/262	pvHCV-10A
pvHCV-86	E1*-GLY 6	EcoRI – BamH I	783/262	pvHCV-10A

nt: nucleotide; aa: amino acid; Kl: Klenow DNA Pol filling; T4: T4 DNA Pol filling
Position: amino acid position in the HCV polyprotein sequence

Table 2 : Summary of anti-E1 tests

S/N ± SD (mean anti-E1 titer)

	Start of treatment	End of treatment	Follow-up
LTR	6.94 ± 2.29 (1:3946)	4.48 ± 2.69 (1:568)	2.99 ± 2.69 (1:175)
NR	5.77 ± 3.77 (1:1607)	5.29 ± 3.99 (1:1060)	6.08 ± 3.73 (1:1978)

LTR : Long-term, sustained response for more than 1 year

NR : No response, response with relapse, or partial response

Table 3 : Synthetic peptides for competition studies

PROTEIN	PEPTIDE	AMINO ACID SEQUENCE	POSITION	SEQ ID NO
E1	E1-31	LLSCLTVPASAYQVRNSTGL	181-200	56
	E1-33	QVRNSTGLYHVTNDCPNSSI	193-212	57
	E1-35	NDCPNSSIVYEAHDAILHTP	205-224	58
	E1-35A	SNSSIVYEAADMIMHTPGCV	208-227	59
	E1-37	HDAILHTPGCVPCVREGNVS	217-236	60
	E1-39	CVREGNVSRCWVAMTPTVAT	229-248	61
	E1-41	AMTPTVATRDGKLPATQLRR	241-260	62
	E1-43	LPATQLRRHIDLLVGSATLC	253-272	63
	E1-45	LVGSATLCSALYVGDLCGSV	265-284	64
	E1-49	QLFTFSPRRHWTTQGCNCSI	289-308	65
	E1-51	TQGCNCSIYPGHITGHRMAW	301-320	66
	E1-53	ITGHRMAWDMMMNWSPTAAL	313-332	67
	E1-55	NWSPTAALVMAQLLRIPQAI	325-344	68
	E1-57	LLRIPQAILDMIAGAHWGVL	337-356	69
	E1-59	AGAHWGVLAGIAYFSMVGNM	349-368	70
	E1-63	VVLLLFAGVDAETIVSGGQA	373-392	71
E2	E2-67	SGLVSLFTPGAKQNIQLINT	397-416	72
	E2-69	QNIQLINTNGSWHINSTALN	409-428	73
	E2-$3B	LNCNESLNTGWWLAGLIYQHK	427-446	74
	E2-$1B	AGLIYQHKFNSSGCPERLAS	439-458	75
	E2-1B	GCPERLASCRPLTDFDQGWG	451-470	76
	E2-3B	TDFDQGWGPISYANGSGPDQ	463-482	77

Table 3 - continued : Synthetic peptides for competition studies

E2-5B	ANGSGPDQRPYCWHYPPKPC	475-494	78
E2-7B	WHYPPKPCGIVPAKSVCGPV	487-506	79
E2-9B	AKSVCGPVYCFTPSPVVVGT	499-518	80
E2-11B	PSPVVVGTTDRSGAPTYSWG	511-530	81
E2-13B	GAPTYSWGENDTDVFVLNNT	523-542	82
E2-17B	GNWFGCTWMNSTGFTKVCGA	547-566	83
E2-19B	GFTKVCGAPPVCIGGAGNNT	559-578	84
E2-21	IGGAGNNTLHCPTDCFRKHP	571-590	85
E2-23	TDCFRKHPDATYSRCGSGPW	583-602	86
E2-25	SRCGSGPWITPRCLVDYPYR	595-614	87
E2-27	CLVDYPYRLWHYPCTINYTI	607-626	88
E2-29	PCTINYTIFKIRMYVGGVEH	619-638	89
E2-31	MYVGGVEHRLEAACNWTPGE	631-650	90
E2-33	ACNWTPGERCDLEDRDRSEL	643-662	91
E2-35	EDRDRSELSPLLLTTTQWQV	655-674	92

Table 4. Change of Envelope Antibody levels over time (complete study, 28 patients)

Wilcoxon Signed Rank test (P values)	E1Ab NR	E1Ab NR All	E1Ab NR	E1Ab LTR type 1b	E1Ab LTR type 3a	E1Ab LTR All	E2Ab NR	E1Ab LTR		
								type 1b	type 3a	All
End of therapy*	0.1167	0.2604	0.285		0.0058**	0.043**	0.0499**	0.0186**	0.0640	
6 months follow up*	0.86		0.7213	0.5930	0.0047**	0.043**	0.063		0.04326	0.0464**
12 months follow up*	0.7989	0.3105	1		0.0051**	0.0679	0.0277**	0.0869	0.0058**	

*Data were compared with values obtained at initiation of therapy

**P values < 0.05

Table 5. Difference between LTR and NR (complete study)

Mann-Withney U test (P values)	E1Ab S/N All	E1Ab titers All	E1Ab S/N type 1b	E1Ab S/N type 3a	E1Ab S/N All	E2Ab S/N
Initiation of therapy	0.0257*	0.05*	0.68		0.1078	
End of therapy	0.1742				0.1295	
6 months follow up	1	0.6099	0.425		0.3081	
12 months follow up	0.67	0.23	0.4386		0.6629	

* P values < 0.05

Table 6. Competition experiments between murine E2 monoclonal antibodies

	Decrease (%) of anti-E2 reactivity of biotinylated anti-E2 mabs									
competitor	17H10F4D10	2F10H10	16A6E7	10D3C4	4H6B2	17C2F2	9G3E6	12D11F1	15C8C1	8G10D1H9
17H10F4D10	-	62	10	ND	11	ND	5	6	30	ND
2F10H10	90	-	1	ND	30	ND	0	4	12	ND
16A6E7	ND	ND	-	ND	ND	ND	ND	ND	ND	ND
10D3C4	11	50	92	-	94	26	28	43	53	30
4H6B2	ND	ND	82	ND	-	ND	ND	ND	ND	ND
17C2F2	2	ND	75	ND	56	-	11	10	0	0
9G3E6	ND	ND	68	ND	11	ND	-	60	76	ND
12D11F1	ND	ND	26	ND	13	ND	ND	-	88	ND
15C8C1	ND	ND	18	ND	10	ND	ND	ND	-	ND
8G10D1H9	2	2	11	ND	15	ND	67	082	81	-
competitor controls										
15B7A2	0	0	9	15	10	9	0	0	0	5
5H6A7	0	2	0	12	8	0	0	4	0	0
23C12H9	ND	ND	2	12	ND	4	ND	ND	ND	2

ND, not done

Table 7. Primers

SEQ ID NO:96	GPT	5'-GTTTAACCACTGCATGATG-3'
SEQ ID NO:97	TK_R	5'-GTCCCATCGAGTGCGGCTAC-3'
SEQ ID NO:98	GLY1	5'-CGTGACATGGTACAT**T**CCGGACAC**T**T**G**GCGCACTTCATAAGCGGA-3'
SEQ ID NO:99	GLY2	5'-TGCCTCATACACAATG**GAGCTC**T**G**GGACGAGTCGTTCGTGAC-3'
SEQ ID NO:100	GLY3	5'-TACCCAGCAGCGGGA**GCTC**T**GT**T**G**CTCCCGAACGCAGGGCAC-3'
SEQ ID NO:101	GLY4	5'-TGTCGTGGTGGGGACG**GA**GGC**C**T**G**CCTAGCTGCGAGCGTGGG-3'
SEQ ID NO:102	GLY5	5'-CGTTATGTGGCC**C**GG**G**TAGATTGAGCA**C**T**G**GCAGTCCTGCACCGTCTC-3'
SEQ ID NO:103	GLY6	5'-CAGGGCCGTTGTAGGC**CT**CCA**C**T**G**CATCATCATATCCCAAGC-3'
SEQ ID NO:104	OVR1	5'-CCGG**A**ATGTACCATGTCACGAACGAC-3'
SEQ ID NO:105	OVR2	5'-**GCTC**CATTGTGTATGAGGCAGCGG-3'
SEQ ID NO:106	OVR3	5'-**GAGC**TCCCGCTGCTGGGTAGCGC-3'
SEQ ID NO:107	OVR4	5'-CC**TC**CGTCCCCACCACGACAATACG-3'
SEQ ID NO:108	OVR5	5'-CTA***CCCGGG***CCACATAACGGGTCACCG-3'
SEQ ID NO:109	OVR6	5'-GG**AG**GCCTACAACGGCCCTGGTGG-3'
SEQ ID NO:110	GPT-2	5'-TTCTATCGATTAAATAGAATTC -3'
SEQ ID NO:111	TK_R-2	5'-GCCATACGCTCACAGCCGATCCC-3'

nucleotides underlined represent additional restriction site

nucleotides in bold represent mutations with respect to the original HCC110A sequence

Table 8. Analysis of E1 glycosylation mutants by ELISA

SERUM

	1	2	3	4	5	6	7	8	9
SN GLY1	1.802462	2.120971	1.403871	1.205597	2.120191	2.866913	1.950345	1.866183	1.730193
SN GLY2	2.400795	1.76818	2.325495	2.639308	2.459019	5.043993	2.146302	1.595477	1.688973
SN GLY3	1.642718	1.715477	2.261646	2.354748	1.591818	4.833742	1.96692	1.482099	1.602222
SN GLY4	2.578154	3.824038	3.874605	1.499387	3.15	4.71302	4.198751	3.959542	3.710507
SN GLY5	2.482051	1.793761	2.409344	2.627358	1.715311	4.964765	2.13912	1.576336	1.708937
SN GLY6	2.031487	1.495737	2.131613	2.527925	2.494833	4.784027	2.02069	1.496489	1.704976
SN E1	2.828205	2.227036	2.512792	2.790881	3.131579	4.869128	2.287753	1.954198	1.805556

	10	11	12	13	14	15	16	17	18
SN GLY1	2.468162	1.220654	1.629403	5.685561	3.233604	3.763498	1.985105	2.317721	6.675179
SN GLY2	2.482212	1.467582	2.070524	7.556682	2.567613	3.621928	3.055649	2.933792	7.65433
SN GLY3	2.191558	1.464216	1.721164	7.930538	2.763055	3.016099	2.945628	2.515305	5.775357
SN GLY4	5.170841	4.250784	3.955153	8.176816	6.561122	5.707668	5.684498	5.604813	6.4125
SN GLY5	3.021807	1.562092	2.07278	8.883408	2.940334	3.125561	3.338912	2.654224	5.424107
SN GLY6	2.677757	1.529608	1.744221	8.005561	2.499952	2.621704	2.572385	2.363301	5.194107
SN E1	2.616822	1.55719	2.593886	8.825112	3.183771	3.067265	3.280335	2.980354	7.191964

	19	20	21	22	23	24	SUM S/N	AVERAGE S/N
SN GLY1	1.93476	2.47171	4.378633	1.188748	2.158889	1.706992	59.88534	2.495223
SN GLY2	2.127712	2.921288	4.680101	1.150781	1.661914	1.632785	69.65243	2.902185
SN GLY3	1.980185	2.557384	4.268633	0.97767	1.336775	1.20376	62.09872	2.587447
SN GLY4	3.813321	3.002535	4.293038	2.393011	3.68213	2.481585	102.6978	4.279076
SN GLY5	2.442804	3.126761	4.64557	1.153656	1.817901	1.638211	69.26511	2.886046
SN GLY6	1.506716	2.665433	2.781063	1.280743	1.475062	1.716423	61.32181	2.555075
SN E1	2.771218	3.678068	5.35443	1.167286	2.083333	1.78252	76.54068	3.189195

Table 8 (continued). Analysis of E1 glycosylation mutants by ELISA

SERUM

	1	2	3	4	5	6	7	8	9
GLY1/E1	0.637316	0.952374	0.55869	0.431977	0.677036	0.588794	0.852516	0.954961	0.958261
GLY2/E1	0.848876	0.793961	0.925463	0.94569	0.785233	1.035913	0.93817	0.816436	0.935431
GLY3/E1	0.580834	0.770296	0.900053	0.84373	0.508312	0.992733	0.859761	0.758418	0.887385
GLY4/E1	0.911587	1.717097	1.541952	0.537245	1.005882	0.967939	1.835317	2.026172	2.05505
GLY5/E1	0.877607	0.805447	0.958831	0.941408	0.547746	1.019642	0.935031	0.806641	0.946488
GLY6/E1	0.718296	0.671626	0.848305	0.90578	0.796669	0.982522	0.883264	0.765781	0.944294

	10	11	12	13	14	15	16	17	18
GLY1/E1	0.94319	0.783882	0.628171	0.644248	1.015652	1.226988	0.605153	0.777666	0.928144
GLY2/E1	0.94856	0.942455	0.798232	0.85627	0.806469	1.180833	0.931505	0.984377	1.064289
GLY3/E1	0.837488	0.940294	0.663547	0.898633	0.867856	0.983319	0.897966	0.843962	0.803029
GLY4/E1	1.976	2.72978	1.524798	0.92654	2.060802	1.860833	1.732902	1.880587	0.89162
GLY5/E1	1.154762	1.003148	0.799102	1.006606	0.923538	1.019006	1.017857	0.890574	0.75419
GLY6/E1	1.023286	0.982288	0.672435	0.907134	0.785217	0.854737	0.784184	0.79296	0.72221

	19	20	21	22	23	24	SUM E1/GLY#	AVERAGE E1/GLY#
GLY1/E1	0.698162	0.672013	0.817759	1.018386	1.036267	0.957628	19.36524	0.806885
GLY2/E1	0.76779	0.794245	0.874061	0.98586	0.797719	0.915998	21.67384	0.903077
GLY3/E1	0.714554	0.695306	0.797215	0.837558	0.641652	0.675314	19.19921	0.799967
GLY4/E1	1.376045	0.816335	0.801773	2.050064	1.767422	1.392178	36.38592	1.51608
GLY5/E1	0.881491	0.850109	0.867612	0.988323	0.872593	0.919042	21.78679	0.907783
GLY6/E1	0.543702	0.724683	0.519395	1.097197	0.70803	0.962919	19.59691	0.816538

Table 9. Profile of adjuvated E1 in Balb/c mice

	alum	T-cell adjuvant	RBI
antibody titre (mean ± SD, n=6)	96000 ± 101000	62000 ± 60000	176000 ± 149000
antibody isotypes	IgG1	IgG1/2b	IgG1/2a
T-cell preliferation in spleen[1] (n=3)	11750 (2/3)	48300 (3/3)	26000 (3/3)
T-cell proliferation in lymph node[2]	no specific stimulation	4000	8000
cytokine profile (spleen)	Il-4	IFN-g/Il-4	IFN-g/Il-4

[1] after three s.c./i.m. immunizations, 3 randomly selected mice were analyzed individually, the result is expressed as the mean specific cpm obtained after 4 days of E1 stimulation (1 µg/ml), the number in brackets refers to the number of mice with specific stimulation above background

[2] after one single intra footpath immunization (n=2), the result is expressed as the mean specific cpm obtained after 5 days of E1 stimulation (1 µg/ml)

Table 10. Humoral Responses: No. of immunizations required for different E-1 antibodies levels

Animal	status	seroconversion[1]	> 1 U/ml[2]	> 10 U/ml
Marcel	chronic	3	4	5
Peggy	chronic	3	5	>12
Femma	chronic	4	5	>12
Yoran	naive	3	4	5
Marti	naive	2	3	5

[1] defined as ELISA signal higher than cut-off level if no E1-antibodies were present prior to immunization, in the other cases the observation of a titer higher than the 3 individual time points of pre-immunization titers was considered as the point of seroconversion.

[2] the unit is defined as follows: the level of E1 antibodies in human chronic carriers prior to interferon therapy and infected with genotype 1b is < 0.1 U/ml for 50% of the patients, between 0.1 to 1 U/ml for 25% of the patients and > 1 U/ml in the remaining 25% of patients, n=58

Example 12: Immunization of a chimpanzee chronically infected with HCV subtype 1b

A chimpanzee (Phil) already infected for over 13 years (5015 days before immunization) with an HCV subtype Ib strain was vaccinated with El (aa 192-326) which was derived from a different strain of genotype 1 b, with a 95.1% identity on the amino acid level (see also Table 2 of WO 99/67285 the whole of which is incorporated herein by reference), and which was prepared as described in examples 1-3 of WO 99/97285. The chimpanzee received in total 6 intramuscular immunizations of each 50 µg E1 in PBS/0.05% CHAPS mixed with RIBI R-730 (MPLA+TDM+CWS) according to the manufacturer's protocol (Ribi Inc. Hamilton, MT). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 6 weeks between the two series. Starting 150 days prior to immunization, during the immunization period and until 1 year post immunization (but see below and WO 99/67285) the chimpanzee was continuously monitored for various parameters indicative for the activity.of the HCV induced disease. These parameters included blood chemistry, ALT ,AST, gammaGT, blood chemistry, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.

Clearly, ALT (and especially gammaGT, data not shown) levels decreased as soon as the antibody level against El reached its maximum (see, Figure 8 of WO 99/67285). ALT rebounded rather rapidly as soon as the antibody levels started to decline, but gammaGT remained at a lower level as long as anti-El remained detectable.

E2 antigen in the liver decreased to almost undetectable levels during the period in which anti-El was detectable and the E2 antigen rebounded shortly after the disappearance of these antibodies. Together with the Core and E2 antigen becoming undetectable in the liver, the inflammation of the liver markedly decreased (see also Table 3 of WO 99/67285). This is a major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the viral antigens from its major target organ, the liver .
The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland),

remained approximately unchanged in the serum during the whole study period.

More detailed analyses of the humoral response revealed that the maximum end-point titer reached 14.5 x 10^3 (after the sixth immunization) and that this titer dropped to undetectable 1 year post immunization (Figure 8 of WO 99/67285). Figure 9 of WO 99/67285 shows that the main epitopes, which can be mimicked by peptides, recognized by the B-cells are located at the N-terminal region of E2 (peptides V1V2 and V2V3, for details on the peptides used see Table 4 of WO 99/67285). Since the reactivity against the recombinant El is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against El. The remaining part is directed against epitopes which cannot be mimicked by peptides, i.e discontinuous epitopes. Such epitopes are only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against El is unique, at least compared to what is normally observed in human chronic HCV carriers (WO 96/13590 to Maertens et al.) and in chimpanzees (van Doorn et al., 1996), who raise anti-E1 antibodies in their natural course of infection. In those patients, anti-E1 is in part also directed to discontinuous epitopes but a large proportion is directed against the C4 epitope (±50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype), and reactivity against V2V3 was only exceptionally recorded (Maertens et al., 1997).

Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 1 to 2.5, and remains somewhat elevated during the follow up period (Figure 10 of WO 99/67285). It is this T cell reactivity that is only seen in Long term responders to interferon therapy (see: PCT/EP 94/03555 to Leroux-Roels et al.;Leroux-Roels et al., 1996).

Example 13: Immunization of a chronic HCV carrier with different subtype

A chimpanzee (Ton) already infected for over 10 years (3809 days before immunization) with HCV from genotype la was vaccinated with El from genotype lb, with only a 79.3 % identity on the amino acid level (see also Table 2 of WO 99/67285), and prepared as described in the previous examples. The chimpanzee received a total of 6 intramuscular immunizations of 50 µg El in PBS/0.05% CHAPS each mixed with RIBI R-730 according

to the manufacturer's protocol (Ribi Inc. Hamilton, MT). The 6 immunizations were given in two series of three shots with a three week interval and with a lag period of 4 weeks between the two series. Starting 250 days prior to immunization, during the immunization period and until 9 months (but see below and WO 99/67285) post immunization the chimpanzee was continuously monitored for various parameters indicative for the activity of the HCV induced disease. These parameters included blood chemistry, ALT, AST, gammaGT, viral load in the serum, viral load in the liver and liver histology. In addition, the immune answer to the immunization was monitored both on the humoral and cellular level. During this period the animal was also monitored for any adverse effects of the immunization, such as change in behaviour, clinical symptoms, body weight, temperature and local reactions (redness, swelling, indurations). Such effects were not detected.

Clearly, ALT levels (and gammaGT levels, data not shown) decreased as soon as the antibody level against El reached its maximum (Figure 11 of WO 99/67285). ALT and gammaGT rebounded as soon as the antibody levels started to decline, but ALT and gammaGT remained at a lower level during the complete follow up period. ALT levels were even significantly reduced after vaccination (62 $\pm$ 6 U/l) as compared to the period before vaccination (85 $\pm$ 11 U/l). Since less markers of tissue damage were recovered in the serum, these findings were a first indication that the vaccination induced an improvement of the liver disease.

E2 antigen levels became undetectable in the period in which anti-E1 remained above a titer of 1.0×10^3, but became detectable again at the time of lower El antibody levels. Together with the disappearance of HCV antigens, the inflammation of the liver markedly decreased from moderate chronic active hepatitis to minimal forms of chronic persistent hepatitis (Table 3 of WO 99/67285). This is another major proof that the vaccine induces a reduction of the liver damage, probably by clearing, at least partially, the virus from its major target organ, the liver .

The viraemia level, as measured by Amplicor HCV Monitor (Roche, Basel, Switzerland), in the serum remained at approximately similar levels during the whole study period. More detailed analysis of the humoral response revealed that the maximum end-point titer reached was 30×10^3 (after the sixth immunization) and that this titer dropped to 0.5×10^3 nine months after immunization (Figure 11 of WO 99/67285). Figure 12 of WO 99/67285

shows that the main epitopes, which can be mimicked by peptides and are recognized by the B-cells, are located at the N-terminal region (peptides V1V2 and V2V3, for details on the peptides used see Table 4 of WO 99/67285). Since the reactivity against the recombinant El is higher and longer lasting, it can also be deduced from this figure, that the antibodies recognizing these peptides represent only part of the total antibody population against El. The remaining part is most likely directed against epitopes which cannot be mimicked by peptides, i.e. discontinuous epitopes. Such epitopes are probably only present on the complete E1 molecule or even only on the particle-like structure. Such an immune response against E1 is unique, at least compared to what is normally observed in human chronic HCV carriers, which have detectable anti-El. In those patients, anti-E1 is in part also discontinuous, but a large proportion is directed against he C4 epitope (50% of the patient sera), a minor proportion against V1V2 (ranging from 2-70% depending on the genotype) and exceptionally reactivity against V2V3 was recorded (Maertens et al., 1997). As this chimpanzee is infected with an la isolate the antibody response was also evaluated for cross-reactivity towards a El-la antigen. As can be seen in Figure 13 of WO 99/67285, such cross-reactive antibodies are indeed generated, although, they form only part of the total antibody population. Remarkable is the correlation between the reappearance of viral antigen in the liver and the disappearance of detectable anti-1a El antibodies in the serum.

Analysis of the T-cell reactivity indicated that also this compartment of the immune system is stimulated by the vaccine in a specific way, as the stimulation index of these T-cells rises from 0.5 to 5, and remains elevated during the follow up period (Figure 14 of WO 99/67285).

Example 14: Reboosting of HCV chronic carriers with El

As the El antibody titers as observed in examples 12 and 13 were not stable and declined over time, even to undetectable levels for the 1b infected chimp, it was investigated if this antibody response could be increased again by additional boosting. Both chimpanzees were immunized again with three consecutive intramuscular immunization with a three week interval (50 μg El mixed with RIBI adjuvant). As can be judged from Figures 8 and 11 of WO 99/67285, the anti-El response could indeed be boosted, once again the viral antigen in the liver decreased below detection limit. The viral load in the serum remained constant

although in Ton (Figure 11 of WO 99/67285). A viremia level of $< 10^5$ genome equivalents per ml was measured for the first time during the follow up period.

Notable is the finding that, as was already the case for the first series of immunizations, the chimpanzee infected with the subtype 1b HCV strain (Phil) responds with lower anti-El titers, than the chimpanzee infected with subtype la HCV strain (maximum titer in the first round 14.5×10^3 versus 30×10^3 for Ton and after additional boosting only 1.2×10^3 for Phil versus 40×10^3 for Ton). Although for both animals the beneficial effect seems to be similar, it could be concluded from this experiment that immunization of a chronic carrier with an El protein derived from another subtype or genotype may be especially beneficial to reach higher titers, maybe circumventing a preexisting and specific immune suppression existing in the host and induced by the infecting subtype or genotype. Alternatively, the lower titers observed in the homologous setting (1b vaccine +1b infection) may indicate binding of the bulk of the antibodies to virus. Therefore, the induced antibodies may possess neutralizing capacity .

Example 15: Demonstration of prophylactic utility of E1-vaccination in chimpanzee

The HCV Els protein (amino acids 192-326) was expressed in Vero cells using recombinant vaccinia virus HCV11B. This vaccinia virus is essentially identical to vvHCV11A (as described in U.S. Patent No. 6,150,134, the entire contents of which is hereby incorporated by reference) but has been passaged from RK13 to Vero cells. The protein was purified (by means of lentil chromatography, reduction-alkylation and size exclusion chromatography) essentially as described in example 9 of PCT/E99/04342 (WO 99/67285), making use of iodoacetamide as alkylating agent for the cysteines. After purification the 3% empigen-BB was exchanged to 3% betain by size exclusion chromatography as described in example 1 of PCT/E99/04342 this process allows to recover Els as a particle. Finally the material was desalted to PBS containing 0.5% betain and an Els concentration of 500 µg/ml. This El was mixed with an equal volume of Alhydrogel 1.3% (Superfos, Denmark) and finally further diluted with 8 volumes of 0.9% NaCl to yield alum-adjuvanted El at a concentration of 50 µg El/ml and 0.13% of Alhydrogel.

The HCV E2deltaHVRI (amino acids 412-715) was expressed in and purified from Vero essentially as described for El using recombinant vaccinia virus HCV101 which has been recombined from pvHCV-101 described in Example 8 of PCT/E99/04342 and wild type vaccinia virus. Also E2deltaHVRI behaves as a particle (measured by dynamic light scattering) after exchange of empigen to betain.

Five chimpanzees were selected which tested negative for HCV-RNA and HCV-antibodies. One of the animals (Huub) was not immunized, 2 animals received 6 immunizations with 50 µg El adjuvanted with alum (Marti and Yoran) while the remaining 2 animals received 6 immunizations with 50 µg E2deltaHVRI adjuvanted with alum (Joost and Karlien). All immunizations were administered intra-muscularly with a 3 week interval. Humoral and cellular immune responses were assessed in each animal against the antigen with which they where immunized and in each animal both type of responses was detected as shown in Table 11.

All chimpanzees became HCV-RNA positive (determined with Monitor HCV, Roche, Basel, Switzerland) on day 7 post challenge and a first ALT and gammaGT peak was measured between days 35 and 63. This evidences that all chimps developed acute hepatitis. Remarkably, both El immunized animals resolved their infection while the E2deltaHVRI and the control animal did not. This is evidenced by the fact that the El immunized animals lost HCV-RNA (determined with Monitor HCV, Roche, Basel, Switzerland) at day 98 (Yoran) and 133 (Marti) and remained negative so far until day 273 with monthly testing. All the other animals stayed RNA-positive during the entire follow up period of 273 days so far with ALT and gammaGT values not returning to normal as for the El immunized chimpanzees but gradually increasing.

Table 11: antibody titers were determined by ELISA two weeks after the 6th immunization. A serial dilution of the sample was compared to an in house standard (this in house standard defined as having 1000 mU/ml of El or anti-E2deltaHVR I antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The stimulation index, which reflects the cellular immune response, was obtained by culturing PBMC, drawn from the animals two weeks after the third immunization, in the presence or absence of envelope antigen and determining the amount of tritiated thymidine

incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. A stimulation index of >3 is considered a positive signal.

Chimpanzee	Anti-E1 response		Anti-E2deltaHVRI response	
	Antibody titer	Stimulation index	Antibody titer	Stimulation Index
Yoran	14110	10.9		
Marti	5630	14.2		
Joost			3210	8.5
Karlien			1770	11.2

Three weeks after the last of 6 immunizations all animals including the control were challenged with 100 CID (chimpanzee infectious doses) of a genotype 1b inoculum (J4.91, kindly provided by Dr. J. Bukh, NIH, Bethesda, Maryland). The amino acid sequence divergence between the vaccine proteins and the J4.91 isolate (of which the sequence information is available under accession number BAA01583) is 7% (9 out of 135 amino acids) for Els and 11% (32 out of 304 amino acids) for E2delta HVRI; Consequently this challenge is considered heterologous and reflects a real life challenge.

In conclusion we have shown that El-immunization changes the natural history of HCV infection by preventing evolution to a chronic infection, which is the major health problem related with HCV.

Example 16: Similar El responses which allowed clearing of infection in chimpanzee can be induced in man

In order to obtain a prophylactic effect of El immunization in man it is required that similar immune responses can be induced in man compared to chimpanzee. Therefore we vaccinated 20 male human volunteers, in which no anti-El responses (humoral or cellular) could be detected, with 3 doses of 20 μg Els formulated on 0.13% Alhydrogel in 0.5 ml. All immunizations were given intramuscularly with a 3 week interval. As evidenced in

Table 12, 17 out of 20 volunteers indeed mounted a significant humoral and cellular immune response against El and this without serious adverse events. Only 1 volunteer (subject 021) should be considered as a non-responder since neither humoral nor cellular responses were above the cut-off level after 3 El immunizations. The observation that the humoral response is lower compared to chimpanzee relates to the fact that only 3 immunizations with 20 μg were given and not 6 with 50 μg.

Table 12: antibody titers were determined by ELISA two weeks after the third immunization. A serial dilution of the sample was compared to an in house standards (this in house standard defined as having 1000 mU/ml of El or anti-E2deltaHVR I antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The stimulation index (cellular immune response) was obtained by culturing PBMC, drawn from the individuals two weeks after the third immunization, in the presence or absence of 1 μg of Els and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. A stimulation index of >3 is considered a positive signal.

Subject no	Antibody titer	Stimulation index	Subject no	Antibody titer	Stimulation index
002	1370	30.9	014	49	4.6
003	717	13.2	015	228	3.8
004	800	9.1	016	324	4.1
007	680	3.8	017	<20*	6.2
008	1026	3.9	018	<20	6.7
009	325	4.6	019	624	3.1
010	898	7.7	020	84	5.5
011	284	4.1	021	<20	2.1
012	181	3.6	022	226	2.7
013	<20	3.5	023	163	7.6

*this individual is considered anti-E1 positive after immunization since a significant increase in ELISA signal was seen between the preimmune sample and the sample after three immunization, the titer however is very low and does not allow accurate determination.

Example 17: Boosting of E1 responses in vaccinated healthy volunteers

19 out of the 20 human volunteers of example 16 were boosted once more with 20 μg E1s formulated on 0.13% Alhydrogel in 0.5 ml at week 26 (i.e. 20 weeks after the third immunization). Again antibody titers and cellular immune responses were determined 2 weeks after this additional immunization. In all individuals the antibody titer had decreased during the 20 week interval but could easily be boosted by this additional immunization to a level equal or higher of that observed at week 8. On average the antibody titer was double as high after this boost compared to the week 8 titer, and 7 times as high compared to the week 26 titer (Table 13).

Remarkably the T-cell responses were for the majority of individuals still high after the 20 week interval. Taking in account a normalization to the tetanos response, which is present in most individuals as a consequence of previous vaccinations, there is no change in the geomeatric mean of the stimulation index. After the additional boost, taking in account a normalization to the tetanos response, no change is noted (figure 51). This confirms that a strong T-help response was induced after 3 E1 immunizations and indicates that these immunizations induced already a very good T-help memory which requires, at leeast for a period of 6 months, no further boosting.

Table 13: antibody titers were determined by ELISA two weeks (= week 8) and 20 weeks (= week 26) after the third immunization and finally also 2 weeks after the boost (= Week 28). A serial dilution of the sample was compared to an in house standards (this in house standard defined as having 1000 mU/ml of E1 antibody, is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). For accurate comparison the determination of the titer at week 8 was repeated within the same assay as for the week 26 and 28 samples, which explains the differences with table 12 of example 16.

Subject no	Antibody titer		
	Week 8	Week 26	Week 28
002	1471	443	3119
003	963	95	2355
004	1006	409	2043
007	630	65	541
008	926	81	819
009	704	77	269
010	1296	657	3773
011	253	65	368
012	254	148	760
013	36	<20	166
014	53	40	123
016	159	45	231
017	109	39	568
018	43	23	50
019	425	157	1894
020	73	33	113
021	25	<20	26
022	280	150	357
024	177	81	184
average	**467**	**138**	**936**

Legend to figure 51: The stimulation index (cellular immune response) was obtained by culturing PBMC (10^5 cells), drawn from the individuals before immunization (week 0), two weeks after the third immunization (week 8), before the booster immunization (week 26) and two weeks after the booster immunization (week 28), in the presence or absence of 3 μg of recombinant E1s or 2 μg tetanos toxoid and determining the amount of tritiated thymidine incorporated in these cells during a pulse of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. Samples of week 0 and 8 were determined in a first assay (A), while the samples of week 26 and 28 were determined in a second assay (B) in which the samples of week 0 were reanalyzed. Results are expressed as the geometric mean stimulation index of all 20 (A, experiment) or 19 (B, experiment) volunteers.

In addition the Th1 cytokine interferon-gamma and Th2 cytokine interleukin-5 were measured in the supernatants of the PBMC cultures of samples taken at week 26 and 28 and restimulated with E1. As can be judged from figure 52 the predominant cytokine secreted by the E1 stimulated PBMC is interferon-gamma. It is highly surprising to see that a strong Th1 biased response is observed with an alum adjuvanted E1, since alum is known to be a Th2 inducer. Once more the results confirm that a good T-cell memory response is induced, as prior to the final boost (week 26) already a very strong response is observed. The interferon-gamma secretion was found to be specific as in an additional experiment we saw no difference in interferon-gamma secretion between E1 stimulated cell cultures and non-stimulated cell cultures of these volunteers using samples drawn at week 0.

Legend to figure 52: PBMC (10^5 cells), drawn from the individuals before the booster immunization (week 26) and two weeks after the booster immunization (week 28), were cultured in the presence of 3 μg of recombinant E1s (E1) or 2 μg of tetanos toxoid (TT) or no antigen (Bl). Cytokines were measured in the supernatant taken after 24 hours (interleukin-5) or after 120 hours (interferon-gamma) by means of ELISA. The stimulation index is the ratio of cytokine measured in the supernatants of cells cultured with envelope antigen versus the ones cultured without antigen. Results are expressed as the geometric mean of pg cytokine/ml secreted of all 19 volunteers. Samples with a cytokine amount below detection limit were assigned the value of the detection limit. Similarly samples with

extremely high concentrations of cytokine out of the linear range of the assay were assigned the value of the limit of the linear range of the assay.

Example 18: Fine mapping of cellular response against E1 in vaccinated healthy volunteers.

In order to map the E1 specific responses a series of 20-mer peptides was synthesized, using standard Fmoc chemistry, with 8 amino acids overlap and covering the entire sequence of E1s. All peptides were C-terminally amidated and N-terminally acetylated, with the exception of IGP 1626 which has a free amino-terminus.

IGP1626: YEVRNVSGIYHVTNDCSNSS (amino acid 192-211)(SEQ ID NO:112)
IGP1627: TNDCSNSSIVYEAADMIMHT (amino acid 204-223)(SEQ ID NO:113)
IGP1628: AADMIMHTPGCVPCVRENNS (amino acid 216-235)(SEQ ID NO:114)
IGP1629: PCVRENNSSRCWVALTPTLA (amino acid 228-247)(SEQ ID NO:115)
IGP1630: VALTPTLAARNASVPTTTIR (amino acid 240-259)(SEQ ID NO:116)
IGP1631: SVPTTTIRRHVDLLVGAAAF (amino acid 252-271)(SEQ ID NO:117)
IGP1632: LLVGAAAFCSAMYVGDLCGS (amino acid 264-283)(SEQ ID NO:118)
IGP1633: YVGDLCGSVFLVSQLFTISP (amino acid 276-295)(SEQ ID NO:119)
IGP1634: SQLFTISPRRHETVQDCNCS (amino acid 288-307)(SEQ ID NO:120)
IGP1635: TVQDCNCSIYPGHITGHRMA (amino acid 300-319)(SEQ ID NO:121)
IGP1636: HITGHRMAWDMMMNWSPTTA (amino acid 312-331)(SEQ ID NO:122)

PBMC from 14 different healthy donors not vaccinated with E1s or 10 donors vaccinated with E1s were cultured in the presence of 25 µg/ml (non vaccinated persons) or 10 µg/ml (vaccinated persons, samples taken after the third or booster injection) of each peptide separately. As can be judged from figure 53 the peptides IGP 1627, 1629, 1630, 1631, 1633, 1635 and 1635 all induced significantly higher responses in vaccinated persons compared to non-vaccinated persons. Using a stimulation index of 3 as cut-off the peptides IGP 1627, 1629, 1631 and 1635 were the most frequently recognized (i.e. recognized by at least half of the vaccinated persons tested).

This experiment proofs that the T-cell responses induced by E1s derived from mammalian cell culture are specific against E1 since these responses can not only be recalled by the same E1s derived from mammalian cell culture but also by synthetic peptides. In addition

this experiment delineates the most immunogenic T-cell domains in E1 are located between amino acids 204-223, 228-271, 276-295, 300-331 and more particularly even between amino acids 204-223, 228-247, 252-271 and 300-319.

Legend to figure 53: The stimulation index (cellular immune response) was obtained by culturing PBMC (3 x10^5 cells), in the presence or absence of peptides and determining the amount of tritiated thymidine incorporated in these cells during a pulse after 5-6 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with peptide versus the ones cultured without peptide. Results are expressed as individual values for vaccinated persons (top panel) or non vaccinated or controls (lower panel).

The present invention also provides therefor, the following E1 peptides, proteins, compisitions and kits containing the same, nucleic acid sequences coding for these peptides and proteins containing the same, and methods of their manufacture and use, as are generally described herein for other E1 and related peptides of the present invention.

IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),
IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),
IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),
IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),
IGP 1631 spanning positions 252-271of the E1 region (SEQ ID NO:117),
IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),
IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),
IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),
IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121),
IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122).

Example 19: Exemplification of therapeutic utility of E1-vaccination in man

The HCV E1s protein (amino acids 192-326 (SEQ 10 NO: 123: YEVRNVSGMYHVTNDCSNSSIVYEAADMIMHTPGCVPCVRENNSSRCWVALTPT LAARNASVPTTTIRRHVDLLVGAAAFCSAMYVGDLCGSVFLVSQLFTISPRRHETV QDCNCSIYPGHITGHRMAWDMMMNW)) was expressed in Vero cells using recombinant vaccinia virus HCV11B. This vaccinia virus is essentially identical to

vvHCV11 A (described in, for example, PCT/EP95/03031 and U.S. Patent No. 6,510,134, the entire contents of each of which are incorporated herein by reference) but has been passaged from RK13 to Vero cells. The protein was purified (by means of lentil chromatography, reduction-alkylation and size exclusion chromatography) essentially as described in Example 9 of PCT/E99/04342 (the entire contents of each of which are incorporated herein by reference), making use of iodoacetamide as alkylating agent for the cysteines. After purification the 3% Empigen-BB (N-Dodecyl-N,N-dimethylglycine) was exchanged to 3% betain by size exclusion chromatography as described in Example 1 of PCT/E99/04342 this process allows to recover E1s as a particle. Finally the material was desalted to PBS containing 0.5% betain and an E1s concentration ot 400 µg/mL. This E1 was mixed with an equal volume of Alhydrogel 1.3% (Superfos, Denmark) and finally further diluted with 8 volumes of 0.9% NaCl to yield alum-adjuvanted E1 at a concentration of 40 µg E1/mL and 0.13% of Alhydrogel.

In order to demonstrate a therapeutic effect of E1 immunization in man, an immune response was induced in chronically infected patients. This immune response was both quantitatively and qualitatively different from the base line response against E1 which is present in such patients.

Twenty-six chronically genotype 1 infected HCV patients were vaccinated with 5 doses ot 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL. All immunizations were given intramuscularly. Immunizations were performed at week 0, 4, 8, 12 and 24. In addition, 9 patients received an identical number of placebo injections consisting of alum only.

As evidenced in the following Table 14, a T -cell response is normally absent in chronic HCV carriers (only 4%, 1 out ot 26, have a detectable T -cell reactivity). Upon immunization this increases to about 70% (18 out of 26) already after 4 immunizations. This observation demonstrates that the immune response has been qualitatively changed from a T -cell non-responsiveness to a clear response. Furthermore this immune response can be sustained, by boosting with larger intervals since after the fifth immunization 3 monhts later, the cellular immune response is still of the same level or slightly increased. No significant changes were observed in the placebo group.

Table 14: The stimulation index (SI; cellular immune response) was obtained by culturing PBMC, drawn from the individuals four weeks (W16) after the fourth immunization and two weeks (W26) after the fifth immunizationt in the presence or absence of 3 µg of E1s and determining the amount of tritiated thymidine incorporated in these cells during a pulse

of 18 hours after 5 days of culture. The stimulation index is the ratio of thymidine incorporated in the cells cultured with envelope antigen versus the ones cultured without antigen. A stimulation index of >3 is considered a positive signal.

	T-cell response		
	W0	W16	W26
SI>3	1/26	18/26	17/25
Mean SI	1.5	13.7	19.3

In addition the antibody titers were determined by ELISA prior to the first immunization (this was done for each patient on three samples taken at different time points before immunization) and after the fifth immunization (this was done for each patient on two samples: W26 and W28). A serial dilution of the sample was compared to an in-house standard (this in-house standard is, as previously described, defined as having 1000 mU/mL of E1 antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). From this analysis it was concluded that, on average, the titer doubled from 331 to 715 mU/mL. This result demonstrates that the humoral arm of the immune response has at least been quantitatively altered.

An E1 vaccine formulated on alum significantly changes both the qualitative and quantitative immune response against E1. Such an E1 based vaccine and/or any of the vaccines described herein may be additionally useful if administered in conjunction with antiviral therapy such but not limited to interferon and alternatively with its combination with ribavirin (i.e., prior to, after or with a composition of the present invention).

The following as well as all previously and subsequently identified text, references, patents, publication, etc., are hereby incorporated herein in their entirety by reference.

Example 20: Effects of therapeutic E1-vaccination in chronically infected patients.

In a first course of this study, 26 patients received 5 doses of 20 µg E1s as described in Example 19. In a second course, 25 of said 26 patients received a further 6 intramuscular doses of 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL (as in Example 19). The immunizations of this second series were administered with 3-week intervals and the first injection was given at week 50. Four weeks after the last injection of the second course, a liver biopsy was performed in 24 out of the 25 patients who completed the two courses of therapeutic E1s vaccination. A liver biopsy was also performed in all patients prior to the

onset of the therapeutic vaccine treatment (i.e. prior to course 1 vaccination scheme). The mean time elapsed between pre-treatment and post-treatment biopsies was 17 months. Liver histology slides thus obtained before and after therapeutic vaccination were scored centrally in a blind way by two expert pathologists for fibrosis and inflammation, this according to the Ishak and Metavir scoring systems (Ishak et al. 1995 which is a modification of the scoring system of Knodell et al. 1981; Bedossa and Poynard 1996), as well as for anti-E2 immunostain using the IGH222 murine anti-E2 HVRI monoclonal antibody as described in International Patent Application WO99/50301. Perisinusoidal fibrosis was assessed based on staining of collagen with Sirius Red (on liver histology slides).

The Ishak scores range from 0 to 18 for grading of inflammation and from 0 to 6 for staging of fibrosis/cirrhosis. The sum of the Ishak inflammation and fibrosis scores comes closest to the Histological Activity Index (HAI; Knodell et al. 1981) which has been widely used. The change in Ishak fibrosis score in the 24 patients who followed the two courses of therapeutic E1s vaccination is –0.04 (with a 95% confidence interval of –0.60 to +0.68) and with a change from baseline- to end-value from 2.54 (baseline) to 2.50 (end).
An overview of the different assessed necro-inflammatory intensities (Ishak scoring) is given in Table 15.
The Ishak equivalent of the HAI scores for the treated patients showed a mean absolute change from baseline of –0.17 (with a 95% confidence interval of –1.36 to 1.03) and with a change from baseline- to end-value from 8.88 (baseline) to 8.71 (end). Furthermore, nine (9) out of the 24 patients (38%) improved 2 points or more on the sum of Ishak inflammation- and Ishak fibrosis- scores whereas ten (10) out of the 24 patients remained stable (no change or a change of +1 or –1) and five (5) patients evolved to a worse condition (worsening of 2 points or more).

The Metavir scores range from 0 to 3 for grading of inflammation and from 0 to 4 for staging of fibrosis/cirrhosis. The overall progression rate of the Metavir score in an untreated patient is estimated to be 0.133 per year (Poynard et al. 1997).
For the patients of the current study, the average progression over the 17-month period based on the linear extension of the baseline score and the estimated duration of the infection (which is reported for 19 out of the 24 patients who followed the two courses of

therapeutic E1s vaccination) would be 0.20. This correlates well with the published overall rate of progression which would be 0.19 for the 17 month period.

The change in Metavir score observed for the treated patients is, however, 0.00 (with a 95% confidence interval of –0.43 to +0.43) and with a mean baseline- an end-score of 1.67. An overview of Metavir scores at baseline and at the end of the second course treatment is given in Table 16. Unblinded comparison of pre- and post treatment slides revealed that 10 patients had diminished perisinusoidal fibrosis based on Sirius Red staining.

The anti-E2 immunostain scores range from 0 to 4, with 0 = no E2 anitgen detectable, 1 = occasional cell with detectable E2 antigen, 2= clusters of E2 antigen positive cells but less than 25% of cells positive, 3 = clusters of E2 antigen positive cells and 25-50% of cells positive, 4 = clusters of E2 antigen positive cells and more than 50% of cells positive. The anti-E2 immunostain scores for the treated patients showed a mean absolute change from baseline of –0.75 (with a 95% confidence interval of –1.64 to 0.14) and with a change from baseline- to end-value from 2.54 (baseline) to 1.79 (end). The reduction seen for anti-E2 immoreactivity in the liver using blind scoring was confimed by unblinded comparison of paired slides per patient. Eleven patients showed negativation or a marked reduction in HCV E2 immunostaining, while only three patients had a stronger immunostain after treatment. Of these 11 patients, 3 also showed a reduction in steatosis.

Serum HCV RNA levels were determined using the Amplicor HCV Monitor kit (Roche, Basel, Switzerland). The serum HCV RNA levels remained unchanged or did not change more than one log from baseline except in 1 patient. This concerned a 37-year old treatment-naïve female patient, infected with a genotype 1a virus and with flu-like symptoms at baseline. HCV-RNA dropped 3 logs from week 8 (after two injections with E1) to reach levels below 3000 IU/ml at weeks 16 and 20, in parallel ALT dropped from a single peak value of 400 U/ml at week 8 to normal ALT values at weeks 16, 20 and 24. This was accompanied by disappearance of the flu-like symptoms. After this period both ALT and HCV-RNA increased again, and symptoms re-appeared. The sequence of the virus present during the emerging viral load increase was compared with the baseline sequence. No evidence for the presence of escape mutant virus was found.

Serum ALT (alanine aminotransferase activity) levels in the treated patients decreased on average 22% (with a 95% confidence interval of −15% to −30%) as compared to the baseline levels. A positive correlation between % change from baseline in ALT levels and absolute change from baseline in fibrosis scores was noticed: a Spearman rank of p=0.0007 for Ishak fibrosis score and of p=0.002 for Metavir fibrosis score were obtained as correlations between the change from baseline in serum ALT and the absolute change from baseline Ishak and Metavir fibrosis scores, respectively.

A further outcome of the current study is the predictive character of the immune response (in terms of increase in serum anti-E1s antibody levels) to treatment for improvement in histological scores (fibrosis and overall) as well as serum ALT levels.
Antibody titers were determined by ELISA. A serial dilution of a serum sample was compared to an in house standard (this in house standard defined as having 1000 mU/mL of E1s antibody is a mixture of three sera from HCV chronic carriers selected based on a high anti-envelope titer). The detection limit for this assay is 5 mU/mL.
A Spearman rank of p=0.007 was obtained as correlation between the change from baseline in serum anti-E1 antibody level and the absolute change from baseline in total Ishak (inflammation plus fibrosis) score. Pearson p-values of p=0.06 and of p=0.009 were obtained as correlation between the change from baseline in serum anti-E1 antibody level and the absolute (p= 0.06) and relative (p=0.009) change from baseline in Ishak fibrosis score, respectively. A Pearson p-value of p=0.01 was obtained as correlation between the change from baseline in serum anti-E1 antibody level and the relative change from baseline in ALT value.
These associations remain after correction for baseline liver histology scores, ALT, serum HCV-RNA viral load, age and sex, and IFN exposure and thus as add to the likelihood of a real positive effect induced by the therapeutic E1s vaccination treatment.

The seven patients with the highest increase in serum antibody levels in response to the therapeutic vaccine candidate (i.e., patients with an increase in anti-E1 antibody level of at least 700 mU/mL) had on average a significant decrease of -0.9 points (with a 95% confidence interval of -0.2 to -1.5) on Metavir liver fibrosis score. In this subgroup, serum ALT on average decreased 37% (with a 95% confidence interval of -25 to – 49%). Table 17 provides an overview of the correlation between immune response (in terms of anti-E1s

antibody levels induced by treatment) and overall change (relative to baseline) in Ishak scores. Figure 54 illustrates the correlation between changes in Ishak fibrosis score, changes in ALT-levels and changes in anti-E1s antibody levels. Figure 55 illustrates the correlation between changes in Metavir fibrosis score, changes in ALT-levels and changes in anti-E1s antibody levels. Figure 56 illustrates Ishak fibrosis score versus ALT levels both at the start of the first treatment course (panel A) and at the end of the second treatment course (panel B). Figure 57 illustrates patient's age versus Ishak fibrosis score both at the start of the first treatment course (panel A) and at the end of the second treatment course (panel B). Both Figures 56 and 57 further indicate the seven patients with the highest increase in anti-E1s antibody levels induced by the therapeutic vaccination treatment.

A positive correlation between serum anti-E1s antibody levels and T cell proliferation index values at the end of the second treatment course was observed, with a Pearson p-value of p=0.009.

Concludingly, the increase in antibody levels to the E1s vaccination significantly predicted improvement in liver fibrosis (Metavir and Ishak scores), sum of inflammation and fibrosis scores (Ishak), and in ALT levels, even after correcting for any other baseline prognostic variables. The increase in anti-E1 antibodies after vaccination was also significantly correlated with an increase in T cell proliferation index to E1.

This study is clearly supportive for a E1-based therapeutic vaccination strategy to have the potential to halt disease progression towards liver cirrhosis.

Table 15. Ishak grading of necro-inflammatory intensities for periportal hepatitis, confluent necrosis, focal inflammation, portal inflammation and the overall total inflammation grading. Scores are indicated as the change from baseline (mean and 95 % confidence interval) and the mean baseline- to end-values.

Score for	Change of score from baseline mean (95% confidence interval)	Change of score from baseline to end (mean)
periportal hepatitis	-0.21 (-0.62 to 0.20)	1.42 to 1.21
confluent necrosis	0.38 (-0.17 to 0.92)	0.00 to 0.38
focal inflammation	-0.17 (-0.59 to 0.26)	2.63 to 2.46
portal inflammation	-0.13 (-0.51 to 0.26)	2.29 to 2.17
total inflammation grading	-0.13 (-1.18 to 0.93)	6.33 to 6.21

Table 16. Overview of frequencies (given as number of patients) of changes of a given baseline Metavir score (given in top row; Baseline 0 to 4) to a given Metavir score at the end of the second course of therapeutic E1s vaccination (given in left row; EOT 0 to 4). For instance, the "5" marked with a "*" (i.e., "5*") means that 5 patients had a baseline Metavir score of 1 and a Metavir score of 0 at the end of the second course treatment (EOT = end of treatment).

	Baseline 0	Baseline 1	Baseline 2	Baseline 3	Baseline 4	Total
EOT 0	0	5*	1	0	0	**6**
EOT 1	1	3	2	0	0	**6**
EOT 2	0	5	1	0	0	**6**
EOT 3	0	0	0	1	1	**2**
EOT4	0	0	1	2	1	**4**
Total	**1**	**13**	**5**	**3**	**2**	**24**

Table 17. Correlation between serum anti-E1 antibody levels induced by therapeutic E1s vaccination and change in overall Ishak scores. Given are the number of patients corresponding to the possible criteria as outlined in the Table.

Overall change of Ishak score (change from baseline)	< -1	-1, 0, or +1	> +1
High anti-E1s antibody response	5	2	0
Low anti-E1s antibody response	4	8	5

Example 21: Effects of therapeutic E1-vaccination regimen.

In a first course of this study, 26 patients received 5 doses of 20 µg E1s ("E1s patients") and 9 patients received an identical number of placebo injections ("placebo patients") consisting of alum only, as described in Example 19. In a second course, 25 of said 26 patients that received E1s during the first course and 9 of said 9 patients that received a placebo were all immunized with a further 6 intramuscular doses of 20 µg E1s formulated on 0.13% Alhydrogel in 0.5 mL (as in Example 19), thus giving rise to two groups of patiens: the "E1s/E1s patients" and "placebo/E1s patients". The immunizations of this second series, i.e. course 2, were administered with 3-week intervals (compared to 4-week intervals during the first series, i.e. course 1) and the first injection was given at week 50.

The median values for anti-E1 antibodies after 4 E1s injections were 195 mU/mL for 4-week intervals (as deduced from the E1s patients) and 274 mU/mL for 3-week intervals (as deduced from the placebo/E1s patients), thus indicating that a 3-week interval regimen induces a stronger humoral immune response in a shorter period of time.

In placebo/E1s patients E1s-specific T cell proliferation increased from 0/9 patients at baseline to 9/9 patients after 6 injections with 3-week intervals at week 69.

If the humoral and cellular immune response to E1s in healthy male volunteers (see Examples 16 and 17) are compared with those in the patient group, a somewhat slower increase in anti-E1 antibody levels and T cell response is observed. The booster effect seen in healthy volunteers was almost absent in patients (median titer of 165 mU/mL after the fifth immunization administered to the E1s/E1s patients as a booster 12 weeks after the 4th immunization), thus suggesting a somewhat impaired build up of immunological memory to E1s in patients. Repeated intramuscular injections at 3-week intervals seem to overcome this impairment (median titer of 530 mU/mL after 6 consecutive immunizations with a 3-week

interval in the placebo/E1s patients), thus indicating another advantage of an E1s vaccination regimen with 3-week intervals and/or administering more than 4 doses in the first series of immunizations.

5

REFERENCES

Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP (2001) J Hepatol **35**(2):272-278.

Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Proc. Natl. Acad. Sci. USA **81**:3297-301.

Bailey, J. and Cole, R. (1959) J. Biol. Chem. **234**, 1733-1739.

Ballou, L., Hitzeman, R., Lewis, M. & Ballou, C. (1991) PNAS **88**, 3209-3212.

Bedossa P, Poynard T. (1996) Hepatology **24**(2):289-293.

Benesch, R., Benesch, R.E., Gutcho, M. & Lanfer, L. (1956) Science **123**, 981.

Cavins, J. & Friedman. (1970) Anal. Biochem. **35**, 489.

Cleland, W. (1964) Biochemistry **3**, 480

Creighton , E. (1988) BioEssays **8**, 57

Darbre, A., John Wiley & Sons Ltd. (1987) Practical Protein Chemistry - A Handbook.

Darbre, A., John Wiley & Sons Ltd. (1987) Practical Proteinchemistry p.69-79.

Doms et al, (1993), Virology **193**, 545-562.

Ellman, G. (1959) Arch. Biochem. Biohys. **82**, 70.

Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Ann Intern Med **136**(4):288-292.

Falkner, F. & Moss, B. (1988) J. Virol. **62**, 1849-1854.

Friedman, M. & Krull. (1969) Biochem. Biophys. Res. Commun. **37**, 630.

Gallagher J. (1988) J. Cell Biol. **107**, 2059-2073.

Glazer, A., Delange, R., Sigman, D. (1975) North Holland publishing company, Elsevier, Biomedical. Part : Modification of protein (p. 116).

Graham, F. & van der Eb, A. (1973) Virology **52**, 456-467.

Grakoui et al. (1993) Journal of Virology **67**:1385-1395.

Grassetti, D. & Murray, J. (1969) Analyt. Chim. Acta. **46**, 139.

Grassetti, D. & Murray, J. (1967) Arch. Biochem Biophys. **119**, 41.

Helenius, Mol. Biol. Cell (1994), **5**: 253-265.

Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. (1991) Proc. Natl. Acad. Sci. U.S.A. **88**(13):5547-51.

Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R., Stüber, D. (1988) Biochemistry **88**, 8976.

Hsu, H., Donets, M., Greenberg, H. & Feinstone, S. (1993) Hepatology **17**:763-771.

Inoue, Y., Suzuki, R., Matsuura, Y., Harada, S., Chiba, J., Watanabe, Y., Saito, I. & Miyamura, T. (1992) J. Gen. Virol. **73**:2151-2154.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. (1995) J Hepatol **22**(6):696-699.

Janknecht, R., de Martynoff, G. *et al.*, (1991) Proc. Natl. Acad. Sci. USA **88**, 8972-8976.

Kayman (1991) J. Virology **65**, 5323-5332.

Kato, N., Oostuyama, Y., Tanaka, T., Nakagawa, M., Muraiso, K., Ohkoshi, S., Hijikata, M., Shimitohno, K. (1992) Virus Res. **22**:107-123.

Kniskern, P., Hagopian, A., Burke, P., Schultz, L., Montgomery, D., Hurni, W., Yu Ip, C., Schulman, C., Maigetter, R., Wampler, D., Kubek, D., Sitrin, R., West, D., Ellis, R., Miller, W. (1994) Vaccine **12**:1021-1025.

Kohara, M., Tsukiyama-Kohara, K., Maki, N., Asano, K., Yoshizawa, K., Miki, K., Tanaka, S., Hattori, N., Matsuura, Y., Saito, I., Miyamura, T. & Nomoto, A. (1992) J. Gen. Virol. **73**:2313-2318.

Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. (1981) Hepatology **1**(5):431-435.

Lauer GM, Walker BD (2001) N Engl J Med **345**(1):41-52.

Lefkowitch JH (1997) Viral Hepatitis Reviews **3**(3):155-166.

Mackett, M., Smith, G. & Moss, B. (1985) In: 'DNA cloning: a practical approach' (Ed. Glover, D.) IRL Press, Oxford.

Mackett, M., & Smith, G. (1986) J. Gen. Virol. **67**, 2067-2082.

Mackett, M., Smith, G. & Moss, B. (1984) J. Virol. **49**, 857-864.

Mackett, M., Smith, G. & Moss, B. (1984) Proc. Natl. Acad. Sci. USA **79**, 7415-7419.

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Proc. Natl. Acad. Sci. USA **84**:7706-10.

Means, G. (1971) Holden Day, Inc.

Means, G. & Feeney, R. (1971) Holden Day p.105 & p. 217.

Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Biochemistry **18**:5134-43.

Mita, E., Hayashi, N., Ueda, K., Kasahara, A., Fusamoto, H., Takamizawa, A., Matsubara, K., Okayama, H. & Kamada T. (1992) Biochem. Biophys. Res. Comm. **183**:925-930.

Moore, S. (1963) J. Biol. Chem. **238**, 235-237.

Nielsen P, Egholm M, Berg R, Buchardt O (1991) Science **254**:1497-500.

Nielsen P, Egholm M, Berg R, Buchardt O (1993) Nucleic-Acids-Res. **21**:197-200.

Okamoto, H., Okada, S., Sugiyama, Y., Yotsumoto, S., Tanaka, T., Yoshizawa, H., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1990) Jpn. J. Exp. Med. **60**:167-177.

Panicali & Paoletti (1982) Proc. Natl. Acad. Sci. USA **79**, 4927-4931.

Piccini, A., Perkus, M. & Paoletti, E. (1987) Meth. Enzymol. **153**, 545-563.

Poynard T, Bedossa P, Opolon P. (1997) Lancet 349(9055):825-832.

Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J (2002) Gastroenterology **122**(5):1303-1313.

Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O (1999) J Hepatol **30**(5):783-787.

Rose (1988) Annu. Rev. Cell Biol. 1988, **4**: 257-288;

Ruegg, V. and Rudinger, J. (1977) Methods Enzymol. **47**, 111-116.

Schvarcz R, Glaumann H, Reichard O, Weiland O (1999) J Viral Hepat **6**(3):237-242.

Shan, S. & Wong (1993) CRC-press p. 30-33.

Shiffman ML (1999) Viral Hepatitis Reviews **5**(1):27-43.

Spaete, R., Alexander, D., Rugroden, M., Choo, Q., Berger, K., Crawford, K., Kuo, C., Leng, S., Lee, C., Ralston, R., et al. (1992) Virology **188**(2):819-30.

Skehel, J., (1984) Proc. Natl. Acad. Sci. USA **81**, 1179-1783.

Stunnenberg, H., Lange, H., Philipson, L., Miltenburg, R. & van der Vliet, R. (1988) Nucl. Acids Res. **16**, 2431-2444.

Stuyver, L., Van Arnhem, W., Wyseur, A., DeLeys, R. & Maertens, G. (1993a) Biochem. Biophys. Res. Commun. **192**, 635-641.

Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., & Maertens, G. (1993b) J. Gen. Virol. **74**, 1093-1102.

Stuyver, L., Van Arnhem, W., Wyseur, A., Hernandez, F., Delaporte, E., Maertens, G. (1994) Proc. Natl. Acad. Sci. USA **91**, 10134-10138.

Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T (2002) Dig Dis Sci. **47**(1):170-176.

Weil, L. & Seibler, S. (1961) Arch. Biochem. Biophys. **95**, 470.

Yokosuka, O., Ito, Y., Imazeki, F., Ohto, M. & Omata, M. (1992) Biochem. Biophys. Res. Commun. **189**:565-571.

WO 96/04385 (PCT/EP95/03031) - Purified Hepatitis C Virus Envelope Proteins for

Diagnostic and Therapeutic Use.

All references cited herein are incorporated in their entirety by reference.

We claim:

1. A therapeutic HCV vaccine composition for reducing liver disease in a chronic HCV-infected mammal.

2. A therapeutic HCV vaccine composition for reducing liver fibrosis progression in a chronic HCV-infected mammal.

3. A therapeutic HCV vaccine composition for reducing liver fibrosis in a chronic HCV-infected mammal.

4. A therapeutic HCV vaccine composition for reducing liver disease by at least 2 points according to the overall Ishak score in a chronic HCV-infected mammal.

5. A therapeutic HCV vaccine composition for reducing liver disease by at least 1 point according to the Ishak fibrosis score in a chronic HCV-infected mammal.

6. A therapeutic HCV vaccine composition for reducing serum ALT levels in a chronic HCV-infected mammal.

7. A therapeutic HCV vaccine composition for reducing steatosis in a chronic HCV-infected mammal.

8. A therapeutic HCV vaccine composition for reducing anti-E2 immunoreactivity in the liver of a chronic HCV-infected mammal.

9. The therapeutic HCV vaccine composition according to any of claims 1 to 8 which comprises a HCV antigen and, optionally, a pharmaceutically acceptable adjuvant.

10. The therapeutic HCV vaccine composition according to claim 9 wherein said HCV antigen is an E1 or E2 antigen, or an immunogenic part of an E1 or E2 antigen.

11. The therapeutic HCV vaccine composition according to claim 9 wherein said pharmaceutically acceptable adjuvant is alum.

12. A method to predict changes in liver disease in a chronic HCV-infected mammal comprising

(i) determining the level of serum anti-E1 antibody level prior to therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;

(ii) determining the level of serum anti-E1 antibody level after therapeutic vaccination with a HCV vaccine composition comprising an E1 antigen;

(iii) inferring the difference in level of serum anti-E1 antibody level determined in (i) and (ii) and, therefrom, predicting the change in liver disease.

13. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of at least one purified HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and E2 proteins, an E1/E2 protein complex formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a pharmaceutically acceptable adjuvant.

14. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

15. A therapeutic HCV vaccine composition comprising a therapeutically effective amount of at least one of the following E1 and E2 peptides:

E1-31 spanning amino acids 181 to 200 of the Core/E1 V1 region (SEQ ID NO:56),

E1-33 spanning amino acids 193 to 212 of the E1 region (SEQ ID NO:57),

E1-35 spanning amino acids 205 to 224 of the E1 V2 region (SEQ ID NO:58),

E1-35A spanning amino acids 208 to 227 of the E1 V2 region (SEQ ID NO:59),
1bE1 spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (SEQ ID NO:53),
E1-51 spanning amino acids 301 to 320 of the E1 region (SEQ ID NO:66),
E1-53 spanning amino acids 313 to 332 of the E1 C4 region (SEQ ID NO:67),
E1-55 spanning amino acids 325 to 344 of the E1 region (SEQ ID NO:68),
Env 67 or E2-67 spanning amino acid positions 397 to 418 of the E2 region (SEQ ID NO:72),
Env 69 or E2-69 spanning amino acid positions 409 to 428 of the E2 region (SEQ ID NO:73),
Env 23 or E2-23 spanning positions 583 to 602 of the E2 region (SEQ ID NO:86),
Env 25 or E2-25 spanning positions 595 to 614 of the E2 region (SEQ ID NO:87),
Env 27 or E2-27 spanning positions 607 to 626 of the E2 region (SEQ ID NO:88),
Env 17B or E2-17B spanning positions 547 to 586 of the E2 region (SEQ ID NO:83),
Env 13B or E2-13B spanning positions 523 to 542 of the E2 region (SEQ ID NO:82),
IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),
IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),
IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),
IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),
IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),
IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),
IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),
IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),
IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and
IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);
and, optionally, a pharmaceutically acceptable adjuvant.

16. A therapeutic HCV composition comprising a therapeutically effective amount of at least one purified HCV single or specific oligomeric recombinant envelope protein selected from the group consisting of an E1 protein, an E2 protein, a part of said E1 and E2 protein, and an E1/E2 protein complex formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins or parts thereof; and optionally a

pharmaceutically acceptable adjuvant.

17. A therapeutic HCV composition comprising a therapeutically effective amount of a combination of at least two purified HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 proteins derived from different HCV genotypes or subtypes, E2 proteins derived from different HCV genotypes or subtypes, parts of said E1 and E2 proteins, and E1/E2 protein complexes formed from purified HCV single or specific oligomeric recombinant E1 or E2 proteins, or parts thereof, derived from different HCV genotypes or subtypes; and optionally a pharmaceutically acceptable adjuvant.

18. A therapeutic HCV composition comprising a therapeutically effective amount of at least one of the following E1 and E2 peptides:
E1-31 spanning amino acids 181 to 200 of the Core/E1 V1 region (SEQ ID NO:56),
E1-33 spanning amino acids 193 to 212 of the E1 region (SEQ ID NO:57),
E1-35 spanning amino acids 205 to 224 of the E1 V2 region (SEQ ID NO:58),
E1-35A spanning amino acids 208 to 227 of the E1 V2 region (SEQ ID NO:59),
1bE1 spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (SEQ ID NO:53),
E1-51 spanning amino acids 301 to 320 of the E1 region (SEQ ID NO:66),
E1-53 spanning amino acids 313 to 332 of the E1 C4 region (SEQ ID NO:67),
E1-55 spanning amino acids 325 to 344 of the E1 region (SEQ ID NO:68),
Env 67 or E2-67 spanning amino acid positions 397 to 418 of the E2 region (SEQ ID NO:72),
Env 69 or E2-69 spanning amino acid positions 409 to 428 of the E2 region (SEQ ID NO:73),
Env 23 or E2-23 spanning positions 583 to 602 of the E2 region (SEQ ID NO:86),
Env 25 or E2-25 spanning positions 595 to 614 of the E2 region (SEQ ID NO:87),
Env 27 or E2-27 spanning positions 607 to 626 of the E2 region (SEQ ID NO:88),
Env 17B or E2-17B spanning positions 547 to 586 of the E2 region (SEQ ID NO:83),
Env 13B or E2-13B spanning positions 523 to 542 of the E2 region (SEQ ID NO:82),
IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),

IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),
IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),
IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),
IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),
IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),
IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),
IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),
IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and
IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);
and, optionally, a pharmaceutically acceptable adjuvant.

19. The therapeutic HCV composition according to any of claims 13 to 18 for at least one of inducing HCV-specific antibodies, stimulating T-cell activity and stimulating cytokine secretion.

20. The therapeutic HCV composition according to any of claims 13 to 18 which is therapeutically effective in a HCV carrier infected with a HCV genotype different from the HCV genotype or HCV genotypes from which said E1, E2, or E1/E2 protein complexes are derived.

21. A composition comprising at least one of the following E1 and E2 peptides:
IGP 1626 spanning positions 192-211 of the E1 region (SEQ ID NO:112),
IGP 1627 spanning positions 204-223 of the E1 region (SEQ ID NO:113),
IGP 1628 spanning positions 216-235 of the E1 region (SEQ ID NO:114),
IGP 1629 spanning positions 228-247 of the E1 region (SEQ ID NO:115),
IGP 1630 spanning positions 240-259 of the E1 region (SEQ ID NO:116),
IGP 1631 spanning positions 252-271 of the E1 region (SEQ ID NO:117),
IGP 1632 spanning positions 264-283 of the E1 region (SEQ ID NO:118),
IGP 1633 spanning positions 276-295 of the E1 region (SEQ ID NO:119),
IGP 1634 spanning positions 288-307 of the E1 region (SEQ ID NO:120),
IGP 1635 spanning positions 300-319 of the E1 region (SEQ ID NO:121) and
IGP 1636 spanning positions 312-331 of the E1 region (SEQ ID NO:122);
and, optionally, a pharmaceutically acceptable adjuvant.

22. The composition according to any of claims 10 and 13 to 21 wherein the cysteines of said E1 or E2 antigen, of said recombinant HCV envelope proteins or of said E1 and E2 peptides are blocked.

23. The composition according to any of claims 10, 13, 14, 16, 17, 19, 20 and 22 wherein said E1 or E2 antigen or said recombinant HCV envelope proteins are added as viral-like particles.

24. The composition according to any of claims 10, 13, 14, 16, 17, 19, 20 and 22 wherein said E1 antigen or said recombinant HCV E1 envelope protein is an E1s protein.

25. The composition according to claim 24 wherein said E1 antigen or said E1s protein is defined by SEQ ID NO:123.

26. The composition according to any of claims 1-10, 13, 14, 16, 17, 19, 20 and 22 to 25 wherein said HCV antigen or said recombinant HCV envelope proteins are produced by recombinant mammalian cells, by recombinant yeast cells or by a recombinant virus.

27. The composition according to any of claims 15 and 18 to 25 wherein said peptides are recombinant peptides or synthetic peptides.

28. The composition according to any one of claims 1 to 11 and 13 to 27 for treating a mammal infected with HCV.

29. The composition according to any of claims 1 to 11 and 28 wherein said mammal is a human.

30. The method according to claim 12 wherein said mammal is a human.


Sma I
BamH I
Xba I
Sal I
Pst I
Sph I
Hind III
Kpn I
Sac I
EcoR I
Cla I
I3
11k
R-tk
Kpn I
EcoR V
gpt
ori
pgpt ATA 18
5300 bp
L-tk
Xba I
Nhe E
Bgl I
Amp
F1(-)
Pvu I
Sca I

Figure 1


Sma I
BamH I
Xba I
Sal I
Pst I
Sph I
Hind III
Pac I
Kpn I
Sac I
EcoR I
Cla I
I3
11k
R-tk
Kpn I
EcoR V
gpt
ori
pgs ATA 18
5300 bp
L-tk
Xba I
Nhe E
Bgl I
Amp
F1(-)
Pvu I
Sca I

Figure 2


Sma I (+2)
Stu I (+3)
Pml I (+1)
Pac I
Pst I
Sph I
Hind III
Kpn I
Sac I
EcoR I
Cla I
I3
11k
R-tk
Kpn I
EcoR V
gpt
ori
pMS 66
5300 bp
L-tk
Xba I
Nhe E
F1(-)
Amp
Bgl I
Pvu I
Sca I

Figure 3


EcoR I
Cla I
Not I
Cla I
Fsp I
I3
Kpn I
EcoR V
11k
E1S
Hind III
gpt
R-tk
L-tk
pvHCV-11A
5900 bp
Xba I
ori
Nhe E
F1(-)
Amp
Bgl I
Pvu I
Sca I

Figure 4


Anti-E1 levels in NON-responders to IFN treatment
S/N
Series 1
IFN
Type 3a
Type 1b
Type 3a
Type 1b
Type 1b
G
J
K
N
Q
10
8
6
4
2
0
-10
-5
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
weeks after start of treatment

Figure 5


Anti-E1 levels in RESPONDERS to IFN treatment
H
I
L
M
O
P
Series 1
S/N
IFN
weeks after start of treatment
12
10
8
6
4
2
0
-10
0
10
20
30
40
50
60
70
80

Figure 6


Anti-E1 levels in patients with COMPLETE response to IFN
S/N
Series 2
D 3a
E 3a
S1
S1
F1
F1
10
8
6
4
2
0
1
5
10
15
20
25
30
35
40
45
50
months after start of treatment

Figure 7


Anti-E1 levels in INCOMPLETE responders to IFN treatment
S/N
months after start of treatment
Series 2
S: start of treatment
F: finish of treatment
A 1b NR
B 1b NR
C 3a RR
F 1b PR
S1
S2
F1
F2
0
2
4
6
8
10
12
14
16
1
5
10
15
20
25
30
35
40
45
50

Figure 8


Anti-E2 levels in RESPONDERS to IFN treatment
G 1b
J 1b
K 1b
N 3a
Q 3a
Series 1
IFN
S/N
10
8
6
4
2
0
-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
weeks after start of treatment

Figure 9


Anti-E2 levels in RESPONDERS to IFN treatment
H 1b
I 1b
L 1b
M 1b
O 3a
P 1b
Series 1
IFN
S/N
weeks after start of treatment
14
12
10
8
6
4
2
0
-10
-5
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80

Figure 10


Anti-E2 levels in INCOMPLETE responders to IFN treatment
A 1b NR
B 1b NR
C 3a RR
F 1b PR
SERIES 2
S/N
10
8
6
4
2
0
1
5
10
15
20
25
30
35
40
45
50
months after start of treatment

Figure 11


Anti-E2 levels in COMPLETE responders to IFN treatment
S/N
SERIES 2
D 3a CR
E 3a CR
F
F
F : finish of treatment
months after start of treatment
0
1
2
3
4
5
6
7
1
5
10
15
20
25
30
35
40
45
50

Figure 12


Human anti-E1 reactivity competed with peptides
IG10919
IG8240
IG5250
OD
peptides
31 33 35 35A 37 39 41 49 51 53 55 /
competed with peptide mix
no peptide mix
IG10925
IG5282
IG5250
IG10919
IG10907
IG8332
IG8248
human sera

Figure 13


Competition of reactivity of anti-E1 Mabs with peptides
11A10D7
6E1A10
23C12H9B10
15G6B2
OD
peptides
/ 31 33 35 35A 37 39 41 49 51 53 55
0 0.2 0.4 0.6 0.8 1 1.2 1.4
0 0.5 1 1.5

Figure 14


Anti-E1 (epitope 1) levels in NON-RESPONDERS to IFN treatment
G 1b
J 1b
K 1b
N 3a
Q 3a
SERIES 1
S/N
IFN
7
6
5
4
3
2
1
0
-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
weeks after start of treatment

Figure 15


Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment
SERIES 1
S/N
IFN
weeks after start of treatment
H 1b
I 1b
L 1b
M 1b
O 3a
P 1b
10
8
6
4
2
0
-10
-5
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80

Figure 16


Anti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment
G 1b
J 1b
K 1b
N 3a
Q 3a
SERIES 1
S/N
4
3
2
1
0
IFN
-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
weeks after start of treatment

Figure 17


Anti-E1 (epitope 2) levels in RESPONDERS to IFN treatment
S/N
SERIES 1
IFN
weeks after start of treatment
H 1b
I 1b
L 1b
M 1b
O 3a
P 1b
6
5
4
3
2
1
0
-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80

Figure 18


Competition of reactivity of anti-E2 Mabs with peptides
16A6E7
4H6B2
2F10H10
12D11F1
OD
peptides
0
0.5
1
1.5
2
63
67
69
$$1B
$$3B
1B
3B
5B
7B
9B
11B
13B
15B
17B
19B
21
23
25
27
29
31
33
35
Co

Figure 19


Human anti-E2 reactivity competed with peptides
19616
5250
8316
8380
OD
peptides
63
67
69
$$
$$1B
$$3B
1B
3B
5B
7B
9B
11B
13B
15B
17B
19B
21
23
25
27
29
31
33
35
0
0.2
0.4
0.6
0.8
1
1.2

Figure 20

5' GGCATGCAAGCTTAATTAATT 3' (SEQ ID NO 1)
3'ACGTCCGTACGTTCGAATTAATTAATCGA 5' (SEQ ID NO 94)

5'CCGGGGAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGTTA
ATTAACTGCA 3' (SEQ ID NO 2)
3'CCTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGTAGTGATTATCAATTAAT
TG 5' (SEQ ID NO 95)

SEQ ID NO 3 (HCC19A)
ATGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCTTTACTGTCCTGTCTGACCATTCCA
GCTTCCGCTTATGAGGTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCC
AACTCAAGCATTGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCC
TGCGTTCGGGAGAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCT
AGGAACGCCAGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCG
GCTGCTCTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTCCTCGTCTCC
CAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATC
TATCCCGGCCACATAACAGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCT
ACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG
GCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGG
GCTAAGGTTTTGATTGTGATGCTACTCTTTGCTCTCTAATAG

SEQ ID NO 5 (HCC110A)
ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTG
GGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGG
CATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGT
ATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTG
CTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCG
GGTCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGATTGTGATGCTACTC
TTTGCTCCCTAATAG

SEQ ID NO 7 (HCC111A)

Figure 21A

ATGTTGGGTAAGGTCATCGATACCCTTACGTGCGGCTTCGCCGACCTCATGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGTGCTGCCAGAGCCCTGGCGCATGGCGTCCGGGTT
CTGGAAGACGGCGTGAACTATGCAACAGGGAATTTGCCTGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTACTGTCCTGTCTGACCATTCCAGCTTCCGCTTATGAGGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACTACGACA
ATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTG
GGGGATCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGG
CATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACAGGTCACCGT
ATGGCTTGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 9 (HCCl12A)
ATGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCCCTGCTGTCCTGTCTGACCATACCA
GCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGGTGTACCATGTCACGAACGACTGCTCC
AACTCAAGCATAGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCC
TGCGTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTCGCGGCC
AGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCT
GCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTTTCCTTGTTTCC
CAGCTGTTCACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCAACTGCTCAATC
TATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGATGAACTGGTCCTAA
TAG

SEQ ID NO 11 (HCCl13A)
ATGTCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCCCTGCTGTCCTGTCTGACCATACCA
GCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGGTGTACCATGTCACGAACGACTGCTCC
AACTCAAGCATAGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCC
TGCGTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTCGCGGCC
AGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCT
GCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTTTCCTTGTTTCC
CAGCTGTTCACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCAACTGCTCAATC
TATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 13 (HCCl17A)
ATGCTGGGTAAGGCCATCGATACCCTTACGTGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAAGACGGCGTGAACTATGCAACAGGGAATTTGCCTGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTACTGTCCTGTCTAACCATTCCAGCTTCCGCTTACGAGGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCGGCTAGGAACGCCAGCATCCCCACTACAACA

Figure 21B

ATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTG
GGGGATCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGG
CATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGT
ATGGCTTGGGATATGATGATGAACTGGTACTAATAG

SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)
ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC

SEQ ID NO 20 (HCPr108)
GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCC137)
ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTG
CAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGGGAT
ATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCA
CAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGTCTCGCCTAC
TATTCCATGGTGGGGAACTGGGCTAAGGTTTTGATTGTGATGCTACTCTTTGCTCCCTAA
TAG

SEQ ID NO 23 (HCC138)
ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG

Figure 21C

GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTG
CAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGGGAT
ATGATGATGAACTGGTAATAG

SEQ ID NO 25 (HCC139)
ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTG
CAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGGGAT
ATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCTC
TAATAG

SEQ ID NO 27 (HCC140)
ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTG
CAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGGGAT
ATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCGTG
ATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 29 (HCC162)
ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCGCCGATCTCATGGGGTACATCCCG
CTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGCCCTT
GAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTTTCCTT
CTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAATACGTCT
GGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGCCGATGAC
GTTATTCTGCACACACCCGGCTGCATACCTTGTGTCCAGGACGGCAATACATCCACGTGC
TGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCACCGCTTCGATA
CGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGCGCTCTACGTGGGT
GACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCAGACCTCGTCGCCAT

Figure 21D

CAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCTTTCAGGACATCGAATG
GCTTGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 31 (HCC163)
ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCCCG
CTCGTAGGCGGCCCCATTGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGTCCTT
GAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCTTTATT
CTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATGCCTCT
GGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCAGATAAC
CTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGAGTAGATGC
TGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCACGGCTCCTCTT
CGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCGTTATACGTAGGA
GACGCGTGTGGGGCACTATTCTTGGTAGGCCAAATGTTCACCTATAGGCCTCGCCAGCAC
GCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGTTACCGGCCACCGGATG
GCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109)
TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)
TGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGG
ATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTC
GCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCC
GGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTT
GTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGT
TGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCC
GCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGT
CGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC
TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCG
TCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACC
GATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTC
AACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGG
TTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTG
ACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCT
GGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCC
TGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGG
TTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGA
TCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTC

Figure 21E

ACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTG
CAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTC
CTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTG
CTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTG
GCCGGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAG
GGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTT
CTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCC141)
GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCT
CGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGC
CGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCT
TGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAG
TTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGC
CGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTG
TCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAG
CTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGC
GTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGAC
CGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCT
CAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGG
GTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTT
GACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC
TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCC
CTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAG
GTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAG
ATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGAGTGGCAGAGCTTAATT
AATTAG

SEQ ID NO 39 (HCC142)
GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCT
CGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGC
CGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCT
TGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAG
TTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGC
CGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTG
TCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAG
CTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGC
GTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGAC
CGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCT
CAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGG
GTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTT

Figure 21F

GACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC
TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCC
CTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAG
GTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAG
ATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGATCGAGGGCAGACACCATCACC
ACCATCACTAATAG

SEQ ID NO 41 (HCC143)
ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGG
CATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTT
AGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAAC
AGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTAC
AAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGAC
AAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG
CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGC
GGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGT
GTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG
CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGACG
TGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACT
GACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTG
ACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAAC
TTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCA
TGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGC
CCGCTGCTGCTGTCTACAACAGAGTGGCAGAGCTTAATTAATTAG

SEQ ID NO 43 (HCC144)
ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGG
CATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTT
AGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAAC
AGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTAC
AAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGAC
AAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG
CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGC
GGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGT
GTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG
CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGACG
TGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACT
GACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTG
ACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAAC
TTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCA
TGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGC

Figure 21G

CCGCTGCTGCTGTCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATA
G

SEQ ID NO 45 (HCCL64)
ATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGG
AACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGC
GTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG
TCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCC
CTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA
TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCT
CAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGC
TGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTG
TATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACG
TATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGA
GGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGC
CCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTT
CGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGG
TGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATC
TTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGG
ACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTG
CTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACCACCCTGCCGGCCCTATCC
ACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGGG
TCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTGTTGCTCTTCCTTCTCCTG
GCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCC
GCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCCGGGGCGCATGGCACTCTT
TCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCG
GCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGA
GCTTATGCCTAGTAA

SEQ ID NO 47 (HCC165)
AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATT
CCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTT
CTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTC
CTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTG
TCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCG
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGC
TGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACA
ATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTG
GGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGG
CATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGT
ATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTG
CTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCG

Figure 21H

GGCCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTC
TTTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGC AGCCTCCGATACCAG
GGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAA
CGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTT
CTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGC
CAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCC
TAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGT
ACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGG
GACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCT
GATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGG
CACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAA
CACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATG
CGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCA
CTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGA
GCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAG
GGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTG
TTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGT
GGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGA
GTATGTCCTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGAT
GATGCTGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGC
GGCCGTGGCCGGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTA
CATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCT
CCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAAGCTT

SEQ ID NO 49 (HCC166)
ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAG
GACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG
GGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGG
AGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGGCTCAGCCCGGG
TACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATGGCTCCTGTCACCC
CGCGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGGTCGCGTAATTTGGGT
AAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACATTCCGCTCGTC
GGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTTCTGGAGGAC
GGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCT
TTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGATG
TACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCGGACATGATC
ATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTCTTCCCGCTGCTGGGTA
GCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCGTCCCCACCACGACAATACGACGC
CACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTGTTCCGCTATGTACGTGGGGGACCTC
TGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACG
GTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGTCACCGTATGGCTTGG

Figure 21I

GATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATC
CCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCC
TACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGC
GTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTG
TCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGG
CACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCA
CTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGC
TCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCG
GACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCT
CAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGAT
CGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAAC
AACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTC
ACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACC
TGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGG
CCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTACCCCTGC
ACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTTC
GAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCA
GAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACC
ACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAA
TACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTG
TTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGCTG
ATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCC
GGGGCGCATGGCACTCTTTCCTTCCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGC
AGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTG
CTGGCCTTACCACCACGAGCTTATGCCTAGTAA

Figure 21J

			OD measured at 450nm construct			
Fraction	Volume	dilution	39 type 1b	40 type 1b	62 type 3a	63 type 5a
Start	23ml	1/20	2.517	1.954	1.426	1.142
Flow through	23ml	1/20	0.087	0.085	0.176	0.120
1	0.4ml	1/200	0.102	0.051	0.048	0.050
2			0.396	0.550	0.090	0.067
3			2.627	2.603	2.481	2.372
4			3	2.967	3	2.694
5			3	2.810	2.640	2.154
6			2.694	2.499	1.359	1.561
7			2.408	2.481	0.347	1.390
8			2.176	1.970	1.624	0.865
9			1.461	1.422	0.887	0.604
10			1.286	0.926	0.543	0.519
11			0.981	0.781	0.294	0.294
12			0.812	0.650	0.249	0.199
13			0.373	0.432	0.239	0.209
14			0.653	0.371	0.145	0.184
15			0.441	0.348	0.151	0.151
16			0.321	0.374	0.098	0.106
17			0.525	0.186	0.099	0.108
18			0.351	0.171	0.083	0.090
19			0.192	0.164	0.084	0.087

Figure 22


Type 1b (construct 39)
Type 1b (construct 40)
Type 3a (construct 62)
Type 5a (construct 63)
OD450 nm
0
0.5
1
1.5
2
2.5
3
FRACTIES
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
POOL

Figure 23

			OD measured at 450nm construct			
Fraction	Volume	dilution	39 type 1b	40 type 1b	62 type 3a	63 type 5a
20	250µl	1/200	0.072	0.130	0.096	0.051
21			0.109	0.293	0.084	0.052
22			0.279	0.249	0.172	0.052
23			0.093	0.151	0.297	0.054
24			0.080	0.266	0.438	0.056
25			0.251	0.100	0.457	0.048
26			3	1.649	0.722	0.066
27			3	3	2.528	0.889
28			3	3	3	2.345
29			3	3	2.849	2.580
30			2.227	1.921	1.424	1.333
31			0.263	0.415	0.356	0.162
32			0.071	0.172	0.154	0.064
33			0.103	0.054	0.096	0.057
34			0.045	0.045	0.044	0.051
35			0.043	0.047	0.045	0.046
36			0.045	0.045	0.049	0.040
37			0.045	0.047	0.046	0.048
38			0.046	0.048	0.047	0.057
39			0.045	0.048	0.050	0.057
40			0.046	0.049	0.048	0.049

Figure 24


157
4
45
AU
0.6
0.4
660
440
220
0.2
3
2
1
0
-0.02
WASTE
1 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
6.0
8.0
10
12
14
16
ml

Figure 25



Figure 26



Figure 27



Figure 28



Lane 1: Crude Lysate
Lane 2: Flow through Lentil Chromatography
Lane 3: Wash with EMPIGEN Lentil Chromatography
Lane 4: Eluate Lentil Chromatography
Lane 5: Flow through during concentration lentil eluate
Lane 6: Pool of E1 after Size Exclusion Chromatography

Figure 29


AU
CONTAMINANTS
E2 + CONTAMINANTS
(AGGREGATES)
FLOW
THROUGH
EMPIGEN
WASH
ELUTION
ELUTION VOLUME

Figure 30



Figure 31A



Figure 31B


OD
280 nm
0.1
0.5
100
125
150
175
VOLUME (ml)
FLOW THROUGH
EMPIGEN WASH
DP WASH
30mM IMIDAZOLE WASH
POOL
200mM IMIDAZOLE ELUTION

Figure 32

Figure 33: Silver stain of purified E2



1. 30mM imidazole wash Ni-IMAC
2. 0.5µg E2

Figure 33



No.	Ret (ml)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4
Total Area above baseline = 0.796522 ml*AU
Total area in evaluated peaks = 0.796521 ml*AU
Ratio peak area / total area = 0.999999
Total peak duration = 2.613583 ml

Figure 34



Fig. 35A-1



Fig. 35A-2



Fig. 35A-3



Fig. 35A-4



Fig. 35A-5



Fig. 35A-6



Fig. 35A-7



Fig. 35A-8



Fig. 35B-1



Fig. 35B-2



Fig. 35B-3



Fig. 35B-4



Fig. 35B-5



Fig. 35B-6



Fig. 35B-7



Fig. 35B-8



Figure 36A



Figure 36B



Figure 37A



Figure 37B



Figure 37C



Figure 37D

Relative Map Positions of
anti-E2 monoclonal antibodies



Figure 38


PARTIAL DEGLYCOSYLATION
OF HCV E1 ENVELOPE PROTEIN
Endoglycosidase H
(Endo H)
Glycopeptidase F
(PNGase F)
0mu
0.04mu
0.4mu
4mu
40mu
400mu
0mU
0.6mU
6mU
60mU
0.6mu
6mu
106.0
80.0
49.5
32.5
27.5
18.5
0
1
2
3
4
5
6

Figure 39


PARTIAL TREATMENT OF HCV E2\E2s ENVELOPE PROTEINS
BY PNGase F
E2 (vvHCV-64)
E2s (vvHCV-41)
-
0.01µU
0.1µU
1µU
0.01mU
0.1mU
1mU
kDa
106
80
49.5
32.5
0
1
2
3
4
5
6
7
8
9
10
11

Figure 40


In vitro mutagenesis of HCV E1 glycoprotein
10A
GPT
p11
EcoRI
E1
BamHI
TKR
TKr
1. First step of PCR amplification (Gly-# and Ovr-# primers)
Ovr-#
Gly-#
30 cycles (1min at 95°C; 1 min at 50°C, 1 min at 72°C)
Gly-#
Ovr-#

Figure 42A


2. Overlap extension and nested PCR
a. Overlap extension
Gly-# sense strand
Ovr-# antisense strand
2 cycles (1min at 95°C; 1min at 50°C; 1min at 72°C)
b. Nested PCR amplification (GPT-2 and TKr-2 primers)
GPT-2
TKr-2
25 cycles (1min at 95°C; 1min at 55°C; 1min at 72°C)
E1Gly-#
EcoRI
BamHI

Figure 42B


In vitro mutagenesis of HCV E1 glycoprotein
ATG
CORE
E1
E2
196
192
209
233/234
250
305
325
384
E. coli gpt
I3
p11
GPT
EcoRI
BamHI
TKR
TKr
10A
81
82
83
84
85
86
E1Gly-1
E1Gly-2
E1Gly-3
E1Gly-4
E1Gly-5
E1Gly-6
OVR-1
OVR-2
OVR-3
OVR-4
OVR-5
OVR-6
GLY-1
GLY-2
GLY-3
GLY-4
GLY-5
GLY-6
770 nt
630 nt
550 nt
500 nt
340 nt
280 nt
380 nt
420 nt
500 nt
550 nt
710 nt
770 nt

Figure 43


RK 13 cells
2 1 3 4 5 6 7 8
80,0 49.5 32.5 27.5 18.5
HeLa cells
1 2 3 4 5 6 7
80,0 49.5 32.5 27.5 18.5

Figure 44A


710
489
404
325
242
190
157
147
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
710
489
404
325
242
190
157
147

Figure 44B

Figure 45



Figure 46

	age (years)	HCV infection (years)	genotype
Marcel	17	9	1a
Peggy	21	16,5	1b
Femma	15	9	1a
Yoran	12	none	
Marti	12	none	



Figure 47


48a
T-cell proliferation
# of cells
0
3
6
9
12
15
Femma
Marcel
Peggy
Yoran
Marti
48b
Il-2 secretion
# of cells
0
2
4
6
8
10
Femma
Marcel
Peggy
Yoran
Marti
48c
IFN-g secretion
# of cells
0
1
2
3
4
5
Femma
Marcel
Peggy
Yoran
Marti
48d
Il-4 secretion
# of cells
0
8
16
24
32
40
Femma
Marcel
Peggy
Yoran
Marti

Figure 48



1: Femma, 2: Marcel, 3: Peggy

Figure 49


T-cell proliferation
50
40
30
20
10
0
# of cells
Ton
Philomena
Fauzi
Lianne
Il-2 secretion
25
20
15
10
5
0
# of cells
Ton
Philomena
Fauzi
Lianne

Figure 50



Figure 51


1000
750
500
250
0
pg/ml
IFN-gamma w26
IFN-gamma w28
IL-5 w26
IL-5 w28
E1
TT
BI

Figure 52


vaccinated
SI
30
20
10
0
1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636
controls
SI
30
20
10
0
1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636

Figure 53



FIGURE 54



FIGURE 55



FIGURE 56

A



B



FIGURE 57

Sequence Listing

<110> Innogenetics N.V.

<120> Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use.

<140> PCT/EP02/00219
<160> 123

<170> PatentIn 3.1

<210> 1

<211> 21
<212> DNA
<213> Hepatitis C virus

<400> 1

ggcatgcaag cttaattaat t 21

<210> 2

<211> 68
<212> DNA
<213> Hepatitis C virus

<400> 2

ccggggaggc ctgcacgtga tcgagggcag acaccatcac caccatcact aatagttaat 60

taactgca 68

<210> 3

<211> 642
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..639

<220>
<221> mat_peptide
<222> 1..636

<400> 3

atg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct tta ctg tcc tgt 48
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
1 5 10 15

ctg acc att cca gct tcc gct tat gag gtg cgc aac gtg tcc ggg atg 96
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met
20 25 30

```
tac cat gtc acg aac gac tgc tcc aac tca agc att gtg tat gag gca       144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
         35                  40                  45

gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc gtt cgg gag       192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
     50                  55                  60

aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg ctc gca gct       240
Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65                  70                  75                  80

agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac gtc gat ttg       288
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
                 85                  90                  95

ctc gtt ggg gcg gct gct ctc tgt tcc gct atg tac gtg ggg gat ctc       336
Leu Val Gly Ala Ala Ala Leu Cys Ser Ala Met Tyr Val Gly Asp Leu
            100                 105                 110

tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc tcg cct cgc       384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile Ser Pro Arg
        115                 120                 125

cgg cat gag acg gtg cag gac tgc aat tgc tca atc tat ccc ggc cac       432
Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130                 135                 140

ata aca ggt cac cgt atg gct tgg gat atg atg atg aac tgg tcg cct       480
Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro
145                 150                 155                 160

aca acg gcc ctg gtg gta tcg cag ctg ctc cgg atc cca caa gct gtc       528
Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val
                165                 170                 175

gtg gac atg gtg gcg ggg gcc cat tgg gga gtc ctg gcg ggc ctc gcc       576
Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala
            180                 185                 190

tac tat tcc atg gtg ggg aac tgg gct aag gtt ttg att gtg atg cta       624
Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu
        195                 200                 205

ctc ttt gct ctc taatag                                               642
Leu Phe Ala Leu
    210
```

<210> 4

<211> 212
<212> PRT
<213> Hepatitis C virus

<400> 4

```
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
  1               5                  10                  15
```

```
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met
            20                  25                  30

Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
         35                  40                  45

Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
     50                  55                  60

Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65                  70                  75                  80

Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
                85                  90                  95

Leu Val Gly Ala Ala Ala Leu Cys Ser Ala Met Tyr Val Gly Asp Leu
            100                 105                 110

Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile Ser Pro Arg
        115                 120                 125

Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130                 135                 140

Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro
145                 150                 155                 160

Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val
                165                 170                 175

Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala
            180                 185                 190

Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu
        195                 200                 205

Leu Phe Ala Leu
    210


<210> 5

<211> 795
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..792

<220>
<221> mat_peptide
<222> 1..789
<400> 5

atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
```

```
            20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt tcc gct atg tac gtg       480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

ggg gac ctc tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc       528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175
tcg cct cgc cgg cat gag acg gtg cag gac tgc aat tgc tca atc tat       576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

ccc ggc cac ata acg ggt cac cgt atg gct tgg gat atg atg atg aac       624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

tgg tcg cct aca acg gcc ctg gtg gta tcg cag ctg ctc cgg atc cca       672
Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
    210                 215                 220

caa gct gtc gtg gac atg gtg gcg ggg gcc cat tgg gga gtc ctg gcg       720
Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
225                 230                 235                 240

ggt ctc gcc tac tat tcc atg gtg ggg aac tgg gct aag gtt ttg att       768
Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile
                245                 250                 255

gtg atg cta ctc ttt gct ccc taatag                                   795
Val Met Leu Leu Phe Ala Pro
            260
<210> 6
```

<211> 263
<212> PRT
<213> Hepatitis C virus

<400> 6

```
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
            20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
    210                 215                 220

Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
225                 230                 235                 240

Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile
                245                 250                 255

Val Met Leu Leu Phe Ala Pro
            260
```

<210> 7

<211> 633
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..630

<220>
<221> mat_peptide
<222> 1..627
<400> 7

```
atg ttg ggt aag gtc atc gat acc ctt acg tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

atg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggt gct gcc aga        96
Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gaa gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg cct ggt tgc tct ttc tct atc ttc ctc ttg gct tta       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

ctg tcc tgt ctg acc att cca gct tcc gct tat gag gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc act acg aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt tcc gct atg tac gtg       480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

ggg gat ctc tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc       528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

tcg cct cgc cgg cat gag acg gtg cag gac tgc aat tgc tca atc tat       576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190
```

```
ccc ggc cac ata aca ggt cac cgt atg gct tgg gat atg atg atg aac       624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

tgg taatag                                                        633
Trp
    210
```

<210> 8

<211> 209
<212> PRT
<213> Hepatitis C virus

<400> 8

```
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

Trp
```

<210> 9

<211> 483
<212> DNA
<213> Hepatitis C virus
<220>
<221> CDS
<222> 1..480

<220>
<221> mat_peptide
<222> 1..477
<400> 9

```
atg ccc ggt tgc tct ttc tct atc ttc ctc ttg gcc ctg ctg tcc tgt        48
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
  1               5                  10                  15

ctg acc ata cca gct tcc gct tat gaa gtg cgc aac gtg tcc ggg gtg        96
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val
             20                  25                  30

tac cat gtc acg aac gac tgc tcc aac tca agc ata gtg tat gag gca       144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
         35                  40                  45

gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc gtt cgg gag       192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
     50                  55                  60

ggc aac tcc tcc cgt tgc tgg gtg gcg ctc act ccc acg ctc gcg gcc       240
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65                  70                  75                  80

agg aac gcc agc gtc ccc aca acg aca ata cga cgc cac gtc gat ttg       288
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
                 85                  90                  95

ctc gtt ggg gct gct gct ttc tgt tcc gct atg tac gtg ggg gat ctc       336
Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
            100                 105                 110

tgc gga tct gtt ttc ctt gtt tcc cag ctg ttc acc ttc tca cct cgc       384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
        115                 120                 125

cgg cat caa aca gta cag gac tgc aac tgc tca atc tat ccc ggc cat       432
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130                 135                 140

gta tca ggt cac cgc atg gct tgg gat atg atg atg aac tgg tcc taatag     483
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser
145                 150                 155                 160
```

<210> 10

<211> 159
<212> PRT
<213> Hepatitis C virus

<400> 10

Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
1 5 10 15

Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val
20 25 30

Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
35 40 45

Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
50 55 60

Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
65 70 75 80

Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
85 90 95

Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
100 105 110

Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
115 120 125

Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
130 135 140

Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser
145 150 155
<210> 11

<211> 480
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..477

<220>
<221> mat_peptide
<222> 1..474
<400> 11

atg tcc ggt tgc tct ttc tct atc ttc ctc ttg gcc ctg ctg tcc tgt 48
Met Ser Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
1 5 10 15

ctg acc ata cca gct tcc gct tat gaa gtg cgc aac gtg tcc ggg gtg 96
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val
20 25 30

tac cat gtc acg aac gac tgc tcc aac tca agc ata gtg tat gag gca 144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
35 40 45

gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc gtt cgg gag 192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu

```
     50                  55                  60

ggc aac tcc tcc cgt tgc tgg gtg gcg ctc act ccc acg ctc gcg gcc       240
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65                  70                  75                  80

agg aac gcc agc gtc ccc aca acg aca ata cga cgc cac gtc gat ttg       288
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
                85                  90                  95

ctc gtt ggg gct gct gct ttc tgt tcc gct atg tac gtg ggg gat ctc       336
Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
            100                 105                 110

tgc gga tct gtt ttc ctt gtt tcc cag ctg ttc acc ttc tca cct cgc       384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
        115                 120                 125

cgg cat caa aca gta cag gac tgc aac tgc tca atc tat ccc ggc cat       432
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130                 135                 140

gta tca ggt cac cgc atg gct tgg gat atg atg atg aac tgg taatag       480
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
145                 150                 155
<210> 12

<211> 158
<212> PRT
<213> Hepatitis C virus


<400> 12

Met Ser Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
  1               5                  10                  15

Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val
             20                  25                  30

Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
         35                  40                  45

Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
     50                  55                  60

Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65                  70                  75                  80

Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
                85                  90                  95

Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
            100                 105                 110

Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
        115                 120                 125

Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
    130                 135                 140
```

```
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
145                 150                 155
<210> 13

<211> 636
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..633

<220>
<221> mat_peptide
<222> 1..630


<400> 13

atg ctg ggt aag gcc atc gat acc ctt acg tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Ala Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15
gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gaa gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg cct ggt tgc tct ttc tct atc ttc ctc ttg gct tta       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60
ctg tcc tgt cta acc att cca gct tcc gct tac gag gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gcg gct agg aac gcc agc atc ccc act aca aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Ile Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt tcc gct atg tac gtg       480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

ggg gat ctc tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc       528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175
```

```
tcg cct cgc cgg cat gag acg gtg cag gac tgc aat tgc tca atc tat       576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

ccc ggc cac ata acg ggt cac cgt atg gct tgg gat atg atg atg aac       624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

tgg tac taatag                                                       640
Trp Tyr
    210
```

<210> 14

<211> 210
<212> PRT
<213> Hepatitis C virus

<400> 14

```
Met Leu Gly Lys Ala Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Ile Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

Trp Tyr
```

210
<210> 15

<211> 26
<212> DNA
<213> Hepatitis C virus
<400> 15

atgcccggtt gctctttctc tatctt 26

<210> 16

<211> 26
<212> DNA
<213> Hepatitis C virus

<400> 16

atgttgggta aggtcatcga taccct 26

<210> 17

<211> 30
<212> DNA
<213> Hepatitis C virus

<220>
<221> misc_feature
<223>/note="antisense"

<400> 17

ctattaggac cagttcatca tcatatccca 30

<210> 18

<211> 27
<212> DNA
<213> Hepatitis C virus

<400> 18

ctattaccag ttcatcatca tatccca 27

<210> 19

<211> 36
<212> DNA
<213> Hepatitis C virus
<400> 19

atacgacgcc acgtcgattc ccagctgttc accatc 36

<210> 20

<211> 36
<212> DNA
<213> Hepatitis C virus
<220>
<221> misc_feature
<223>/note="antisense"

<400> 20

gatggtgaac agctgggaat cgacgtggcg tcgtat 36

<210> 21

<211> 723
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..720

<220>
<221> mat_peptide
<222> 1..717
<400> 21

```
atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
            20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
```

```
    130                 135                 140
gtc gat tcc cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg       480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

cag gac tgc aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt       528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

atg gct tgg gat atg atg atg aac tgg tcg cct aca acg gcc ctg gtg       576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
            180                 185                 190

gta tcg cag ctg ctc cgg atc cca caa gct gtc gtg gac atg gtg gcg       624
Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala
        195                 200                 205

ggg gcc cat tgg gga gtc ctg gcg ggt ctc gcc tac tat tcc atg gtg       672
Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val
    210                 215                 220

ggg aac tgg gct aag gtt ttg att gtg atg cta ctc ttt gct ccc taatag    723
Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Pro
225                 230                 235                 240
<210> 22

<211> 239
<212> PRT
<213> Hepatitis C virus


<400> 22

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
```

```
145                 150                 155                 160

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
            180                 185                 190

Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala
        195                 200                 205

Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val
    210                 215                 220

Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Pro
225                 230                 235
<210> 23

<211> 561
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..558

<220>
<221> mat_peptide
<222> 1..555
<400> 23

atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
            20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
        35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
    50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
```

```
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac      432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat tcc cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg      480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

cag gac tgc aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt      528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

atg gct tgg gat atg atg atg aac tgg taatag                          561
Met Ala Trp Asp Met Met Met Asn Trp
            180                 185
<210> 24

<211> 185
<212> PRT
<213> Hepatitis C virus


<400> 24

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

Met Ala Trp Asp Met Met Met Asn Trp
            180                 185
```

<210> 25

<211> 606
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..603

<220>
<221> mat_peptide
<222> 1..600
<400> 25

```
atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
            20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
        35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
    50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat tcc cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg       480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

cag gac tgc aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt       528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

atg gct tgg gat atg atg atg aac tgg tcg cct aca acg gcc ctg gtg       576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
```

```
           180                 185                 190

gta tcg cag ctg ctc cgg atc ctc taatag                                606
Val Ser Gln Leu Leu Arg Ile Leu
        195                 200
<210> 26

<211> 200
<212> PRT
<213> Hepatitis C virus


<400> 26

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
            180                 185                 190

Val Ser Gln Leu Leu Arg Ile Leu
        195                 200
<210> 27

<211> 636
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..633
```

<220>
<221> mat_peptide
<222> 1..630
<400> 27

```
atg ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca       144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg       192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg       240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg       288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc       336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg       384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac       432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat tcc cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg       480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

cag gac tgc aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt       528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
            165                 170                 175

atg gct tgg gat atg atg atg aac tgg tcg cct aca acg gcc ctg gtg       576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
        180                 185                 190

gta tcg cag ctg ctc cgg atc gtg atc gag ggc aga cac cat cac cac       624
Val Ser Gln Leu Leu Arg Ile Val Ile Glu Gly Arg His His His His
    195                 200                 205

cat cac taatag                                                       636
His His
    210
```

<210> 28

<211> 210
<212> PRT
<213> Hepatitis C virus

<400> 28

```
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145                 150                 155                 160

Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
                165                 170                 175

Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
            180                 185                 190

Val Ser Gln Leu Leu Arg Ile Val Ile Glu Gly Arg His His His His
        195                 200                 205

His His
    210
```

<210> 29

<211> 630
<212> DNA
<213> Hepatitis C virus
<220>
<221> CDS
<222> 1..627

<220>
<221> mat_peptide

<222> 1..624
<400> 29

```
atg ggt aag gtc atc gat acc ctt acg tgc gga ttc gcc gat ctc atg        48
Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
  1               5                  10                  15

ggg tac atc ccg ctc gtc ggc gct ccc gta gga ggc gtc gca aga gcc        96
Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala Arg Ala
             20                  25                  30

ctt gcg cat ggc gtg agg gcc ctt gaa gac ggg ata aat ttc gca aca       144
Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe Ala Thr
         35                  40                  45

ggg aat ttg ccc ggt tgc tcc ttt tct att ttc ctt ctc gct ctg ttc       192
Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Phe
     50                  55                  60

tct tgc tta att cat cca gca gct agt cta gag tgg cgg aat acg tct       240
Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn Thr Ser
 65                  70                  75                  80

ggc ctc tat gtc ctt acc aac gac tgt tcc aat agc agt att gtg tac       288
Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr
                 85                  90                  95

gag gcc gat gac gtt att ctg cac aca ccc ggc tgc ata cct tgt gtc       336
Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Cys Ile Pro Cys Val
            100                 105                 110

cag gac ggc aat aca tcc acg tgc tgg acc cca gtg aca cct aca gtg       384
Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro Thr Val
        115                 120                 125

gca gtc aag tac gtc gga gca acc acc gct tcg ata cgc agt cat gtg       432
Ala Val Lys Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser His Val
    130                 135                 140

gac cta tta gtg ggc gcg gcc acg atg tgc tct gcg ctc tac gtg ggt       480
Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr Val Gly
145                 150                 155                 160

gac atg tgt ggg gct gtc ttc ctc gtg gga caa gcc ttc acg ttc aga       528
Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr Phe Arg
                165                 170                 175

cct cgt cgc cat caa acg gtc cag acc tgt aac tgc tcg ctg tac cca       576
Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu Tyr Pro
            180                 185                 190

ggc cat ctt tca gga cat cga atg gct tgg gat atg atg atg aac tgg       624
Gly His Leu Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
        195                 200                 205

taatag                                                               634
```

<210> 30

<211> 208
<212> PRT
<213> Hepatitis C virus

<400> 30

Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
1 5 10 15

Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala Arg Ala
20 25 30

Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe Ala Thr
35 40 45

Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Phe
50 55 60

Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn Thr Ser
65 70 75 80

Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr
85 90 95

Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Cys Ile Pro Cys Val
100 105 110

Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro Thr Val
115 120 125

Ala Val Lys Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser His Val
130 135 140

Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr Val Gly
145 150 155 160

Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr Phe Arg
165 170 175

Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu Tyr Pro
180 185 190

Gly His Leu Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
195 200 205

<210> 31

<211> 630
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..627

<220>
<221> mat_peptide
<222> 1..624
<400> 31

atg ggt aag gtc atc gat acc cta acg tgc gga ttc gcc gat ctc atg 48
Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
1 5 10 15

```
ggg tat atc ccg ctc gta ggc ggc ccc att ggg ggc gtc gca agg gct        96
Gly Tyr Ile Pro Leu Val Gly Gly Pro Ile Gly Gly Val Ala Arg Ala
            20                  25                  30

ctc gca cac ggt gtg agg gtc ctt gag gac ggg gta aac tat gca aca       144
Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr
        35                  40                  45

ggg aat tta ccc ggt tgc tct ttc tct atc ttt att ctt gct ctt ctc       192
Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Ile Leu Ala Leu Leu
    50                  55                  60

tcg tgt ctg acc gtt ccg gcc tct gca gtt ccc tac cga aat gcc tct       240
Ser Cys Leu Thr Val Pro Ala Ser Ala Val Pro Tyr Arg Asn Ala Ser
65                  70                  75                  80

ggg att tat cat gtt acc aat gat tgc cca aac tct tcc ata gtc tat       288
Gly Ile Tyr His Val Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr
                85                  90                  95

gag gca gat aac ctg atc cta cac gca cct ggt tgc gtg cct tgt gtc       336
Glu Ala Asp Asn Leu Ile Leu His Ala Pro Gly Cys Val Pro Cys Val
            100                 105                 110

atg aca ggt aat gtg agt aga tgc tgg gtc caa att acc cct aca ctg       384
Met Thr Gly Asn Val Ser Arg Cys Trp Val Gln Ile Thr Pro Thr Leu
        115                 120                 125

tca gcc ccg agc ctc gga gca gtc acg gct cct ctt cgg aga gcc gtt       432
Ser Ala Pro Ser Leu Gly Ala Val Thr Ala Pro Leu Arg Arg Ala Val
    130                 135                 140

gac tac cta gcg gga ggg gct gcc ctc tgc tcc gcg tta tac gta gga       480
Asp Tyr Leu Ala Gly Gly Ala Ala Leu Cys Ser Ala Leu Tyr Val Gly
145                 150                 155                 160

gac gcg tgt ggg gca cta ttc ttg gta ggc caa atg ttc acc tat agg       528
Asp Ala Cys Gly Ala Leu Phe Leu Val Gly Gln Met Phe Thr Tyr Arg
                165                 170                 175

cct cgc cag cac gct acg gtg cag aac tgc aac tgt tcc att tac agt       576
Pro Arg Gln His Ala Thr Val Gln Asn Cys Asn Cys Ser Ile Tyr Ser
            180                 185                 190

ggc cat gtt acc ggc cac cgg atg gca tgg gat atg atg atg aac tgg       624
Gly His Val Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
        195                 200                 205

taatag                                                                630
```

<210> 32
<211> 208
<212> PRT
<213> Hepatitis C virus

<400> 32

```
Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
  1               5                  10                  15
```

```
Gly Tyr Ile Pro Leu Val Gly Gly Pro Ile Gly Gly Val Ala Arg Ala
            20                  25                  30

Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr
         35                  40                  45

Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Ile Leu Ala Leu Leu
     50                  55                  60

Ser Cys Leu Thr Val Pro Ala Ser Ala Val Pro Tyr Arg Asn Ala Ser
 65                  70                  75                  80

Gly Ile Tyr His Val Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr
                85                  90                  95

Glu Ala Asp Asn Leu Ile Leu His Ala Pro Gly Cys Val Pro Cys Val
            100                 105                 110

Met Thr Gly Asn Val Ser Arg Cys Trp Val Gln Ile Thr Pro Thr Leu
        115                 120                 125

Ser Ala Pro Ser Leu Gly Ala Val Thr Ala Pro Leu Arg Arg Ala Val
    130                 135                 140

Asp Tyr Leu Ala Gly Gly Ala Ala Leu Cys Ser Ala Leu Tyr Val Gly
145                 150                 155                 160

Asp Ala Cys Gly Ala Leu Phe Leu Val Gly Gln Met Phe Thr Tyr Arg
                165                 170                 175

Pro Arg Gln His Ala Thr Val Gln Asn Cys Asn Cys Ser Ile Tyr Ser
            180                 185                 190

Gly His Val Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
        195                 200                 205
<210> 33

<211> 23
<212> DNA
<213> Hepatitis C virus
<400> 33
tgggatatga tgatgaactg gtc                                          23


<210> 34

<211> 30
<212> DNA
<213> Hepatitis C virus
<400> 34

ctattatggt ggtaagccac agagcaggag                                   30


<210> 35

<211> 1476
<212> DNA
<213> Hepatitis C virus
```

<220>
<221> CDS
<222> 1..1473

<220>
<221> mat_peptide
<222> 1..1470
<400> 35

```
tgg gat atg atg atg aac tgg tcg cct aca acg gcc ctg gtg gta tcg        48
Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser
  1               5                  10                  15

cag ctg ctc cgg atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc        96
Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala
             20                  25                  30

cat tgg gga gtc ctg gcg ggc ctc gcc tac tat tcc atg gtg ggg aac       144
His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn
         35                  40                  45

tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc ggc gtc gac ggg       192
Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly
     50                  55                  60

cat acc cgc gtg tca gga ggg gca gca gcc tcc gat acc agg ggc ctt       240
His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu
 65                  70                  75                  80

gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc cag ctc gta aac       288
Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn
                 85                  90                  95

acc aac ggc agt tgg cac atc aac agg act gcc ctg aac tgc aac gac       336
Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp
            100                 105                 110

tcc ctc caa aca ggg ttc ttt gcc gca cta ttc tac aaa cac aaa ttc       384
Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe
        115                 120                 125

aac tcg tct gga tgc cca gag cgc ttg gcc agc tgt cgc tcc atc gac       432
Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp
    130                 135                 140

aag ttc gct cag ggg tgg ggt ccc ctc act tac act gag cct aac agc       480
Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser
145                 150                 155                 160

tcg gac cag agg ccc tac tgc tgg cac tac gcg cct cga ccg tgt ggt       528
Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly
                165                 170                 175

att gta ccc gcg tct cag gtg tgc ggt cca gtg tat tgc ttc acc ccg       576
Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro
            180                 185                 190

agc cct gtt gtg gtg ggg acg acc gat cgg ttt ggt gtc ccc acg tat       624
Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr
        195                 200                 205
```

```
aac tgg ggg gcg aac gac tcg gat gtg ctg att ctc aac aac acg cgg       672
Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg
    210                 215                 220

ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg atg aat ggc act ggg       720
Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly
225                 230                 235                 240

ttc acc aag acg tgt ggg ggc ccc ccg tgc aac atc ggg ggg gcc ggc       768
Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly
                245                 250                 255

aac aac acc ttg acc tgc ccc act gac tgt ttt cgg aag cac ccc gag       816
Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu
            260                 265                 270

gcc acc tac gcc aga tgc ggt tct ggg ccc tgg ctg aca cct agg tgt       864
Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys
        275                 280                 285

atg gtt cat tac cca tat agg ctc tgg cac tac ccc tgc act gtc aac       912
Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn
    290                 295                 300

ttc acc atc ttc aag gtt agg atg tac gtg ggg ggc gtg gag cac agg       960
Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg
305                 310                 315                 320

ttc gaa gcc gca tgc aat tgg act cga gga gag cgt tgt gac ttg gag      1008
Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu
                325                 330                 335

gac agg gat aga tca gag ctt agc ccg ctg ctg ctg tct aca aca gag      1056
Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu
            340                 345                 350

tgg cag ata ctg ccc tgt tcc ttc acc acc ctg ccg gcc cta tcc acc      1104
Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr
        355                 360                 365

ggc ctg atc cac ctc cat cag aac atc gtg gac gtg caa tac ctg tac      1152
Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr
    370                 375                 380

ggt gta ggg tcg gcg gtt gtc tcc ctt gtc atc aaa tgg gag tat gtc      1200
Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val
385                 390                 395                 400

ctg ttg ctc ttc ctt ctc ctg gca gac gcg cgc atc tgc gcc tgc tta      1248
Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu
                405                 410                 415

tgg atg atg ctg ctg ata gct caa gct gag gcc gcc tta gag aac ctg      1296
Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu
            420                 425                 430

gtg gtc ctc aat gcg gcg gcc gtg gcc ggg gcg cat ggc act ctt tcc      1344
Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser
        435                 440                 445

ttc ctt gtg ttc ttc tgt gct gcc tgg tac atc aag ggc agg ctg gtc      1392
```

```
Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val
    450                 455                 460

cct ggt gcg gca tac gcc ttc tat ggc gtg tgg ccg ctg ctc ctg ctt      1440
Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu
465                 470                 475                 480

ctg ctg gcc tta cca cca cga gct tat gcc tagtaa                      1476
Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
                485                 490
<210> 36

<211> 490
<212> PRT
<213> Hepatitis C virus


<400> 36

Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser
  1               5                  10                  15

Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala
             20                  25                  30

His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn
         35                  40                  45

Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly
     50                  55                  60

His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu
 65                  70                  75                  80

Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn
                 85                  90                  95

Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp
            100                 105                 110

Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe
        115                 120                 125
Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp
    130                 135                 140

Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser
145                 150                 155                 160

Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly
                165                 170                 175

Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro
            180                 185                 190

Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr
        195                 200                 205

Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg
    210                 215                 220

Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly
```

225 230 235 240

Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly
245 250 255

Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu
260 265 270

Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys
275 280 285

Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn
290 295 300

Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg
305 310 315 320

Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu
325 330 335

Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu
340 345 350

Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr
355 360 365

Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr
370 375 380

Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val
385 390 395 400

Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu
405 410 415

Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu
420 425 430

Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser
435 440 445

Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val
450 455 460

Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu
465 470 475 480

Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
485 490

<210> 37

<211> 1021
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 2..1018

<220>
<221> mat_peptide
<222> 2..1015
<400> 37

```
g atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc cat tgg gga          46
  Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly
    1               5                  10                  15

gtc ctg gcg ggc ctc gcc tac tat tcc atg gtg ggg aac tgg gct aag        94
Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys
                20                  25                  30

gtt ttg gtt gtg atg cta ctc ttt gcc ggc gtc gac ggg cat acc cgc       142
Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg
            35                  40                  45

gtg tca gga ggg gca gca gcc tcc gat acc agg ggc ctt gtg tcc ctc       190
Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu
        50                  55                  60

ttt agc ccc ggg tcg gct cag aaa atc cag ctc gta aac acc aac ggc       238
Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly
    65                  70                  75

agt tgg cac atc aac agg act gcc ctg aac tgc aac gac tcc ctc caa       286
Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln
80                  85                  90                  95

aca ggg ttc ttt gcc gca cta ttc tac aaa cac aaa ttc aac tcg tct       334
Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser
                100                 105                 110

gga tgc cca gag cgc ttg gcc agc tgt cgc tcc atc gac aag ttc gct       382
Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala
            115                 120                 125

cag ggg tgg ggt ccc ctc act tac act gag cct aac agc tcg gac cag       430
Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln
        130                 135                 140

agg ccc tac tgc tgg cac tac gcg cct cga ccg tgt ggt att gta ccc       478
Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro
    145                 150                 155

gcg tct cag gtg tgc ggt cca gtg tat tgc ttc acc ccg agc cct gtt       526
Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val
160                 165                 170                 175
gtg gtg ggg acg acc gat cgg ttt ggt gtc ccc acg tat aac tgg ggg       574
Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly
                180                 185                 190

gcg aac gac tcg gat gtg ctg att ctc aac aac acg cgg ccg ccg cga       622
Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg
            195                 200                 205

ggc aac tgg ttc ggc tgt aca tgg atg aat ggc act ggg ttc acc aag       670
Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys
        210                 215                 220

acg tgt ggg ggc ccc ccg tgc aac atc ggg ggg gcc ggc aac aac acc       718
```

```
Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr
    225                 230                 235

ttg acc tgc ccc act gac tgt ttt cgg aag cac ccc gag gcc acc tac      766
Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr
240                 245                 250                 255

gcc aga tgc ggt tct ggg ccc tgg ctg aca cct agg tgt atg gtt cat      814
Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His
                260                 265                 270

tac cca tat agg ctc tgg cac tac ccc tgc act gtc aac ttc acc atc      862
Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile
            275                 280                 285

ttc aag gtt agg atg tac gtg ggg ggc gtg gag cac agg ttc gaa gcc      910
Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala
        290                 295                 300

gca tgc aat tgg act cga gga gag cgt tgt gac ttg gag gac agg gat      958
Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp
    305                 310                 315

aga tca gag ctt agc ccg ctg ctg ctg tct aca aca gag tgg cag agt     1006
Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ser
320                 325                 330                 335

ggc aga gct taatta                                                  1021
Gly Arg Ala
```

<210> 38

<211> 338
<212> PRT
<213> Hepatitis C virus

<400> 38

```
Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val
  1               5                  10                  15

Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val
             20                  25                  30

Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val
         35                  40                  45

Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe
     50                  55                  60

Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser
 65                  70                  75                  80

Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr
                 85                  90                  95

Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly
            100                 105                 110

Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln
```

```
        115                 120                 125

Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg
    130                 135                 140

Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala
145                 150                 155                 160

Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val
                165                 170                 175

Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala
            180                 185                 190

Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly
        195                 200                 205

Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr
    210                 215                 220

Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu
225                 230                 235                 240

Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala
                245                 250                 255

Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr
            260                 265                 270

Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe
        275                 280                 285

Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala
    290                 295                 300

Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg
305                 310                 315                 320

Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ser Gly
                325                 330                 335

Arg Ala
```

<210> 39

<211> 1034
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 2..1032

<220>
<221> mat_peptide
<222> 2..1029
<400> 39

g atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc cat tgg gga 46

```
  Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly
    1               5                  10                  15

gtc ctg gcg ggc ctc gcc tac tat tcc atg gtg ggg aac tgg gct aag        94
Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys
                20                  25                  30

gtt ttg gtt gtg atg cta ctc ttt gcc ggc gtc gac ggg cat acc cgc       142
Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg
            35                  40                  45

gtg tca gga ggg gca gca gcc tcc gat acc agg ggc ctt gtg tcc ctc       190
Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu
        50                  55                  60

ttt agc ccc ggg tcg gct cag aaa atc cag ctc gta aac acc aac ggc       238
Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly
    65                  70                  75

agt tgg cac atc aac agg act gcc ctg aac tgc aac gac tcc ctc caa       286
Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln
80                  85                  90                  95

aca ggg ttc ttt gcc gca cta ttc tac aaa cac aaa ttc aac tcg tct       334
Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser
                100                 105                 110

gga tgc cca gag cgc ttg gcc agc tgt cgc tcc atc gac aag ttc gct       382
Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala
            115                 120                 125

cag ggg tgg ggt ccc ctc act tac act gag cct aac agc tcg gac cag       430
Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln
        130                 135                 140

agg ccc tac tgc tgg cac tac gcg cct cga ccg tgt ggt att gta ccc       478
Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro
    145                 150                 155

gcg tct cag gtg tgc ggt cca gtg tat tgc ttc acc ccg agc cct gtt       526
Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val
160                 165                 170                 175

gtg gtg ggg acg acc gat cgg ttt ggt gtc ccc acg tat aac tgg ggg       574
Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly
                180                 185                 190

gcg aac gac tcg gat gtg ctg att ctc aac aac acg cgg ccg ccg cga       622
Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg
            195                 200                 205

ggc aac tgg ttc ggc tgt aca tgg atg aat ggc act ggg ttc acc aag       670
Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys
        210                 215                 220

acg tgt ggg ggc ccc ccg tgc aac atc ggg ggg gcc ggc aac aac acc       718
Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr
    225                 230                 235
ttg acc tgc ccc act gac tgt ttt cgg aag cac ccc gag gcc acc tac       766
Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr
240                 245                 250                 255
```

```
gcc aga tgc ggt tct ggg ccc tgg ctg aca cct agg tgt atg gtt cat       814
Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His
               260                 265                 270

tac cca tat agg ctc tgg cac tac ccc tgc act gtc aac ttc acc atc       862
Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile
           275                 280                 285

ttc aag gtt agg atg tac gtg ggg ggc gtg gag cac agg ttc gaa gcc       910
Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala
       290                 295                 300

gca tgc aat tgg act cga gga gag cgt tgt gac ttg gag gac agg gat       958
Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp
   305                 310                 315

aga tca gag ctt agc ccg ctg ctg ctg tct aca aca ggt gat cga ggg      1006
Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly
320                 325                 330                 335

cag aca cca tca cca cca tca cta at ag                              1034
Gln Thr Pro Ser Pro Pro Ser Leu
               340
<210> 40

<211> 343
<212> PRT
<213> Hepatitis C virus


<400> 40

Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val
  1               5                  10                  15

Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val
             20                  25                  30

Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val
         35                  40                  45

Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe
     50                  55                  60

Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser
 65                  70                  75                  80

Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr
                 85                  90                  95

Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly
            100                 105                 110

Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln
        115                 120                 125

Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg
    130                 135                 140

Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala
```

```
145                 150                 155                 160
Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val
                165                 170                 175

Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala
            180                 185                 190

Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly
        195                 200                 205

Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr
    210                 215                 220

Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu
225                 230                 235                 240

Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala
                245                 250                 255

Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr
            260                 265                 270

Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe
        275                 280                 285

Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala
    290                 295                 300

Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg
305                 310                 315                 320

Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln
                325                 330                 335

Thr Pro Ser Pro Pro Ser Leu
            340
<210> 41

<211> 945
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..942

<220>
<221> mat_peptide
<222> 1..939
<400> 41

atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc        48
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
  1               5                  10                  15

ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat        96
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
             20                  25                  30

acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc       144
Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
```

```
         35                  40                  45

cag ctc gta aac acc aac ggc agt tgg cac atc aac agg act gcc ctg       192
Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
     50                  55                  60

aac tgc aac gac tcc ctc caa aca ggg ttc ttt gcc gca cta ttc tac       240
Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
 65                  70                  75                  80

aaa cac aaa ttc aac tcg tct gga tgc cca gag cgc ttg gcc agc tgt       288
Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
                 85                  90                  95

cgc tcc atc gac aag ttc gct cag ggg tgg ggt ccc ctc act tac act       336
Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
            100                 105                 110

gag cct aac agc tcg gac cag agg ccc tac tgc tgg cac tac gcg cct       384
Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
        115                 120                 125

cga ccg tgt ggt att gta ccc gcg tct cag gtg tgc ggt cca gtg tat       432
Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
    130                 135                 140

tgc ttc acc ccg agc cct gtt gtg gtg ggg acg acc gat cgg ttt ggt       480
Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
145                 150                 155                 160

gtc ccc acg tat aac tgg ggg gcg aac gac tcg gat gtg ctg att ctc       528
Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
                165                 170                 175

aac aac acg cgg ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg atg       576
Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
            180                 185                 190

aat ggc act ggg ttc acc aag acg tgt ggg ggc ccc ccg tgc aac atc       624
Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
        195                 200                 205

ggg ggg gcc ggc aac aac acc ttg acc tgc ccc act gac tgt ttt cgg       672
Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
    210                 215                 220

aag cac ccc gag gcc acc tac gcc aga tgc ggt tct ggg ccc tgg ctg       720
Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu
225                 230                 235                 240

aca cct agg tgt atg gtt cat tac cca tat agg ctc tgg cac tac ccc       768
Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro
                245                 250                 255

tgc act gtc aac ttc acc atc ttc aag gtt agg atg tac gtg ggg ggc       816
Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly
            260                 265                 270

gtg gag cac agg ttc gaa gcc gca tgc aat tgg act cga gga gag cgt       864
Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
        275                 280                 285
```

```
tgt gac ttg gag gac agg gat aga tca gag ctt agc ccg ctg ctg ctg       912
Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
    290                 295                 300
tct aca aca gag tgg cag agc tta att aat tag                           945
Ser Thr Thr Glu Trp Gln Ser Leu Ile Asn
305                 310
<210> 42

<211> 314
<212> PRT
<213> Hepatitis C virus


<400> 42

Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
  1               5                  10                  15

Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
             20                  25                  30

Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
         35                  40                  45

Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
     50                  55                  60

Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
 65                  70                  75                  80

Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
                 85                  90                  95

Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
            100                 105                 110

Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
        115                 120                 125

Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
    130                 135                 140

Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
145                 150                 155                 160

Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
                165                 170                 175

Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
            180                 185                 190

Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
        195                 200                 205

Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
    210                 215                 220

Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu
225                 230                 235                 240
```

```
Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro
                245                 250                 255

Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly
            260                 265                 270

Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
        275                 280                 285
Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
    290                 295                 300

Ser Thr Thr Glu Trp Gln Ser Leu Ile Asn
305                 310


<210> 43

<211> 961
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..958

<220>
<221> mat_peptide
<222> 1..955
<400> 43

atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt gcc        48
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
  1               5                  10                  15

ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc gat        96
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
            20                  25                  30

acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa atc       144
Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
        35                  40                  45

cag ctc gta aac acc aac ggc agt tgg cac atc aac agg act gcc ctg       192
Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
    50                  55                  60

aac tgc aac gac tcc ctc caa aca ggg ttc ttt gcc gca cta ttc tac       240
Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
65                  70                  75                  80

aaa cac aaa ttc aac tcg tct gga tgc cca gag cgc ttg gcc agc tgt       288
Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
                85                  90                  95

cgc tcc atc gac aag ttc gct cag ggg tgg ggt ccc ctc act tac act       336
Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
            100                 105                 110

gag cct aac agc tcg gac cag agg ccc tac tgc tgg cac tac gcg cct       384
Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
        115                 120                 125
```

```
cga ccg tgt ggt att gta ccc gcg tct cag gtg tgc ggt cca gtg tat       432
Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
    130                 135                 140

tgc ttc acc ccg agc cct gtt gtg gtg ggg acg acc gat cgg ttt ggt       480
Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
145                 150                 155                 160

gtc ccc acg tat aac tgg ggg gcg aac gac tcg gat gtg ctg att ctc       528
Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
                165                 170                 175

aac aac acg cgg ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg atg       576
Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
            180                 185                 190

aat ggc act ggg ttc acc aag acg tgt ggg ggc ccc ccg tgc aac atc       624
Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
        195                 200                 205

ggg ggg gcc ggc aac aac acc ttg acc tgc ccc act gac tgt ttt cgg       672
Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
    210                 215                 220

aag cac ccc gag gcc acc tac gcc aga tgc ggt tct ggg ccc tgg ctg       720
Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu
225                 230                 235                 240

aca cct agg tgt atg gtt cat tac cca tat agg ctc tgg cac tac ccc       768
Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro
                245                 250                 255

tgc act gtc aac ttc acc atc ttc aag gtt agg atg tac gtg ggg ggc       816
Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly
            260                 265                 270

gtg gag cac agg ttc gaa gcc gca tgc aat tgg act cga gga gag cgt       864
Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
        275                 280                 285

tgt gac ttg gag gac agg gat aga tca gag ctt agc ccg ctg ctg ctg       912
Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
    290                 295                 300

tct aca aca ggt gat cga ggg cag aca cca tca cca cca tca cta a         958
Ser Thr Thr Gly Asp Arg Gly Gln Thr Pro Ser Pro Pro Ser Leu
305                 310                 315

tag                                                                  961
<210> 44

<211> 319
<212> PRT
<213> Hepatitis C virus


<400> 44

Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
  1               5                  10                  15
```

```
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
            20                  25                  30

Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
        35                  40                  45

Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
    50                  55                  60

Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
65                  70                  75                  80

Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
                85                  90                  95

Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
            100                 105                 110

Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
        115                 120                 125

Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
    130                 135                 140

Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
145                 150                 155                 160

Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
                165                 170                 175

Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
            180                 185                 190

Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
        195                 200                 205

Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
    210                 215                 220

Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu
225                 230                 235                 240

Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro
                245                 250                 255

Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly
            260                 265                 270

Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
        275                 280                 285

Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
    290                 295                 300

Ser Thr Thr Gly Asp Arg Gly Gln Thr Pro Ser Pro Pro Ser Leu
305                 310                 315
```

<210> 45

<211> 1395
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..1392

<220>
<221> mat_peptide
<222> 1..1389
<400> 45

```
atg gtg gcg ggg gcc cat tgg gga gtc ctg gcg ggc ctc gcc tac tat        48
Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr
  1               5                  10                  15

tcc atg gtg ggg aac tgg gct aag gtt ttg gtt gtg atg cta ctc ttt        96
Ser Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe
             20                  25                  30

gcc ggc gtc gac ggg cat acc cgc gtg tca gga ggg gca gca gcc tcc       144
Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser
         35                  40                  45

gat acc agg ggc ctt gtg tcc ctc ttt agc ccc ggg tcg gct cag aaa       192
Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys
     50                  55                  60

atc cag ctc gta aac acc aac ggc agt tgg cac atc aac agg act gcc       240
Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala
 65                  70                  75                  80

ctg aac tgc aac gac tcc ctc caa aca ggg ttc ttt gcc gca cta ttc       288
Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe
                 85                  90                  95

tac aaa cac aaa ttc aac tcg tct gga tgc cca gag cgc ttg gcc agc       336
Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser
            100                 105                 110

tgt cgc tcc atc gac aag ttc gct cag ggg tgg ggt ccc ctc act tac       384
Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr
        115                 120                 125

act gag cct aac agc tcg gac cag agg ccc tac tgc tgg cac tac gcg       432
Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala
    130                 135                 140

cct cga ccg tgt ggt att gta ccc gcg tct cag gtg tgc ggt cca gtg       480
Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val
145                 150                 155                 160

tat tgc ttc acc ccg agc cct gtt gtg gtg ggg acg acc gat cgg ttt       528
Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe
                165                 170                 175

ggt gtc ccc acg tat aac tgg ggg gcg aac gac tcg gat gtg ctg att       576
Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile
            180                 185                 190

ctc aac aac acg cgg ccg ccg cga ggc aac tgg ttc ggc tgt aca tgg       624
```

```
Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp
        195                 200                 205

atg aat ggc act ggg ttc acc aag acg tgt ggg ggc ccc ccg tgc aac      672
Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn
    210                 215                 220

atc ggg ggg gcc ggc aac aac acc ttg acc tgc ccc act gac tgt ttt      720
Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe
225                 230                 235                 240

cgg aag cac ccc gag gcc acc tac gcc aga tgc ggt tct ggg ccc tgg      768
Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp
                245                 250                 255

ctg aca cct agg tgt atg gtt cat tac cca tat agg ctc tgg cac tac      816
Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr
            260                 265                 270

ccc tgc act gtc aac ttc acc atc ttc aag gtt agg atg tac gtg ggg      864
Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly
        275                 280                 285

ggc gtg gag cac agg ttc gaa gcc gca tgc aat tgg act cga gga gag      912
Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu
    290                 295                 300

cgt tgt gac ttg gag gac agg gat aga tca gag ctt agc ccg ctg ctg      960
Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu
305                 310                 315                 320

ctg tct aca aca gag tgg cag ata ctg ccc tgt tcc ttc acc acc ctg     1008
Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu
                325                 330                 335

ccg gcc cta tcc acc ggc ctg atc cac ctc cat cag aac atc gtg gac     1056
Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp
            340                 345                 350

gtg caa tac ctg tac ggt gta ggg tcg gcg gtt gtc tcc ctt gtc atc     1104
Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile
        355                 360                 365

aaa tgg gag tat gtc ctg ttg ctc ttc ctt ctc ctg gca gac gcg cgc     1152
Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg
    370                 375                 380

atc tgc gcc tgc tta tgg atg atg ctg ctg ata gct caa gct gag gcc     1200
Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala
385                 390                 395                 400

gcc tta gag aac ctg gtg gtc ctc aat gcg gcg gcc gtg gcc ggg gcg     1248
Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala
                405                 410                 415

cat ggc act ctt tcc ttc ctt gtg ttc ttc tgt gct gcc tgg tac atc     1296
His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile
            420                 425                 430

aag ggc agg ctg gtc cct ggt gcg gca tac gcc ttc tat ggc gtg tgg     1344
Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp
```

```
        435                 440                 445

ccg ctg ctc ctg ctt ctg ctg gcc tta cca cca cga gct tat gcc tagtaa    1395
Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
    450                 455                 460
<210> 46

<211> 463
<212> PRT
<213> Hepatitis C virus


<400> 46

Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr
  1               5                  10                  15

Ser Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe
             20                  25                  30
Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser
         35                  40                  45

Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys
     50                  55                  60

Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala
 65                  70                  75                  80

Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe
                 85                  90                  95

Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser
            100                 105                 110

Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr
        115                 120                 125

Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala
    130                 135                 140

Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val
145                 150                 155                 160

Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe
                165                 170                 175

Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile
            180                 185                 190

Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp
        195                 200                 205

Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn
    210                 215                 220

Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe
225                 230                 235                 240

Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp
                245                 250                 255
```

```
Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr
            260                 265                 270

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly
        275                 280                 285

Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu
    290                 295                 300

Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu
305                 310                 315                 320

Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu
                325                 330                 335

Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp
            340                 345                 350

Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile
        355                 360                 365

Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg
    370                 375                 380

Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala
385                 390                 395                 400

Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala
                405                 410                 415

His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile
            420                 425                 430

Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp
        435                 440                 445

Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
    450                 455                 460
<210> 47

<211> 2082
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..2079

<220>
<221> mat_peptide
<222> 1..2076
<400> 47

aat ttg ggt aag gtc atc gat acc ctt aca tgc ggc ttc gcc gac ctc        48
Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

gtg ggg tac att ccg ctc gtc ggc gcc ccc cta ggg ggc gct gcc agg        96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30
```

```
gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac ggc gtg aac tat gca        144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45

aca ggg aat ttg ccc ggt tgc tct ttc tct atc ttc ctc ttg gct ttg        192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

ctg tcc tgt ctg acc gtt cca gct tcc gct tat gaa gtg cgc aac gtg        240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

tcc ggg atg tac cat gtc acg aac gac tgc tcc aac tca agc att gtg        288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                 85                  90                  95

tat gag gca gcg gac atg atc atg cac acc ccc ggg tgc gtg ccc tgc        336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

gtt cgg gag aac aac tct tcc cgc tgc tgg gta gcg ctc acc ccc acg        384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

ctc gca gct agg aac gcc agc gtc ccc acc acg aca ata cga cgc cac        432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt tcc gct atg tac gtg        480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

ggg gac ctc tgc gga tct gtc ttc ctc gtc tcc cag ctg ttc acc atc        528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

tcg cct cgc cgg cat gag acg gtg cag gac tgc aat tgc tca atc tat        576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

ccc ggc cac ata acg ggt cac cgt atg gct tgg gat atg atg atg aac        624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

tgg tcg cct aca acg gcc ctg gtg gta tcg cag ctg ctc cgg atc cca        672
Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
    210                 215                 220

caa gct gtc gtg gac atg gtg gcg ggg gcc cat tgg gga gtc ctg gcg        720
Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
225                 230                 235                 240

ggc ctc gcc tac tat tcc atg gtg ggg aac tgg gct aag gtt ttg gtt        768
Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Val
                245                 250                 255

gtg atg cta ctc ttt gcc ggc gtc gac ggg cat acc cgc gtg tca gga        816
Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val Ser Gly
            260                 265                 270

ggg gca gca gcc tcc gat acc agg ggc ctt gtg tcc ctc ttt agc ccc        864
```

```
Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro
        275                 280                 285

ggg tcg gct cag aaa atc cag ctc gta aac acc aac ggc agt tgg cac       912
Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His
    290                 295                 300

atc aac agg act gcc ctg aac tgc aac gac tcc ctc caa aca ggg ttc       960
Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe
305                 310                 315                 320

ttt gcc gca cta ttc tac aaa cac aaa ttc aac tcg tct gga tgc cca      1008
Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro
                325                 330                 335

gag cgc ttg gcc agc tgt cgc tcc atc gac aag ttc gct cag ggg tgg      1056
Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp
            340                 345                 350

ggt ccc ctc act tac act gag cct aac agc tcg gac cag agg ccc tac      1104
Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr
        355                 360                 365

tgc tgg cac tac gcg cct cga ccg tgt ggt att gta ccc gcg tct cag      1152
Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln
    370                 375                 380

gtg tgc ggt cca gtg tat tgc ttc acc ccg agc cct gtt gtg gtg ggg      1200
Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly
385                 390                 395                 400
acg acc gat cgg ttt ggt gtc ccc acg tat aac tgg ggg gcg aac gac      1248
Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp
                405                 410                 415

tcg gat gtg ctg att ctc aac aac acg cgg ccg ccg cga ggc aac tgg      1296
Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp
            420                 425                 430

ttc ggc tgt aca tgg atg aat ggc act ggg ttc acc aag acg tgt ggg      1344
Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly
        435                 440                 445

ggc ccc ccg tgc aac atc ggg ggg gcc ggc aac aac acc ttg acc tgc      1392
Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys
    450                 455                 460

ccc act gac tgt ttt cgg aag cac ccc gag gcc acc tac gcc aga tgc      1440
Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys
465                 470                 475                 480

ggt tct ggg ccc tgg ctg aca cct agg tgt atg gtt cat tac cca tat      1488
Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr
                485                 490                 495

agg ctc tgg cac tac ccc tgc act gtc aac ttc acc atc ttc aag gtt      1536
Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val
            500                 505                 510

agg atg tac gtg ggg ggc gtg gag cac agg ttc gaa gcc gca tgc aat      1584
Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn
        515                 520                 525
```

```
tgg act cga gga gag cgt tgt gac ttg gag gac agg gat aga tca gag      1632
Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu
    530                 535                 540

ctt agc ccg ctg ctg ctg tct aca aca gag tgg cag ata ctg ccc tgt      1680
Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys
545                 550                 555                 560

tcc ttc acc acc ctg ccg gcc cta tcc acc ggc ctg atc cac ctc cat      1728
Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His
                565                 570                 575

cag aac atc gtg gac gtg caa tac ctg tac ggt gta ggg tcg gcg gtt      1776
Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val
            580                 585                 590

gtc tcc ctt gtc atc aaa tgg gag tat gtc ctg ttg ctc ttc ctt ctc      1824
Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu
        595                 600                 605

ctg gca gac gcg cgc atc tgc gcc tgc tta tgg atg atg ctg ctg ata      1872
Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile
    610                 615                 620

gct caa gct gag gcc gcc tta gag aac ctg gtg gtc ctc aat gcg gcg      1920
Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala
625                 630                 635                 640

gcc gtg gcc ggg gcg cat ggc act ctt tcc ttc ctt gtg ttc ttc tgt      1968
Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys
                645                 650                 655

gct gcc tgg tac atc aag ggc agg ctg gtc cct ggt gcg gca tac gcc      2016
Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala
            660                 665                 670

ttc tat ggc gtg tgg ccg ctg ctc ctg ctt ctg ctg gcc tta cca cca      2064
Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro
        675                 680                 685

cga gct tat gcc tagtaa                                               2082
Arg Ala Tyr Ala
    690
<210> 48

<211> 692
<212> PRT
<213> Hepatitis C virus


<400> 48

Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
  1               5                  10                  15

Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
             20                  25                  30

Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
         35                  40                  45
```

```
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
     50                  55                  60

Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65                  70                  75                  80

Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
                85                  90                  95

Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
            100                 105                 110

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
        115                 120                 125

Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
    130                 135                 140

Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
145                 150                 155                 160

Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
                165                 170                 175

Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
            180                 185                 190

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
        195                 200                 205

Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
    210                 215                 220

Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
225                 230                 235                 240

Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Val
                245                 250                 255

Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val Ser Gly
            260                 265                 270
Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro
        275                 280                 285

Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His
    290                 295                 300

Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe
305                 310                 315                 320

Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro
                325                 330                 335

Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp
            340                 345                 350

Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr
        355                 360                 365

Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln
```

```
    370                 375                 380

Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly
385                 390                 395                 400

Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp
                405                 410                 415

Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp
            420                 425                 430

Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly
        435                 440                 445

Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys
    450                 455                 460

Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys
465                 470                 475                 480

Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr
                485                 490                 495

Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val
            500                 505                 510

Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn
        515                 520                 525

Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu
    530                 535                 540

Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys
545                 550                 555                 560

Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His
                565                 570                 575

Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val
            580                 585                 590

Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu
        595                 600                 605

Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile
    610                 615                 620

Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala
625                 630                 635                 640

Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys
                645                 650                 655

Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala
            660                 665                 670

Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro
        675                 680                 685

Arg Ala Tyr Ala
    690
```

<210> 49

<211> 2433
<212> DNA
<213> Hepatitis C virus

<220>
<221> CDS
<222> 1..2430

<220>
<221> mat_peptide
<222> 1..2427
<400> 49

```
atg agc acg aat cct aaa cct caa aga aaa acc aaa cgt aac acc aac        48
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
  1               5                  10                  15

cgc cgc cca cag gac gtc aag ttc ccg ggc ggt ggt cag atc gtt ggt        96
Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
            20                  25                  30

gga gtt tac ctg ttg ccg cgc agg ggc ccc agg ttg ggt gtg cgc gcg       144
Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
        35                  40                  45

act agg aag act tcc gag cgg tcg caa cct cgt ggg agg cga caa cct       192
Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
    50                  55                  60

atc ccc aag gct cgc cga ccc gag ggt agg gcc tgg gct cag ccc ggg       240
Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly
65                  70                  75                  80

tac cct tgg ccc ctc tat ggc aat gag ggc atg ggg tgg gca gga tgg       288
Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp
                85                  90                  95

ctc ctg tca ccc cgc ggc tct cgg cct agt tgg ggc cct aca gac ccc       336
Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro
            100                 105                 110

cgg cgt agg tcg cgt aat ttg ggt aag gtc atc gat acc ctt aca tgc       384
Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125
ggc ttc gcc gac ctc gtg ggg tac att ccg ctc gtc ggc gcc ccc cta       432
Gly Phe Ala Asp Leu Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu
    130                 135                 140

ggg ggc gct gcc agg gcc ctg gcg cat ggc gtc cgg gtt ctg gag gac       480
Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

ggc gtg aac tat gca aca ggg aat ttg ccc ggt tgc tct ttc tct atc       528
Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

ttc ctc ttg gct ttg ctg tcc tgt ctg acc gtt cca gct tcc gct tat       576
```

```
Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr
            180                 185                 190

gaa gtg cgc aac gtg tcc ggg atg tac cat gtc acg aac gac tgc tcc       624
Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser
        195                 200                 205

aac tca agc att gtg tat gag gca gcg gac atg atc atg cac acc ccc       672
Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro
    210                 215                 220

ggg tgc gtg ccc tgc gtt cgg gag aac aac tct tcc cgc tgc tgg gta       720
Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val
225                 230                 235                 240

gcg ctc acc ccc acg ctc gca gct agg aac gcc agc gtc ccc acc acg       768
Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr
                245                 250                 255

aca ata cga cgc cac gtc gat ttg ctc gtt ggg gcg gct gct ttc tgt       816
Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys
            260                 265                 270

tcc gct atg tac gtg ggg gac ctc tgc gga tct gtc ttc ctc gtc tcc       864
Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser
        275                 280                 285

cag ctg ttc acc atc tcg cct cgc cgg cat gag acg gtg cag gac tgc       912
Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys
    290                 295                 300

aat tgc tca atc tat ccc ggc cac ata acg ggt cac cgt atg gct tgg       960
Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp
305                 310                 315                 320

gat atg atg atg aac tgg tcg cct aca acg gcc ctg gtg gta tcg cag      1008
Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln
                325                 330                 335

ctg ctc cgg atc cca caa gct gtc gtg gac atg gtg gcg ggg gcc cat      1056
Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His
            340                 345                 350

tgg gga gtc ctg gcg ggc ctc gcc tac tat tcc atg gtg ggg aac tgg      1104
Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp
        355                 360                 365

gct aag gtt ttg gtt gtg atg cta ctc ttt gcc ggc gtc gac ggg cat      1152
Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His
    370                 375                 380

acc cgc gtg tca gga ggg gca gca gcc tcc gat acc agg ggc ctt gtg      1200
Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val
385                 390                 395                 400

tcc ctc ttt agc ccc ggg tcg gct cag aaa atc cag ctc gta aac acc      1248
Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr
                405                 410                 415

aac ggc agt tgg cac atc aac agg act gcc ctg aac tgc aac gac tcc      1296
Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
```

```
            420                 425                 430

ctc caa aca ggg ttc ttt gcc gca cta ttc tac aaa cac aaa ttc aac      1344
Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn
        435                 440                 445

tcg tct gga tgc cca gag cgc ttg gcc agc tgt cgc tcc atc gac aag      1392
Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys
    450                 455                 460

ttc gct cag ggg tgg ggt ccc ctc act tac act gag cct aac agc tcg      1440
Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser
465                 470                 475                 480

gac cag agg ccc tac tgc tgg cac tac gcg cct cga ccg tgt ggt att      1488
Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile
                485                 490                 495

gta ccc gcg tct cag gtg tgc ggt cca gtg tat tgc ttc acc ccg agc      1536
Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser
            500                 505                 510

cct gtt gtg gtg ggg acg acc gat cgg ttt ggt gtc ccc acg tat aac      1584
Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn
        515                 520                 525

tgg ggg gcg aac gac tcg gat gtg ctg att ctc aac aac acg cgg ccg      1632
Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro
    530                 535                 540

ccg cga ggc aac tgg ttc ggc tgt aca tgg atg aat ggc act ggg ttc      1680
Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe
545                 550                 555                 560

acc aag acg tgt ggg ggc ccc ccg tgc aac atc ggg ggg gcc ggc aac      1728
Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn
                565                 570                 575

aac acc ttg acc tgc ccc act gac tgt ttt cgg aag cac ccc gag gcc      1776
Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala
            580                 585                 590

acc tac gcc aga tgc ggt tct ggg ccc tgg ctg aca cct agg tgt atg      1824
Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met
        595                 600                 605

gtt cat tac cca tat agg ctc tgg cac tac ccc tgc act gtc aac ttc      1872
Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe
    610                 615                 620

acc atc ttc aag gtt agg atg tac gtg ggg ggc gtg gag cac agg ttc      1920
Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe
625                 630                 635                 640

gaa gcc gca tgc aat tgg act cga gga gag cgt tgt gac ttg gag gac      1968
Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp
                645                 650                 655

agg gat aga tca gag ctt agc ccg ctg ctg ctg tct aca aca gag tgg      2016
Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp
            660                 665                 670
```

```
cag ata ctg ccc tgt tcc ttc acc acc ctg ccg gcc cta tcc acc ggc      2064
Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly
        675                 680                 685

ctg atc cac ctc cat cag aac atc gtg gac gtg caa tac ctg tac ggt      2112
Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly
    690                 695                 700

gta ggg tcg gcg gtt gtc tcc ctt gtc atc aaa tgg gag tat gtc ctg      2160
Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu
705                 710                 715                 720

ttg ctc ttc ctt ctc ctg gca gac gcg cgc atc tgc gcc tgc tta tgg      2208
Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp
                725                 730                 735

atg atg ctg ctg ata gct caa gct gag gcc gcc tta gag aac ctg gtg      2256
Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val
            740                 745                 750

gtc ctc aat gcg gcg gcc gtg gcc ggg gcg cat ggc act ctt tcc ttc      2304
Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe
        755                 760                 765

ctt gtg ttc ttc tgt gct gcc tgg tac atc aag ggc agg ctg gtc cct      2352
Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro
    770                 775                 780

ggt gcg gca tac gcc ttc tat ggc gtg tgg ccg ctg ctc ctg ctt ctg      2400
Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu
785                 790                 795                 800

ctg gcc tta cca cca cga gct tat gcc tagtaa                           2433
Leu Ala Leu Pro Pro Arg Ala Tyr Ala
                805                 810
```

<210> 50

<211> 809
<212> PRT
<213> Hepatitis C virus

<400> 50

```
Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
  1               5                  10                  15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
            20                  25                  30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
        35                  40                  45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
    50                  55                  60

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly
65                  70                  75                  80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp
```

```
                85                  90                  95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro
            100                 105                 110

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys
        115                 120                 125
Gly Phe Ala Asp Leu Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu
    130                 135                 140

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145                 150                 155                 160

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
                165                 170                 175

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr
            180                 185                 190

Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser
        195                 200                 205

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro
    210                 215                 220

Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val
225                 230                 235                 240

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr
                245                 250                 255

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys
            260                 265                 270

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser
        275                 280                 285

Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys
    290                 295                 300

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp
305                 310                 315                 320

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln
                325                 330                 335

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His
            340                 345                 350

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp
        355                 360                 365

Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His
    370                 375                 380

Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val
385                 390                 395                 400

Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr
                405                 410                 415
```

```
Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
          420                 425                 430

Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn
      435                 440                 445

Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys
  450                 455                 460

Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser
465                 470                 475                 480

Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile
                485                 490                 495

Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser
          500                 505                 510

Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn
      515                 520                 525

Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro
  530                 535                 540

Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe
545                 550                 555                 560

Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn
                565                 570                 575

Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala
          580                 585                 590

Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met
      595                 600                 605

Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe
  610                 615                 620

Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe
625                 630                 635                 640

Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp
                645                 650                 655

Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp
          660                 665                 670

Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly
      675                 680                 685

Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly
  690                 695                 700

Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu
705                 710                 715                 720

Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp
                725                 730                 735

Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val
```

740 745 750

Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe
755 760 765

Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro
770 775 780

Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu
785 790 795 800

Leu Ala Leu Pro Pro Arg Ala Tyr Ala
805

<210> 51

<211> 17
<212> PRT
<213> Hepatitis C virus
<220>
<221> Modified-site
<222> 1..17
<400> 51

Ser Asn Ser Ser Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys
1 5 10 15

Val

<210> 52

<211> 22
<212> PRT
<213> Hepatitis C virus
<220>
<221> Modified-site
<222> 1..22
<400> 52

Gly Gly Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
1 5 10 15

Ser Pro Thr Thr Ala Leu
20

<210> 53

<211> 37
<212> PRT
<213> Hepatitis C virus
<220>
<221> Modified-site
<222> 1..37
<400> 53

Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys
1 5 10 15

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
20 25 30

Pro Gly Cys Gly Lys
35

<210> 54

<211> 25
<212> PRT
<213> Hepatitis C virus
<220>
<221> Modified-site
<222> 1..25
<400> 54

Gly Gly Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr
1 5 10 15

Gln Leu Arg Arg His Ile Asp Leu Leu
20 25

<210> 55

<211> 25
<212> PRT
<213> Hepatitis C virus
<220>
<221> Modified-site
<222> 1..25
<400> 55

Gly Gly Thr Pro Thr Leu Ala Ala Arg Asp Ala Ser Val Pro Thr Thr
1 5 10 15

Thr Ile Arg Arg His Val Asp Leu Leu
20 25

<210> 56

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 56

Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Gln Val Arg Asn
1 5 10 15

Ser Thr Gly Leu
20

<210> 57

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 57

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro
1 5 10 15

Asn Ser Ser Ile
20

<210> 58

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 58

Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile
1 5 10 15

Leu His Thr Pro
20

<210> 59

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 59

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
1 5 10 15

Pro Gly Cys Val
20

<210> 60

<211> 19
<212> PRT
<213> Hepatitis C virus

<400> 60

His Asp Ala Ile Leu His Thr Pro Gly Val Pro Cys Val Arg Glu Gly
1 5 10 15

Asn Val Ser

<210> 61

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 61

Cys Val Arg Glu Gly Asn Val Ser Arg Cys Trp Val Ala Met Thr Pro
1 5 10 15

Thr Val Ala Thr
20

<210> 62

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 62

Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr
1 5 10 15

Gln Leu Arg Arg
20

<210> 63

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 63

Leu Pro Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser
1 5 10 15

Ala Thr Leu Cys
20

<210> 64
<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 64

Leu Val Gly Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu
1 5 10 15

Cys Gly Ser Val
20

<210> 65

<211> 20

<212> PRT
<213> Hepatitis C virus

<400> 65

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys
1 5 10 15

Asn Cys Ser Ile
20

<210> 66

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 66

Thr Gln Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His
1 5 10 15

Arg Met Ala Trp
20

<210> 67

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 67

Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro
1 5 10 15

Thr Ala Ala Leu
20

<210> 68

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 68

Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln Leu Leu Arg Ile
1 5 10 15

Pro Gln Ala Ile
20

<210> 69

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 69

Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His
1 5 10 15

Trp Gly Val Leu
20

<210> 70

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 70

Ala Gly Ala His Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met
1 5 10 15

Val Gly Asn Met
20

<210> 71

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 71

Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val Ser
1 5 10 15

Gly Gly Gln Ala
20

<210> 72

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 72

Ser Gly Leu Val Ser Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln
1 5 10 15

Leu Ile Asn Thr

20

<210> 73

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 73

Gln Asn Ile Gln Leu Ile Asn Thr Asn Gly Gln Trp His Ile Asn Ser
1 5 10 15

Thr Ala Leu Asn
20

<210> 74

<211> 21
<212> PRT
<213> Hepatitis C virus

<400> 74

Leu Asn Cys Asn Glu Ser Leu Asn Thr Gly Trp Trp Leu Ala Gly Leu
1 5 10 15

Ile Tyr Gln His Lys
20

<210> 75

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 75

Ala Gly Leu Ile Tyr Gln His Lys Phe Asn Ser Ser Gly Cys Pro Glu
1 5 10 15

Arg Leu Ala Ser
20

<210> 76

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 76

Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp
1 5 10 15

Gln Gly Trp Gly
20

<210> 77

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 77

Thr Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser
1 5 10 15

Gly Pro Asp Gln
20

<210> 78

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 78

Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro
1 5 10 15

Pro Lys Pro Cys
20

<210> 79

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 79

Trp His Tyr Pro Pro Lys Pro Cys Gly Ile Val Pro Ala Lys Ser Val
1 5 10 15

Cys Gly Pro Val
20

<210> 80

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 80

Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val
1 5 10 15

Val Val Gly Thr
20

<210> 81

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 81

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr
1 5 10 15

Tyr Ser Trp Gly
20

<210> 82

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 82

Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn Asp Thr Asp Val Phe Val
1 5 10 15

Leu Asn Asn Thr
20

<210> 83

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 83

Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys
1 5 10 15

Val Cys Gly Ala
20

<210> 84

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 84

Gly Phe Thr Lys Val Cys Gly Ala Pro Pro Val Cys Ile Gly Gly Ala
1 5 10 15

Gly Asn Asn Thr
20

<210> 85

<211> 19
<212> PRT
<213> Hepatitis C virus

<400> 85

Ile Gly Gly Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Arg
1 5 10 15

Lys His Pro

<210> 86

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 86

Thr Asp Cys Phe Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly
1 5 10 15

Ser Gly Pro Trp
20

<210> 87

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 87

Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu Val Asp
1 5 10 15

Tyr Pro Tyr Arg
20

<210> 88

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 88

Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile
1 5 10 15

Asn Tyr Thr Ile
20

<210> 89

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 89

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly
1 5 10 15

Gly Val Glu His
20

<210> 90

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 90

Met Tyr Val Gly Gly Val Glu His Arg Leu Glu Ala Ala Cys Asn Trp
1 5 10 15

Thr Pro Gly Glu
20

<210> 91

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 91

Ala Cys Asn Trp Thr Pro Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp
1 5 10 15

Arg Ser Glu Leu
20

<210> 92

<211> 20

<212> PRT
<213> Hepatitis C virus

<400> 92

Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr Thr
1 5 10 15

Gln Trp Gln Val
20

<210> 93

<211> 9
<212> PRT
<213> Hepatitis C virus

<400> 93

Tyr Gln Val Arg Asn Ser Thr Gly Leu
1 5

<210> 94

<211> 29
<212> DNA
<213> Hepatitis C virus

<400> 94

agctaattaa ttaagcttgc atgcctgca 29

<210> 95

<211> 60
<212> DNA
<213> Hepatitis C virus

<400> 95

gttaattaac tattagtgat ggtggtgatg gtgtctgccc tcgatcacgt gcaggcctcc 60

<210> 96

<211> 19
<212> DNA
<213> Hepatitis C virus

<400> 96

gtttaaccac tgcatgatg 19

<210> 97

<211> 20

<212> DNA
<213> Hepatitis C virus

<400> 97

gtcccatcga gtgcggctac 20

<210> 98

<211> 45
<212> DNA
<213> Hepatitis C virus

<400> 98

cgtgacatgg tacattccgg acacttggcg cacttcataa gcgga 45

<210> 99

<211> 42
<212> DNA
<213> Hepatitis C virus

<400> 99

tgcctcatac acaatggagc tctgggacga gtcgttcgtg ac 42

<210> 100

<211> 42
<212> DNA
<213> Hepatitis C virus

<400> 100

tacccagcag cgggagctct gttgctcccg aacgcagggc ac 42

<210> 101

<211> 42
<212> DNA
<213> Hepatitis C virus

<400> 101

tgtcgtggtg gggacggagg cctgcctagc tgcgagcgtg gg 42

<210> 102

<211> 48
<212>

<400> 102

cgttatgtgg cccgggtaga ttgagcactg gcagtcctgc accgtctc 48

<210> 103

<211> 42
<212> DNA
<213> Hepatitis C virus

<400> 103

cagggccgtt ctaggcctcc actgcatcat catatcccaa gc 42

<210> 104

<211> 26
<212> DNA
<213> Hepatitis C virus

<400> 104

ccggaatgta ccatgtcacg aacgac 26

<210> 105

<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 105
gctccattgt gtatgaggca gcgg 24

<210> 106

<211> 23
<212> DNA
<213> Hepatitis C virus

<400> 106

gagctcccgc tgctgggtag cgc 23

<210> 107

<211> 25
<212> DNA
<213> Hepatitis C virus

<400> 107

cctccgtccc caccacgaca atacg 25

<210> 108

<211> 27
<212> DNA
<213> Hepatitis C virus

<400> 108

ctacccgggc cacataacgg gtcaccg 27

<210> 109

<211> 24
<212> DNA
<213> Hepatitis C virus

<400> 109

ggaggcctac aacggccctg gtgg 24

<210> 110

<211> 22
<212> DNA
<213> Hepatitis C virus

<400> 110

ttctatcgat taaatagaat tc 22

<210> 111

<211> 23
<212> DNA
<213> Hepatitis C virus

<400> 111

gccatacgct cacagccgat ccc 23

<210> 112

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 112

Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys
1 5 10 15

Ser Asn Ser Ser
20

<210> 113

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 113

Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp
1 5 10 15

Met Ile Met His Thr
20

<210> 114

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 114

Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val
1 5 10 15

Arg Glu Asn Asn Ser
20

<210> 115

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 115

Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu
1 5 10 15

Thr Pro Thr Leu Ala
20

<210> 116

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 116

Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro
1 5 10 15

Thr Thr Thr Ile Arg
20

<210> 117

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 117

Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu Leu Val
1 5 10 15

Gly Ala Ala Ala Phe
20

<210> 118

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 118

Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly
1 5 10 15

Asp Leu Cys Gly Ser
20

<210> 119

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 119

Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu
1 5 10 15

Phe Thr Ile Ser Pro
20

<210> 120

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 120

Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln
1 5 10 15

Asp Cys Asn Cys Ser
20

<210> 121

<211> 20
<212> PRT

<213> Hepatitis C virus

<400> 121

```
Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr
  1               5                  10                  15

Gly His Arg Met Ala
                20
```

<210> 122

<211> 20
<212> PRT
<213> Hepatitis C virus

<400> 122

```
His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
  1               5                  10                  15
Ser Pro Thr Thr Ala
                20
```

<210> 123

<211> 135
<212> PRT
<213> hepatitis C virus

<400> 123

```
Tyr Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys
1               5                  10                  15

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
            20                  25                  30

Pro Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp
        35                  40                  45

Val Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr
    50                  55                  60

Thr Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe
65                  70                  75                  80

Cys Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val
                85                  90                  95

Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val Gln Asp
            100                 105                 110

Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala
```

115 120 125

Trp Asp Met Met Met Asn Trp
130 135